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Malaria is a devastating disease caused by one of the world‟s most pathogenic 
parasites, Plasmodium. Five species of Plasmodium infect humans: P. falciparum, P. vivax, 
P. ovale, P. malariae and P. knowlesi. P. falciparum is the most pathogenic and causes the 
greatest numbers of deaths. To date, no licensed vaccine against malaria is available, 
although there are numerous vaccine candidates in various stages of development. 
Pca 96 is a 96 kDa Plasmodium chabaudi adami protein shown to have a protective 
property in mice challenged with P. chabaudi adami. Thus, a P. falciparum orthologue of 
Pca 96 may be useful in vaccine development. BLAST searches with the Pca 96 amino 
acid and nucleotide sequences revealed proteins with high sequence identity to Pca 96 
including the hypothetical P. falciparum PFC0760c and P. yoelii yoelii PY05757 proteins. 
A peptide sequence FKLGSCYLYIINRNLKEI was found to be conserved in all 
homologues of Pca 96, including PFC0760c, PY05757 and in the sequences of proteins 
from 5 other Plasmodium species.  
Bioinformatic approaches were explored to attempt to find a possible role of the 
protein and the possible importance of the conserved sequence. The conserved sequence 
was predicted to be an alpha helix and to contain possible HLA-DRB1*1101 and HLA-
DRB1*0401(Dr4Dw4) T-cell epitopes (GSCYLYIINRNLKEI) in addition to a possible 
H2-Kd T-cell epitope (CYLYIINRNL). Protein-protein interaction predictions revealed that 
PFC0760c was likely to interact with proteins involved with nucleic acid binding. 
PFC0760c was predicted to have a domain found in proteins involved in the structural 
maintenance of chromosomes, which may suggest the protein is involved in chromatid 
cohesion during mitotic chromosome condensation. PFC0760c was also predicted to be 
located in the nucleus by the sub cellular prediction program, SubLoc.  
Anti-peptide antibodies were raised against the conserved amino acid sequence and 
against a peptide specific for PY05757 (SDDDNRQIQDFE). Both antibodies detected 
native antigens with immunofluorescence microscopy. The fluorescent signal appeared 
throughout the parasite cytoplasm and as an intense signal in the parasite nucleus. These 
immunofluorescence data supports the predicted nuclear location of the protein. 
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A 822 bp portion of PFC0760c gene was expressed as a maltose-binding protein 
fusion protein (Pf33-MBP). Pf33-MBP was expressed and purified. Reducing SDS-PAGE 
and western blotting analysis revealed the fusion protein to be expressed at low levels as 
four bands (79, 60, 45 and 37 kDa). The purified fusion protein was cleaved with Factor 
Xa. MBP and Pf33 were of similar molecular mass after cleavage. To attempt to obtain 
better expression and purification, the 822 bp insert from pTS822 was sub-cloned into 
pGEX4T1. A glutathione-S-transferase (GST)-fusion protein (Pf33-GST) was expressed. 
The level of expression was poor and therefore not pursued. 
To take the study further, potential proteins that interact with PFC0760c and Pf33 
need to be identified. In addition, immunisation of mice with the protein and subsequent 
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1.1 Overview of malaria 
Malaria is a devastating disease caused by one of the world‟s most pathogenic parasites, 
Plasmodium. The Plasmodium parasite is transmitted by the bite of an infected female 
anophelene mosquito. There are four species of Plasmodium infecting humans: P. 
falciparum, P. vivax, P. ovale and P. malariae, with P. falciparum causing the greatest 
numbers of deaths (Girard et al., 2007). P. falciparum was estimated to have caused 451 
(range 349-552) million infections worldwide in 2007 (Hay et al., 2010). In 2008 
Plasmodium was estimated to cause 243 million cases of malaria, resulting in 863 thousand 
deaths (World Health Organisation, 2009). Approximately 85% (208 million) of the 
malaria cases were in Africa and resulted in the deaths of 767 thousand people, of which 
88% were children under the age of 5 (World Health Organisation, 2009). 
Malaria has in the past, been endemic all over the world. The use of insecticides 
saw its eradication from North America, Australia and Europe by 1950‟s. However, it is 
still prevalent in Africa, South East Asia and the Western Pacific region today (Girard et 
al., 2007). In South Africa, 10% of the population is at risk of contracting a malaria 
infection. Provinces in South Africa having the highest risks for malaria infection are 
Mpumalanga, Limpopo and Northern KwaZulu Natal. The statistics of malaria cases and 
related deaths provided by the National Department of Health show that Limpopo province 
experiences the greatest number of malaria infections and deaths, with 6 369 cases and 57 
deaths recorded for 2006 (http://www.doh.gov.za/issues/malaria/statistics.html). The 
second and third most affected provinces are Mpumalanga and KwaZulu-Natal. In 2006, 
Mpumalanga experienced 4 558 malaria cases, of which 21 were fatal. KwaZulu Natal 
experienced 1 211 malaria cases and 11 malaria–related deaths in 2006. 
 
1.2 Life cycle 
The Plasmodium parasite is able to constantly change its gene expression (Bannister 
and Mitchell, 2003). This allows the parasite to exploit a number of different environments, 
such as the salivary glands, gut and vascular system of the mosquito, and the hepatocytes 
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(liver cells) and erythrocytes of humans (Figure 1.1). The life cycle essentially has two 
parts to it, the human stages and the mosquito stages. When a mosquito feeds on the blood 
of a human previously infected by a mosquito carrying Plasmodium parasites, it obtains 
parasites in the form of gametocytes. These gametocytes are fertilized to form a zygote, 
which divides and develops to produce large numbers of sporozoites (Figure 1.1). The 
sporozoites make their way into the salivary glands of the mosquito. When the mosquito 
feeds, it injects the sporozoites into the blood stream of a human. Sporozoites are 
transported in the blood stream to the liver, where they invade the liver cells (Figure 1.1). 
The sporozoites differentiate and replicate asexually as schizonts, producing tens of 
thousands of merozoites. The merozoites are released from the liver cells and enter the 
blood stream and infect erythrocytes. This stage of the life cycle is known as the asexual 
erythrocytic stage (Figure 1.1). 
When a merozoite comes into contact with an erythrocyte, the parasite forms a close 
irreversible connection between itself and the erythrocyte and the parasite becomes 
completely enclosed in a membranous vacuole, known as the parasitophorous vacuole 
(Bannister and Mitchell, 2003). 
Not all parasites within the infected erythrocytes enter into the cyclic asexual stage. 
Some differentiate into sexual forms known as gametocytes (Figure 1.1). When these 
gametocytes are taken up in the blood by a feeding mosquito, they transform themselves 
into gametes, and are eventually fertilized, leading to infection of the mosquito, and further 
transmission to human hosts.  
Those parasites entering into the asexual erythrocytic stage spread into thin 
biconcave discs within the erythrocytes. These discs are thicker around their perimeter, due 
to the elongated nucleus, and thin in their centre, making them appear ring-shaped when 
stained with Giemsa stain (Bannister and Mitchell, 2003). The parasites feed and enlarge 
during this stage and synthesize specific proteins necessary for the duration of the asexual 
erythrocytic stage. The parasites export some of these proteins into the erythrocyte, which 
causes modification of the erythrocyte membrane, resulting in the erythrocytes adhering to 
the lining of blood vessels.  
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Figure 1.1. The life cycle of Plasmodium falciparum. 
The liver stage, the erythrocytic sexual and asexual stages within humans, and the stages of parasite 
life within the salivary glands and gut of the mosquito are shown. (http://parasites.trends.com; 




The rings grow into rounded trophozoites, which undergo schizogony. Schizogony involves 
a number a nuclear divisions, generating approximately 16 nuclei from 1 schizont. These 
nuclei bud off from the central cytoplasmic body of the schizont. These are newly formed 
merozoites and they are released from the erythrocyte, to infect new erythrocytes, 
continuing the life cycle of the parasite.  
Due to the parasites severe pathogenicity and ability to exploit these different 
environments, it is apparent that an effective method of protection from the disease is 
urgently needed.  
 
1.3 Malaria control 
Malaria is becoming increasingly problematic to control and combat. A number of 
strategies have been implemented to aid in combating malaria: anti-malarial drug 
treatments, long lasting insecticide-treated mosquito nets and residual indoor spraying with 
insecticides (World Health Organisation, 2008). However, surveys performed by the World 
Health Organisation, revealed that insecticide-treated mosquito nets and effective anti-
malarial drugs were not reaching a sufficient portion of the malaria-affected population, 
especially in Africa. In addition, anti-malarial drugs are becoming ineffective due to 
Plasmodium developing resistance to the drugs (Baird, 2005; Mutabingwa, 2005), and the 
artemisinin-based combination therapies that are effective are very costly, especially for 
those who are economically disadvantaged (Mutabingwa, 2005). Furthermore, 
Plasmodium‟s vector, the mosquito, is becoming increasingly resistant to insecticides 
(Bannister and Mitchell, 2003), thereby making insecticide spraying increasingly 
ineffective. Therefore it appears as though the most effective long-term solution would be 
to develop an effective, inexpensive vaccine against Plasmodium, which could be used in 
combination with mosquito nets and insecticides. However, developing a malaria vaccine is 
a complex undertaking. Plasmodium is a very complex parasite with great antigenic 
variation between species and strains and one has to identify suitable antigens from a 
genome of approximately 5300 genes (Gardner et al., 2002), of which less than half have 
been assigned a function (Tedder et al., 2010). Once suitable antigens have been identified, 
those antigens need to be recombinantly produced, which can be problematic due to a 
number of factors. Among the factors contributing to the difficulties of recombinantly 
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expressing the antigens are: the rich adenine and thymine content of the genome (Gardner 
et al., 2002); Plasmodium using a different set of codons to that of the expression hosts; the 
expressed antigens may not be correctly folded which raises problems for immunogenic 
conformational epitopes that may be on the native protein. The antigens chosen may also 
have a large degree of variability across species and strains, which may result in the 
immune response elicited by that antigen to be ineffective at protecting against a different 
strain or species. The adjuvant used with the antigen can also make large differences in 
whether the antigen elicits a strong protective response or not, as experienced with the 
RTS,S vaccine candidate (Stoute et al., 1997). 
 
1.4 Immune response to malaria 
Humans living in a malaria-endemic area are able to naturally acquire protective 
immunity to Plasmodium. However, obtaining this protective immunity is a slow process 
requiring repeated exposure to parasites and rarely results in sterile immunity, as low levels 
of parasites and rare occurrences of severe clinical disease are still observed (Perlmann and 
Troye-Blomberg, 2000; Hviid, 2005; Langhorne et al., 2008). Both B cells and T cells and 
their products are required for immunity against malaria. For the purpose of this study, the 
role of T cells in the immune response to malaria will be briefly discussed here.  
Studies have been done with regards to the immune response to malaria in both B 
cell deficient and T cell deficient (athymic) mice (Weinbaum, et al., 1976; Grun and 
Weidanz, 1981; Grun et al., 1985; Cavacini et al., 1990; van der Heyde et al., 1994). Grun 
and Weidanz (1981) showed that in B cell deficient mice, P. chabaudi adami infection was 
resolved by a T cell dependent immune response, similar to that seen in immunologically 
intact mice. In contrast, athymic nude mice (mice without functioning T cells) were unable 
to resolve P. chabaudi adami infection (Grun et al., 1985; Brake et al., 1988; Cavacini et 
al., 1986; Cavacini et al., 1990). B cell deficient mice infected with P. vinckei petteri or P. 
chabaudi chabaudi resolved their infections in a manner similar to immunologically intact 
mice (Cavacini et al., 1990).  
In order to identify the individual T cells, revised experiments were conducted using 
subsets of T cells. Adoptive transfer of spleen cells has also been investigated (Cavacini et 
al., 1986; Brake et al, 1988; Goldring et al., 1989; van der Heyde et al., 1994). In these 
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studies, non-immune and immune spleen cells or a cloned T cell line were adoptively 
transferred to athymic mice. Infections in mice adoptively transferred with immune spleen 
cells, resolved their infections earlier than mice adoptively transferred with normal spleen 
cells. In addition, athymic mice adoptively transferred with T cell enriched spleen cells 
were able to resolve their infections. In contrast, mice adoptively transferred with B cell 
enriched spleen cells succumbed to infection and died. 
Severe combined immunodeficient (SCID) mice reconstituted either with immune 
spleen cells or immune T cells were able to suppress infection with P. chabaudi adami (van 
der Heyde et al., 1994). In contrast, unreconstituted SCID mice were unable to control their 
infections. Mice that received immune spleen cells had lower parasitemia than mice that 
received non-immune T cells (van der Heyde et al., 1994).  
In addition, a T cell clone designated CTR2.1 was able to adoptively transfer 
protection against P. chabaudi adami infection, to athymic mice (Brake et al., 1988). 
Athymic mice adoptively transferred with the CTR2.1 T cell clone, produced antibodies 
against an array of P. chabaudi adami proteins (Goldring et al., 1989). Immmunologically 
intact mice produced a similar antibody response, whereas athymic mice not adoptively 
transferred did not. These antibodies were shown to not contribute towards protection in 
challenged mice. T cells exhibiting a Th1 phenotype have also been shown to provide 
protection against P. yoelii infection in adoptively transferred SCID mice (Makobongo et 
al., 2003).  
 
1.5 Immune evasion by the parasite 
The parasite is able to evade the immune system by a number of different means, 
including, among other strategies, antigenic variation, alternative red blood cell invasion 
pathways and the presence of cryptic epitopes. 
 
1.5.1 Antigenic variation 
The parasite uses antigenic variation to evade the host immune system. P. 
falciparum has large families of variant genes known as var, rif, stevor and Pfmc-2TCM. 
These genes are located at the sub-telomeres and respectively code for the erythrocyte 
membrane protein 1 (PfEMP1), repetitive interspersed family (Rifin), subtelomeric variable 
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open reading frame (Stevor) and Mauer‟s cleft two transmembrane (Pfmc-2Tm) proteins 
(Casares and Richie, 2009). These proteins bind to host receptors, mediating rosetting and 
sequestration of the host erythrocytes, causing major mortality. Antibodies to these proteins 
form an important part of the host immune response to the parasite. As the parasite has 
many var, stevor, rif and Pfmc-2Tm genes, the parasite is able to evade the host immune 
system antibody response by simply expressing different variants of the proteins which will 
not be recognised by the antibodies (Casares and Richie, 2009). 
 
1.5.2 Alternative erythrocyte invasion pathways 
During the blood stage of the parasite life cycle, merozoites attach to erythrocytes 
randomly via merozoite surface protein-1 (MSP-1). Apical membrane antigen-1 (AMA-1) 
mediates the re-orientation of the merozoite in order for a tight junction to be formed 
between the parasite apical complex and the red blood cell, allowing the parasites 
hydrolytic enzymes to disrupt the red blood cell membrane. This tight junction is formed by 
erythrocyte binding ligands (EBLs) and reticulocyte binding protein homologues (RBLs) 
(Cortes, 2008). The EBL are encoded by the EBA175, EBA140/BAEBL and 
EBA181/JESEBL genes. The RBL genes express the PfRh1, PfRH2a, PfRH2b and PfRH4 
ligands. The parasite typically uses a sialic acid dependent invasion pathway, which uses 
the EBLs and PfRh1. However, antibodies against these proteins are able to prevent red 
blood cell invasion (Kinyanjui et al., 2004; Gao et al., 2008). The parasite is able to switch 
to using a sialic acid independent pathway, which utilise PfRh2a and PfRh4, thereby 
escaping the effects of the antibodies against the EBLs and PfRh1 (Stubbs, et al., 2005). 
 
1.5.3 Cryptic epitopes 
Immunogenic epitopes that are „hidden‟ or „invisible‟ to the host immune system 
are known as cryptic epitopes. Cryptic epitopes have been identified in P. chabaudi adami 
apical membrane protein 1 (AMA-1) (Amante et al., 1997), P. falciparum circumsporozoite 
protein (CSP) (Rathore et al., 2005). Cryptic epitopes that appear conserved across many 
species of Plasmodium have been identified in thrombospondin-related anonymous protein 
(TRAP) and CSP (Bharadwaj et al., 1998). These epitopes have been shown to induce 
invasion-blocking antibodies, although only when the epitopes are immunised in peptide 
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form, and not when the protein is in its native form or recombinantly produced, suggesting 
that these immunologically unresponsive epitopes are an evasion strategy for the parasite 
(Rathore et al., 2005). 
 
1.6 Vaccines 
Malaria vaccine candidates typically target different stages of the parasite life cycle 
(Figure 1.2). There are numerous vaccine candidates in various stages of research, 
production and trials, against multiple Plasmodium targets. An overview of a few of the 



















1.6.1 Attenuated sporozoite vaccine 
Attenuated sporozoites are able to infect the hosts liver, but maturation and 
differentiation into merozoites is hampered, resulting in the Plasmodium infection not 
developing into clinical malaria (Frevert and Nardin, 2005).  
Figure 1.2. Malaria vaccine candidates and the stages of the parasite life cycle the vaccines 
target. 
(Image adapted from http://sciencetrio.files.wordpress.com/2009/07/malaria-cycle1.jpg). 
Pre-erythrocytic liver stage vaccine 
candidates 















Other vaccine candidates 
Anti-GPI anchor vaccine; multi-antigen, multi-
stage vaccine candidates; DNA vaccines 
Asexual erythrocytic vaccine candidates 
MSP-1; MSP-2; MSP-3; GLURP, AMA-1; 
SPf66; SERA (P126); PfCP-2.9 (MSP-1 and 




Sedegah et al. (2007) showed that protection could be achieved in mice against 
different Plasmodium strains. Mice immunised with radiation-attenuated P. yoelii 
sporozoites were 100% protected when challenged with P. yoelii sporozoites and 63% 
protected when challenged with P. berghei sporozoites. Mice immunised with P. berghei 
radiation-attenuated sporozoites were 100% protected when challenged with P. berghei 
sporozoites and 79% protected when challenged with P. yoelii sporozoites. Humans have 
also been shown to be protected with radiation-attenuated sporozoites: in total, 24 of 26 
volunteers were protected against P. falciparum challenge (Hoffman et al., 2002). Those 
protected included volunteers challenged 23-42 weeks after their second immunisation and 
challenge with P. falciparum. 
A concern with radiation attenuated sporozoites is that the radiation dose needs to 
be precise for the immunisation to work effectively and safely (VanBuskirk et al., 2009). 
Although there is concern about precise radiation dose for attenuated sporozoites, 
Chattopadhyay et al. (2009) have shown that increasing the minimal dose necessary to 
attenuate sporozoites for immunisation in mice can safely be doubled and still provide 
protection, thereby indicating that this may be possible for sporozoites for immunisation in 
humans which will ensure safety without reducing the efficacy. 
Alternative methods for attenuating parasites exist. One way is to chemically 
attenuate them with the DNA binding drug, centanamycin, as Purcell et al. (2008) did. The 
immunised sporozoites provided sterile immunity and cross protection against heterologous 
challenge.  
Another method of attenuation is genetic attenuation. The pre-erythrocytic stage of 
P. berghei has been genetically attenuated by deletion of genes called „up-regulated in 
infectious sporozoites gene 3‟ (UIS3) (Mueller et al., 2005b) and UIS4 (Mueller et al., 
2005a). Two other genes, P36 and P52, have been simultaneously deleted in P. yoelii 
sporozoites, resulting in the parasites not forming a parasitophorous vacuole within liver 
cells in vitro or in vivo. Genetically modified sporozites such as P36/52 deficient and UIS3 
and UIS4 deficient sporozoites develop normally within the mosquito host and invade the 
liver, but cannot develop into liver stage parasites and therefore become arrested in the 
liver. The sporozoites do not develop into blood stage forms, irrespective of the number of 
sporozoites inoculated (Labaied et al., 2007). Mice immunised with UIS3 deficient 
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sporozoites or UIS4 deficient sporozoites, were completely protected when challenged with 
P. berghei, (Mueller et al., 2005b; Mueller et al., 2005a). Mice immunised with P36/P52 
deficient sporozoites were also completely protected when challenged with infected 
sporozoites (Labaied et al., 2007). It is for this reason that these genes were deleted in P. 
falciparum sporozoites and used to inoculate a humanised mouse model (Van Buskirk et 
al., 2009). The parasites did not develop into blood stage forms. 
Thus, an attenuated sporozoite vaccine appears to be the most promising vaccine for 
providing sterile immunity to malaria. However, there are concerns of attenuation efficacy 
as mentioned above. As the sporozoites are obtained from dissecting mosquito salivary 
glands a further concern is whether it will be possible to provide large quantities of sterile 
sporozoites that are not contaminated with mosquito debris (Luke and Hoffman, 2003; 
Fervert and Nardin, 2005). Additional concerns are the route of immunisation and cryo 
preservation of the sporozoites (Luke and Hoffman, 2003; Fervert and Nardin, 2005), 
especially considering that most of the people requiring the vaccine, live in climates with 
excessive heat and are unlikely to have the facilities to store the sporozoites.  
 
1.6.2 Pre-erythrocytic vaccines 
The aim of pre-erythrocytic or liver stage vaccines is to protect against malaria 
infection. Ideally these vaccines should prevent invading sporozoites from entering the 
liver, and alternatively, or additionally, inhibit sporozoite maturation. There are a number 
of pre-erythrocytic candidate vaccines in various stages of development. A few are listed in 
Table 1.1. The most advanced liver-stage candidate vaccine at the moment is the 
recombinant RTS,S vaccine, which consists of amino acids 207-395 of the C-terminus of P. 
falciparum circumsporozoite protein (CSP), fused to the hepatitis B surface antigen (Stoute 
et al., 1997). In initial phase I clinical trials, RTS,S was administered with AS02 adjuvant, 
which is a combination of an oil-in water emulsion, monophosphoryl lipid A and saponin 
isolated from the soapbark tree Quillaja saponaria (QS21). Six out of seven volunteers 
were protected against malaria challenge. At sixty days post-challenge, those protected 
individuals that were still malaria-free and asymptomatic remained so for more than three 
additional months (Stoute et al., 1997). 
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RTS,S has been tested with two different adjuvant systems:AS01 and AS02 (Bejon 
et al., 2008). AS02 consists of an oil-in-water emulsion, QS21 and monophosphoryl lipid 
A, and AS01 consists of a liposome-based related adjuvant containing monophosphoryl 
lipid A and QS21. The RTS,S vaccine given with the adjuvant AS01B was shown to have 
an efficacy of 50% in contrast to 32% for the RTS,S vaccine given with the adjuvant 
AS02A (Kester et al., 2009). Protected individuals were re-challenged 5 months after their 
initial challenge and 44% were protected. Protected individuals had higher CSP specific 
IgG titres and a higher number of CSP-specific, IFN-γ-producing, CD4
+
 T cells. Sun et al. 




 T-cells producing IFN-
γ, during their studies of volunteers protected from malaria by RTS,S immunisation. 
Efficacy of RTS,S/AS01 has been tested in young children of 5-17 months old. Of 
the 402 children who received RTS,S/AS01 vaccinations, 32 developed malaria, resulting 
in an adjusted vaccine efficacy of 56% (Bejon et al., 2008). In addition, Sacarlal et al. 
(2009) performed a Phase 2b trial in Mozambican children aged 1-4 years old. There was a 
notable decrease in malaria-related mortality in the group that were immunised with 
RTS,S/AS02 in comparison to the control group: over the 45 month surveillance period, 63 
cases of severe malaria were experienced by volunteers who were immunised with 
RTS,S/AS02 (4.6%) in comparison to 83 cases in the control group (7%). Thus the RTS,S 
vaccine appears to be a promising vaccine candidate providing moderate protection. 
 
1.6.3 Asexual erythrocytic stage vaccines 
Asexual eryhtrocytic stage vaccines aim to protect against malaria by reducing the 
number of parasites and thereby reducing the number of deaths of infected people. Table 
1.2 lists a number of the asexual erythrocytic stage candidate vaccines under investigation. 
Possibly the most advanced asexual erythrocytic stage vaccine candidates at the moment 
are those using the antigens glutamate-rich protein (GLURP), apical membrane antigen 1 






Table 1.1. Pre-erythrocytic vaccine candidates  
Vaccine candidate Composition of vaccine Protective efficacy 
CS102 CS102 is a 102 amino acid peptide 
representing the C-terminus of CSP. 
Immunisation of human volunteers with CS102 induced 




 T-cells (Prato 
et al., 2005). However the vaccine candidate has failed to protect 
against experimental malaria challenge in Phase I and IIa clinical 
trials (Girard et al., 2007). 
   
ICC-1132/ Malariavax  A modified Hepatitis B virus core 
protein, expressing the central repeat 
regions of P. falciparum CSP. This 
region contains a B-cell epitope 
(NANP)3 and a CD4
+
T-cell epitope 
(NANPNVDPNANP), in addition to a 
universal T cell epitope (Gregson et 
al., 2008). 
The ICC-1132 vaccine candidate is well tolerated (Oliveira et 
al., 2005; Walther et al., 2005; Gregson et al., 2008). T-cells 
secreting IFN-γ and IL-2, in addition to antibodies to CSP and 
Hepatitis B virus core protein, were detected (Nardin et al., 
2004; Oliveira et al., 2005, Walther et al., 2005). However, no 
protection was observed in volunteers challenged with P. 
falciparum sporozoites (Walther et al., 2005). It was proposed 
that more potent adjuvants should be used to increase the 
immunogenicity of the vaccine candidate (Gregson et al., 2008). 
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Table 1.2. Erythrocytic stage vaccine candidates under development and their relative efficacies 
Vaccine candidate Composition of vaccine Protective efficacy 
SPf66 Synthetic peptide vaccine containing blood 
stage and sporozoite stage antigens, but is 
predominantly targeted against the blood 
stage of the parasite life cycle 
Trials of SPf66 revealed the efficacy to be too low, especially in 
Africa. It was mildly protective in some trials in South America but 
was deemed to be too weak to warrant further testing (Acosta et al., 
1999; Graves and Gelband 2006). 
   
Glutamate-rich protein 
(GLURP)  
A long synthetic peptide (AA 85-213 of 
GLURP) 
A Phase I trial induced a cellular and humoral immune response 
with large quantities of antibodies, predominantly cryophilic IgG1. 
Serum collected from volunteers thirty days after their last 
immunisation inhibited parasite growth in vitro in the presence of 
monocytes (Hermsen et al., 2007). 
   
Merozoite surface protein 
(MSP)-1  
The 42 kDa C-terminus of MSP-1(FMP1) FMP1/AS02 was considered to not have sufficient potential as a 
monovalent vaccine candidate in a Phase IIb trial (Ogutu et al., 
2009).  
   
MSP-119 The 19 kDa C-terminus of MSP-1 Antibodies to MSP-119 were shown to play an important role in 
suppressing parasitemia in mice (de Koning-Ward et al., 2003) and 





Table 1.2. Erythrocytic stage vaccine candidates under development and their relative efficacies (continued) 
 
Vaccine candidate Composition of vaccine Protective efficacy 
MSP-2 Two long synthetic peptides 
(LSP) representing both allelic 
forms of MSP-2. 
Peptide specific antibodies were associated with protection 
against malaria, and immunisation of mice with the peptides 
elicited a strong antibody response. The antibodies 
recognised native MSP-2 (Flueck et al., 2009). 
   
MSP-3 MSP-3 LSP Phase Ib trial was found to be safe, well tolerated in 
Tanzanian children aged 12-24 months. The vaccine elicited 
cytophilic antibodies, thereby providing affirmation that the 
vaccine should be evaluated in a phase II trial to test MSP-
3‟s ability of protecting against P. falciparum infection 
(Lusingu et al., 2009).  
   
Apical membrane antigen 
(AMA)-1 
Recombinant AMA-1 A Phase I/IIa efficacy trial revealed AMA-1 to be highly 
immunogenic, however, the immunogenicity did not 
translate into adequate protection against sporozoite 









Table 1.2. Erythrocytic stage vaccine candidates under development and their relative efficacies (continued) 
 
 
Vaccine candidate Composition of vaccine Protective efficacy 
„Combination B‟ The „combination B‟ vaccine consists 
of MSP-1, MSP-2 and ring-stage 
infected-erythrocyte surface antigen 
(RESA). 
A 62% reduction in parasites was observed in 
volunteers vaccinated with the „combination B‟ vaccine 
candidate in a phase I/IIb trial (Genton et al., 2002). 
Only the one allelic form (3D7) of MSP-2 was used in 
the vaccine which resulted in breakthrough infections 
with parasites of the FC27 allele genotype, thereby 
indicating that both allelic forms of MSP-2 need to be 
included in the vaccine for it to be completely effective 
(Flück et al., 2004).  
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1.6.4 Transmission blocking vaccines 
Transmission blocking vaccines aim to prevent the development of infectious 
sporozoites in the salivary glands of Anopheles mosquitoes, thereby preventing the infection 
of human hosts. These vaccines aim to achieve this by inducing the production of antibodies 
against sexual stage antigens (Lavazec and Bourgouin, 2008; Sutherland, 2009). Among the 
candidate transmission blocking vaccines in development at the moment are the P. falciparum 
ookinete surface antigens Pfs25 and Pfs28, the P. vivax ookinete surface antigens Pvs25 and 
Pvs28, Pfs230 and Pfs48/45. 
Evaluation of Pfs48/45 immunity using membrane feeding assays in mice showed 
effective transmission blocking action (Outchkourov et al., 2008; Chowdhury et al., 2009). 
High antibody titres and transmission blocking activity of greater than 93% was experienced 
when Pfs48/45 was given to Olive baboons (Chowdhury et al., 2009), indicating its potential 
as a promising transmission blocking vaccine candidate for humans. 
Mice vaccinated with Pvs25 and Pvs28 produced antisera that recognised the antigens 
and completely blocked the transmission of parasites (Hisaeda et al., 2000). In a Phase I 
human vaccine trial of Pvs25 adsorbed onto Alhydrogel
®
, transmission blocking immunity 
was observed although the level of transmission blocking was not sufficiently high for a 
feasible vaccine (Malkin et al., 2005). It was thought that a more potent adjuvant would 
provide a more immunogenic result. Thus, Pvs25 and Pfs25 were formulated with Montanide 
ISA 51 and administered to humans during a Phase 1 trial. The trial had to be discontinued due 
to adverse systemic reactions experienced by the volunteers, possibly due to the combination 
of the antigen and the Montanide ISA 51 (Wu et al., 2008). However, sufficient data was 
obtained from the individuals immunised with Pfs25 prior to the closure of the vaccine trial, 
indicating that Pfs25 was able to induce transmission blocking antibodies in humans. Thus 
suggesting that a Pfs25 vaccine would be feasible, provided that the systemic reactions could 
be minimised (Wu et al., 2008). 
 
1.6.5 Alternative vaccine approaches  
1.6.5.1 Multi-stage, multi-antigen vaccines 
Multi-stage, multi-antigen vaccine candidates are composed of a number of parasite 
antigens from many of the stages of the parasites life cycle. The benefits of such an approach 
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are the possibility of overcoming the problems associated with antigenic variation and the 
parasite evading the host immune system (Stanley, 1998; Girard et al., 2007). However, this 
approach may come with problems, including the possibility of the different components of 
the vaccine producing adverse reactions when combined, or interacting negatively with each 
other (Girard et al., 2007). Two of the multi-stage, multi-antigen vaccines that will be 
discussed briefly here, are the NYVAC-Pf7 (Tine et al., 1996) and FALVAC-1A vaccine 
candidates.  
NYVAC-Pf7 was constructed with an attenuated NYVAC vaccinia virus strain, 
expressing seven P. falciparum antigens. The antigens are from different stages of the parasite 
life cycle: CSP, sporozoite surface protein 2. (sporozoite stage); liver stage antigen 1 (liver 
stage); MSP-1, serine repeat antigen (SERA), AMA-1 (blood stage) and a 25 kDa sexual stage 
antigen (gametocyte stage) (Tine et al., 1996). NYVAC-Pf7 was shown to be safe in Rhesus 
monkeys and to produce antibodies against antigens in all stages of the parasite life cycle 
(Tine et al., 1996). Disappointing results were obtained in a phase I/IIa trial as NYVAC-Pf7 
did not protect human volunteers, against P. falciparum infection (Ockenhouse et al., 1998), 
however the time from infection to appearance of parasites in the blood was significantly 
longer in volunteers immunised with NYVAC-Pf7, in comparison to volunteers receiving the 
control. 
FALVAC-1A consists of 21 B-cell, cytotoxic T cell and helper T cell epitopes from P. 
falciparum proteins found in the sporozoite, liver, erythrocytic and sexual stages of the 
parasite life cycle, in addition to a tetanus toxoid helper epitope (Zhou et al., 2006). 
FALVAC-1A was shown to be highly immunogenic in rabbits and to induce in vitro 
sporozoite inhibiting antibodies (Zhou et al., 2006). In 2008, Ravi et al. showed that it was 
possible to produce industrial scale, clinical grade FALVAC-1A for clinical trials at a 
reasonable cost. Mice immunised with FALVAC-1A elicited antibodies capable of 
recognising P. falciparum sporozoites and blood stage parasites (Kaba et al., 2008). Further 
trials need to be completed to assess the efficacy and safety for human trials.  
 
1.6.5.2 Glycophoshatidylinositol (GPI) anchor 
The GPI anchor is involved in securing several Plasmodium antigens to the membrane and 
induces tumour necrosis factor (TNF)- and interleukin (IL)-1 production, in addition to 
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hypoglycaemia. It is therefore postulated that GPI may have a role in the pathogenesis of 
malaria infections (Schofield et al., 1993) and therefore targeting the molecule may provide an 
anti-disease vaccine. Schofield et al. (1993) have shown that monoclonal antibodies to 
Plasmodium GPI were able to neutralise the toxicity of Plasmodium parasites. Mice 
immunised with a synthetic P. falciparum GPI glycan and subsequently challenged, were 
significantly protected (58.3-75% survival) in comparison to control mice (0-8.7% survival). 
This data suggests that an anti-GPI vaccine may be feasible (Schofield et al., 2002). 
 
1.6.5.3 DNA vaccines 
DNA-based vaccines allow expression of recombinant protein in mammalian cells. 
This is made possible by immunisation with a recombinant plasmid or viral vector encoding 
specific protective antigens (Ivory and Chadee 2004). The advantages of DNA-based vaccines 
are that they are considerably cheaper to produce, they do not require to be kept cold and they 
have a long shelf life. In addition, DNA-based vaccines are relatively easy to produce and 
induce strong T-cell responses, making them a promising avenue for producing a malaria 
vaccine (Le et al., 2000). 
The majority of the malaria DNA candidate vaccines undergoing various stages of 
development involve vectors containing the gene expressing CSP. Sedegah et al. (1998) 
showed that BALB/c mice immunised with a plasmid expressing P. yoelii CSP were protected 
by the vaccines induction of CD8
+
 T-cells and IFN-γ. Mice immunised with the plasmid DNA 
and boosted with recombinant vaccinia expressing the P. yoelii CSP were better protected 
(11/16 mice protected) than mice immunised with the plasmid DNA and boosted with the 
plasmid DNA (7/16 mice protected). Similarly, mice immunised with a multi-epitope P. 
chabaudi adami DNA vaccine were protected against P.chabaudi adami challenge via 
opsonising antibodies and IFN-γ production (Scorza et al., 2005). Intramuscular injection of P. 
falciparum CSP plasmid DNA in healthy adults was shown to be safe and well tolerated. No 
antigen-specific antibodies were detected in volunteers; however the vaccine did induce 
cytotoxic T-cell responses (Le et al., 2000).  
Another DNA vaccine candidate in development is the multi-stage DNA vaccine 
operation (MuStDO) 5. MuStDO 5 is a multivalent plasmid DNA vaccine, composed of 5 
plasmids encoding P. falciparum antigens and one plasmid encoding human granulocyte-
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macrophage colony-stimulating factor (GM-CSF) (Parker et al., 2001). GM-CSF is included 
to enhance the immunogenicity of the vaccine. The other 5 plasmids encode CSP; sporozoite 
surface protein-2 (SSP2), also known as thrombospondin-related anonymous protein (TRAP); 
exported protein-1 (EXP-1); liver stage antigen-1 (LSA-1) and liver stage antigen-3 (LSA-3). 
The vaccine was shown to be safe in mice and rabbits as no severe pathology normally 
associated with GM-CSF was observed. The investigators believe that these results show the 
potential for healthy volunteers to be immunised with MuStDO 5 and subsequently challenged 
with P. falciparum in a phase I/II clinical trial (Parker et al., 2001). 
 
1.7 Objective of the present study 
The objective of the present study was to express and purify a 822 bp sequence of the 
P. falciparum gene PFC0760c. PFC0760c is of unknown function and has been shown to have 
high sequence similarity to a 96 kDa P. chabaudi adami protein (Pca 96) (Smallie, 2003). Pca 
96 was shown to illicit a protective immune response in mice (Wanidworanun et al., 1987). 
Thus PFC0760c is of immunological interest. Additional objectives of the study were to 
identify the function of PFC0760c and to raise anti-peptide antibodies against the protein for 




General materials and methods 
 
General biochemical and molecular biology techniques used in the present study are detailed 
in this chapter. Experimental techniques more specific to particular chapters are described in 
their appropriate chapters. 
 
2.1 Materials 
The majority of the chemicals used in the present study were of analytical grade, purchased 
from Sigma (USA), Saarchem (South Africa), Roche Diagnostics (Germany), Merck (South 
Africa), Fluka Chemicals (Germany) and BDH (England). Distilled water (dH2O) from the 
Milli-Q Plus ultra pure water system from Millipore (USA), was used throughout this study.  
Coomassie brilliant blue R-250, Serva blue G, lauryl sulfate (sodium dodecyl sulfate), 
acrylamide, 4-chloro-1-naphthol, L-cysteine hydrochloride monohydrate, 3-hydroxy-4- [2-
sulfo-4- (4-sulfo-phenylazo) phenylazo]-2,7-napthalenedisulfonic acid (Ponceau S), Yeast 
extract powder, Freund‟s complete and incomplete adjuvants, glutathione agarose, reduced 
glutathione, 3-maleimidobenzoic acid N-hydroxysuccinimide ester (MBS), rabbit albumin, 
sodium borohydride (NaBH4), sodium cyanoborohydride (NaCNBH3), dithiothreitol (DTT), 
5,5‟-dithio-bis(2-nitrobenzoic acid) (Ellman's reagent), modified Hanks balanced salt, RPMI-
1640, chloramphenicol, pepstatin A, L-trans-epoxysuccinyl-leucylamido(4-guanidino)butane 
(E-64), soy bean trypsin inhibitor (SBTI), sodium bicarbonate, agarose, peroxidase-conjugated 
avidin, peroxidase-conjugated rabbit anti-chicken IgG and Sephadex G10 were all purchased 
from Sigma (USA). Glutaraldehyde, isopropyl-β-D-thiogalacto-pyranoside (IPTG), ampicillin 
sodium salt, dimethylsulfoxide (DMSO), N, N-dimethylformamide (DMF) and phenol were 
from Fluka (Germany). Nunc-Immuno
TM
 96-well plates were from Nunc Intermed (Denmark). 
Bovine serum albumin (BSA) fraction V, shrimp alkaline phosphatase, 2,2′-Azinobis[3-ethyl-
2,3-dihydrobenzthiazole-6-sulfonate (ABTS), Tris-base, DNTP mix, phenyl-
methylsulfonylfluoride (PMSF) and 4‟,6-diamidine-2‟-phenylindole dihydrochloride (DAPI) 
were purchased from Roche diagnostics (Germany). Peroxidase-conjugated rabbit anti-
chicken IgY, peroxidase-conjugated goat anti-rabbit IgG and fluorescein isothiocyanate 
(FITC)-conjugated donkey anti chicken IgY (IgG) were purchased from Jackson 
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Immunochemicals (USA). Triton X-100, NNN‟N‟-tetramethylethlenediamine (TEMED), 
chloroform and NN‟-methylenebis-acrylamide were purchased from BDH (England). Poly-
Prep
®
 chromatography columns, SDS-PAGE molecular weight standards (low range) and 
Precision Plus molecular weight markers were from Bio-Rad (USA). Whatman No. 1 filter 
paper was from Whatman International Ltd (UK). Leupeptin was purchased from Cambridge 
Research Chemicals (England). The plasmid pGEX4T1 was from GE Healthcare (USA). 
SnakeSkin
®




 resins were from Pierce 
Chemical Company (USA). The DNA MassRuler
TM 
marker was from Fermentas (Lithuania). 
Heparin coated Vacutainer
TM
 tubes were from BD Vacutainer Systems (UK). Sephadex
®
 G25 
fine was purchased from Pharmacia Biotech (Sweden). Tween 20, polyethylene glycol (PEG) 
6000, PEG 20 000, maltose, propan-2-ol, glycerol and D (+) glucose monohydrate were 
purchased from Saarchem (South Africa). Hybond-C extra nitrocellulose was purchased from 
Amersham Life Sciences (UK). FIREPol
®
 DNA polymerase I, 10X PCR buffer (Mg
2+
 and 
detergent free) and MgCl2 were purchased from Solis Biodyne (Estonia). Glycine, 2-
mercaptoethanol, methanol (99.8%), acetic acid (98%), tryptone powder (pancreatic digest of 
casein) and bacteriological agar were purchased from Merck (South Africa). Low melting 
point (LMP) agarose, ethidium bromide solution, 1 kb DNA step ladder, Wizard

 PCR Preps 
DNA Purification System, EcoR1, Wizard
®
 DNA Clean-Up System, and the Wizard

 Plus SV 
Minipreps DNA Purification System were purchased from Promega Corporation (USA). 
DNAse-free RNAse A was purchased from Boehringer Mannheim (Germany). Amylose resin, 
rabbit anti-MBP antiserum, pMAL-c2X, SacI, BamHI, AccI and Factor Xa were purchased 
from New England Biolabs (USA). Biotinylated mouse monoclonal anti-GST Tag IgG was 
from AnaSpec Incorporated (USA). Terumo® U-100 insulin 1cc 27 Gauge x ½” syringes were 
from Terumo medical corporation (USA). BALB/c mice were from the National Health 
Laboratory Service Animal Unit (South Africa). Syringes (2 ml) were from Promex (South 
Africa) and hypodermic 20G x 1½” needles were from Tae-Chang Industrial Company 
(Korea). Glass slides were purchased from Separations (South Africa) and Ziploc
®
 bags were 
from S. C. Johnson & Son (Pty) Ltd. (South Africa). The peptides FKLGSCYLYIINRNLKEI 
and CFKLGSCYLYIINRNLKEI were synthesized by GenScript Corporation (USA) and the 
peptide SDDDNRQIQDFEC by Auspep (Australia). DNA primers were synthesized by 
Integrated DNA Technologies Inc. (USA). Slides (8 mm, 8-well) were purchased from MP 
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Biomedicals (USA). Elite fat-free powdered milk was from Clover (South Africa). Professor 
Wim G.J. Hol (Howard Hughes Medical Institute and Department of Biological Structure, 
University of Washington, USA) kindly provided the RIG plasmid.   The plasmids pKK223-3-
PfLDH (expressing Plasmodium falciparum lactate dehydrogenase) and pKK223-3-PvLDH 
(expressing Plasmodium vivax lactate dehydrogenase) were kindly supplied by Leo Brady 
(Department of Biochemistry, University of Bristol, UK).   
Images of western blots, SDS-PAGE gels and agarose gels were captured using the 
VersaDoc
TM
 imaging system and Quantity One software from Bio-Rad (USA). The 
absorbance of ELISA plates were read with a Versamax tunable microplate reader using 
SOFTmax
®
PRO software from Molecular Devices (USA).  Polymerase chain reaction (PCR) 
was performed using the GeneAMp
®
 PCR system 2700 or 9700 from Applied Biosystems 
(USA). Sonication of bacterial cells was performed with the VirSonic 60 Virtis from The 
Virtis Company (USA). Absorbance readings were taken using the Ultrospec 2100 pro 





 (Germany). Centrifugation was performed with the following 
centrifuges: Biofuge pico microcentrifuge from Heraeus Sepatech (Germany), Sigma 3K20 
from Sigma Laboratory centrifuges (USA), the J2-21M and J2-21 from Beckman (USA), and 
the Avanti J-26 XPI from Beckman Coulter (USA). SDS-PAGE gels were run using the Mini-
Protean
®
 II equipment and western blotting was performed using the Mini Trans-Blot
®
 cell, 
both from Bio-Rad (USA). Agarose gels were run using the GES and mini-GES 
electrophoresis equipment from Wealtec Corporation (USA). Incubation of western blots with 
antibodies and silverstaining was performed on The Belly Dancer (Stovall Life Science Inc., 
USA),  
Ethical approval for the animal procedures performed in the present study was 
obtained from the University of KwaZulu-Natal animal ethics committee (025/08/animal). 
 
2.2 Bradford protein assay 
The Bradford method (Bradford, 1976) of protein concentration determination was used 
routinely to determine the amount of protein present in samples. The assay involves the dye 
reagent binding predominantly to arginine residues of proteins (Compton and Jones, 1985). 
The Bradford assay is rapid, highly sensitive and produces reproducible results. Read and 
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Northcote (1981) modified the assay, resulting in increased sensitivity and less variation in 
response to different proteins. The dye can be dissolved in a solution of ethanol: phosphoric 
acid (1:2) which is stable for 1-2 weeks kept in the cold, or 2% (v/v) perchloric acid which is 
the preferable method due to the dye being indefinitely stable (Scopes, 1994). 
 
2.2.1. Reagents 
Bradford dye reagent. Coomassie brilliant blue G-250 (0.6 g) was dissolved in 2% (v/v) 
perchloric acid (1 l) by stirring for approximately 1 h. The dye was filtered through Whatman 
no. 1 paper and stored in an amber bottle at room temperature. If precipitate was observed, the 
dye was filtered and the standard curve was recalibrated. 
2% (v/v) perchloric acid. Perchloric acid (27.8 ml) was made up to 1 l with dH2O. 
Ovalbumin stock solution (1 mg/ml). Ovalbumin (0.001 g) was dissolved in 1 ml dH2O.  
 
2.2.2 Procedure 
Ovalbumin standards (0-100 μg) were used to construct a standard curve (Figure 2.1). 
Quintuplicate samples of 0-100 μl of the 1 mg/ml ovalbumin solution were made up to 100 μl 
with dH2O. Bradford dye reagent (900 μl) was added to each of the ovalbumin samples (100 
μl) and vortexed. The samples were left for 5 minutes before reading the absorbance at 595 
nm. Protein samples of unknown concentration were made up to 100 μl with dH2O and mixed 
with Bradford dye reagent (900 μl) as explained for the standard ovalbumin samples. The 
standard curve (Figure 2.1) was then used to determine the protein concentration, from the 

























2.3 Concentration of protein samples 
It was often necessary to concentrate dilute protein solutions before analysing them with SDS-
PAGE or before continuing with further purification steps. Dilute protein samples were 
concentrated by dialysis against polyethylene glycol (PEG) 20 000 or SDS-KCl precipitation 
for proteins requiring further concentration before loading onto sodium dodecyl sulfate poly 
acrylamide gel electrophoresis (SDS-PAGE) gels (Trask and Muller, 1983). 
 
2.3.1 Dialysis against PEG 20 000 
PEG 20 000 is a dry hydrophilic polymer that can be used as a simple, cost-effective method 
of concentrating dilute protein samples. The PEG 20 000 draws water in the protein sample 
through the dialysis membrane, thereby concentrating the protein sample. 
 
2.3.1.1 Materials 
Dialysis tubing (10 000 MW cut-off). 
PEG 20 000. 
Figure 2.1. Bradford standard curve constructed from ovalbumin. 
y = -4E-05x
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Gloves were worn throughout the concentration procedure to eliminate contamination of the 
protein sample with skin keratins. The protein sample to be concentrated was placed into 
dialysis tubing (10 000 MW cut-off) and sealed with dialysis clips. The dialysis bag was 
placed into a container and covered with thick layer of PEG 20 000. The container was left at 
4˚C until the protein sample had been sufficiently concentrated. The dialysis bag was removed 
from the container and rinsed with dH2O to remove any PEG 20 000 that had adhered to the 
dialysis tubing, before removing the concentrated protein sample.  
 
2.3.2 SDS-KCl precipitation of proteins 
Proteins were precipitated with the SDS-KCl method (Trask and Muller, 1983) whenever the 
volume of protein solutions was too large to load into SDS-PAGE wells or when protein 
solutions were too dilute to view on an SDS-PAGE gel. The protein becomes coated with 
SDS, which then complexes to the potassium ion (K
+
). This results in an insoluble complex, 
which is effectively precipitated with centrifugation. The pellet can then be resuspended in a 
smaller volume, resulting in concentrated protein solution. 
 
2.3.2.1 Reagents 
5% (w/v) SDS. SDS (0.5 g) was dissolved in 10 ml dH20. 
3 M KCl. KCl (2.24g) dissolved in 10 ml dH20. 
 
2.3.2.2 Procedure 
10% (v/v) of a 5% (w/v) SDS solution and 10% (v/v) of a 3 M KCl solution were gently 
mixed with the protein solution. The solution was centrifuged (10 000 g, 2 min) in a desktop 
micro centrifuge. The pellet was resuspended in a reduced volume of solution C (Section 
2.4.1). An equivalent volume of reducing sample buffer (Section 2.4.1) was added, and the 
solution boiled for 2 min before loading onto an SDS-PAGE gel. 
 
2.4. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was performed according to the method described by Laemmli (1970) to analyse 
protein samples. The method involves boiling the proteins to be analysed with sodium dodecyl 
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sulphate (SDS), a strong anionic detergent. Under these conditions, the proteins become 
denatured and coated with SDS. The SDS masks the proteins with a negative charge thereby 
allowing the proteins to migrate through the gel matrix, toward the anode, separating, based on 
their molecular weight (Dennison, 1999). 
The gel is made up of chains of polymerized acrylamide, cross-linked by N, N-
methylene bis-acrylamide. The cross-linking forms pores for the protein to migrate through 
and provides the gel with rigidity and strength (Sambrook and Russell, 2001). The proportions 
of acrylamide and N, N-methylene bis-acrylamide can be varied to give a different pore size, 
which in turn results in gels capable of different ranges of protein separation. 
The protein samples were routinely boiled in the presence of β-mercaptoethanol, in 
addition to SDS. β-mercaptoethanol is a reducing agent able to cleave disulfide bonds. 
Cleaving disulfide bonds allows for the separation of protein subunits and polypeptide chains 
held together by disulfide bonds. 
 
2.4.1 Reagents 
Solution A: Monomer solution [30% (w/v) acrylamide, 2.7% (w/v) bis-acrylamide]. 
Acrylamide (29.9 g) and bis-acrylamide (0.8 g) were dissolved in 100 ml dH2O and filtered 
through Whatman no. 1 paper. The solution was stored in an amber, glass bottle at 4˚C. 
Solution B: Running gel buffer [1.5 M Tris-HCl, pH 8.8]. Tris (18.148 g) was dissolved in 
approximately 80 ml of dH2O and adjusted to pH 8.8 with HCl and the volume made up to 
100 ml. The solution was filtered through Whatman no. 1 paper and stored at 4˚C 
Solution C: Stacking gel buffer [0.5 M Tris-HCl, pH 6.8]. Tris (1.5 g) was dissolved in 20 ml 
dH2O and adjusted the pH to 6.8 with HCl. The volume was made up to 25 ml with dH2O. The 
solution was filtered through Whatman no. 1 paper and stored at 4˚C. 
Solution D: 10% (w/v) SDS (lauryl sulfate). SDS (10 g) was dissolved in 100 ml dH2O. 
Solution E: 10% (w/v) ammonium persulfate. Ammonium persulfate (0.1 g) made up to 1 ml 
with dH2O. 
Solution F: Tank buffer [250mM Tris-HCl, 192 mM glycine, 0.1% (w/v) SDS]. Tris (3 g) and 
glycine (14.4 g) were dissolved in dH2O and made up to 1 l. Just prior to use 10% (w/v) SDS 
(Solution D) was added (1 ml of 10% (w/v) SDS per 100 ml of tank buffer). 
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0.1% (m/v) Bromophenol blue. Bromophenol blue (0.001 g) was dissolved in 1 ml dH2O and 
stored at room temperature. 
SDS-PAGE sample buffer. 0.5 M Tris-HCl, pH 6.8 (solution C) (1.2 ml), glycerol (1 ml), 10% 
(w/v) SDS (solution D) (2 ml), 0.1% (w/v) bromophenol blue (0.5 ml) were mixed together 
and made up to 9.5 ml with dH2O. The buffer was stored at 4˚C. 
SDS-PAGE reducing sample buffer. Sample buffer (475 μl) was added to β-mercaptoethanol 
(25 μl) just before use, in a fume hood.  
N, N, N‟,N‟-tetramethylenediamine (TEMED). 
 
2.4.2 Procedure 
Running and stacking gels were prepared according to Table 2.1 depending on the 
concentration of acrylamide required. The gels were cast using a Bio-Rad Mini Protean
®
 II 
vertical slab electrophoresis unit. The running gel was cast first and allowed to set under a 
small layer of dH2O. The dH2O was poured off and the stacking gel layered on top of the 
running gel. The combs were placed into the stacking gel to form wells and left to set. The 
gels were assembled in the running tank and covered with tank buffer (Solution F). Protein 
samples for reducing SDS-PAGE were combined with reducing treatment buffer in a 1: 1 ratio 
and boiled for 2 min before loading. The β-mercaptoethanol reduces the proteins disulphide 
bonds, thus disrupting the protein structure for ease of separation on the SDS-PAGE gel. The 
gels were electrophoresed at 18 mA per gel until the dye front was approximately 0.5 cm from 
the bottom of the gel. The gels were removed from the electrophoresis apparatus and placed 
into the appropriate staining solution (Section 2.5) or used for western blotting (Section 2.6). 
Molecular weight markers were run alongside protein samples in order for the 
molecular mass of sample proteins to be determined. A standard curve of the log of the 
molecular weight marker proteins vs. the motility (Rf value) of the protein standards was 
constructed. The size of sample protein was calculated from the curve. A standard curve was 
constructed for each percentage gel and for each type of molecular weight marker. 
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Table 2.1. Preparation of running gels and stacking gels for Laemmli SDS-PAGE gels 
Solution  Volume (ml) 
 Running gel (%)  Stacking gel (%) 
 12.5 10.0 7.5 5.0  4.0 3.0* 
A 6.25 5.0 3.75 2.5  0.94 0.71 
B 3.75 3.8 3.75 3.75  0 0 
C 0 0 0 0  1.75 1.75 
D 0.15 0.15 0.15 0.15  0.07 0.07 
E 0.075 0.15 0.075 0.075  0.035 0.035 
dH2O 4.75 5.9 7.25 8.5  4.3 4.53 
TEMED 0.0075 0.006 0.0075 0.0075  0.015 0.015 
*A stacking gel concentration of 3% was used only with a running gel of 5%. 
 
2.5 Staining protein gels 
2.5.1 Coomassie staining  
Coomassie Blue R-250 dye was routinely used to detect protein bands after SDS-
PAGE. It is an aminotriarylmethane dye with the ability to bind to the NH3
+
 groups on 
proteins by a combination of van der Waals forces and electrostatic interactions (Sambrook 
and Russell, 2001). This method of staining protein is simpler than silver staining (Section 
2.5.2) but is far less sensitive.  
 
2.5.1.1 Reagents   
Coomassie stain stock solution [1% (w/v) Coomassie Blue R-250]. Coomassie Blue R-250 (1 
g) dissolved in dH2O (100 ml) with stirring for 1 h at room temperature. The solution was 
filtered through Whatman No. 1 filter paper. 
Coomassie staining solution [0.125% (w/v) Coomassie Blue R-250, 50% (v/v) methanol, 10% 
(v/v) acetic acid]. Coomassie stain stock solution (62.5 ml) was mixed with methanol (250 ml) 
and acetic acid (50 ml). The solution was made up to 500 ml with dH2O and stored in an 
airtight bottle. 
Destaining solution I [50% (v/v) methanol, 10% (v/v) acetic acid]. Methanol (500 ml) mixed 
with acetic acid (100 ml) and made up to 1 l with dH2O. 
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Destaining solution II [5% (v/v) methanol, 7% (v/v) acetic acid]. Methanol (50 ml) mixed with 
acetic acid (70 ml) and made up to 1 l with dH2O. 
 
2.5.1.2 Procedure 
Immediately following electrophoresis, gels were left in Coomassie staining solution in 
a sealed container (4 h or overnight). Destaining of the gel was achieved by soaking the gel in 
destain I (overnight or until the gel had a fairly clear background). This step was followed by 
soaking the gel in destain II until the background was completely clear. The gel was stored in 
a Ziploc
®
 plastic bag with a small volume of dH2O. 
 
2.5.2 Silver staining 
Silver staining was used to view small quantities of protein on SDS-PAGE gels. With 
the method of silver staining used (Blum et al., 1987), the gel is placed in silver nitrate, which 
provides silver ions for reaction with protein. The formaldehyde reduces the silver ions to 
metallic silver, resulting in the development of the protein bands (Merril, 2002). 
 
2.5.2.1 Reagents 
Fixing solution [50% (v/v) methanol, 12% (v/v) acetic acid, 0.0185% (v/v) formaldehyde]. 
Methanol (50 ml), glacial acetic acid (12 ml), and formaldehyde (50 µl of a 37% solution) 
were made up to 100 ml with dH2O. 
50% (v/v) Ethanol. Absolute ethanol (50 ml) was made up to 100 ml with dH2O. 
Pretreatment solution [0.02% (w/v) Na2S2O3.5H2O]. Na2S2O3.5H2O (0.02 g) was dissolved in 
100 ml dH2O. 
Silver nitrate impregnation solution [0.2% (w/v) AgNO3, 0.02775% (v/v) formaldehyde]. 
AgNO3 (0.2 g) was dissolved in 100 ml dH2O, and formaldehyde (75 µl of a 37% solution) 
was added. 
Developing solution [6% (w/v) Na2CO3, 0.0004 % (w/v) Na2S2O3.5H2O, 0.0185% (v/v) 
formaldehyde]. Na2CO3 (6 g) was dissolved in 95 ml of dH2O, Na2S2O3.5H2O (2 ml of 
pretreatment solution) and formaldehyde (50 µl of a 37% solution) were added and the volume 
was made up to 100 ml. 
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Stopping solution [50% (v/v) methanol, 12% (v/v) acetic acid]. Methanol (50 ml) and glacial 
acetic acid (12 ml) were made up to 100 ml with dH2O. 
50% (v/v) methanol. Methanol (50 ml) was made up to 100 ml with dH2O. 
 
2.5.2.2 Procedure 
All steps were carried out on a rocker (The Belly Dancer), at room temperature and in 
glassware that had been thoroughly cleaned. The glassware was cleaned with soap and water, 
followed by 70% (v/v) ethanol and then rinsed with dH2O, to avoid background staining. After 
electrophoresis the gel was left in fixing solution overnight. The gel was washed in 50 % (v/v) 
ethanol (3 x 20 min), followed by incubation in pretreatment solution (1 min). The gel was 
washed with dH2O (3 x 20 s) and then soaked in impregnation solution (20 min). This was 
followed by washing with dH2O (3 x 20 s). The gel was then placed in developing solution 
until the first protein bands started to become visible. The developing solution was 
immediately replaced with dH2O and the protein bands were allowed to develop fully. Colour 
development was stopped by soaking the gel in stopping solution (10 min). The gel was then 
washed with 50% (v/v) methanol (approximately 20 min), photographed and then stored in a 
Ziploc
®
 plastic bag. 
 
2.6 Western blotting  
Towbin et al. (1979) were the first to describe the transfer of proteins from SDS-PAGE 
to nitrocellulose membranes. The procedure involves transferring protein from a replica SDS-
PAGE gel to nitrocellulose electrophoretically. The SDS-PAGE gel is placed with the 
nitrocellulose in a “sandwich” which is then placed into the blotting apparatus in such an 
orientation that the gel is positioned on the cathode side and the nitrocellulose is positioned on 
the anode side. This results in the negatively charged SDS-coated proteins being transferred 
out of the gel towards the positive anode, and therefore becoming bound to the nitrocellulose. 
Ponceau S stain was used to determine whether the transfer of protein from the gel to the 
nitrocellulose was successful before continuing with the blotting procedure. A blocking step 
was required to block the remaining sites on the nitrocellulose, preventing antibodies from 
binding to the nitrocellulose non-specifically. In the present study the nitrocellulose was 
blocked with a solution of 5% (w/v) non-fat milk powder in tris buffered saline. This is a cost-
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effective blocking solution that results in low background. The disadvantage of using non-fat 
milk to block the nitrocellulose is that it can cause the transferred protein to be removed from 
the nitrocellulose if it is incubated for an exceptionally long period (Harlow and Lane, 1999). 
 
2.6.1 Reagents 
Blotting buffer. Tris (6.05 g) and glycine (14.4 g) dissolved in dH2O (750 ml). Methanol (200 
ml) added and volume made up to 1 l with dH2O. Just prior to use, 10% (w/v) SDS was added 
(100 μl 10% (w/v) SDS (Section 2.4.1) per 100 ml of blotting buffer). 
Tris buffered saline (TBS) [20 mM Tris, 200 mM NaCl, pH 7.4]. Tris (2.42 g) and NaCl 
(11.69 g) dissolved in dH2O (approximately 980 ml) and adjusted to pH 7.4 with HCl. The 
volume was made up to 1 l with dH2O. 
5% (w/v) Fat-free powdered milk. Elite powdered milk (5 g) was dissolved in TBS (100 ml). 
0.5% (w/v) Bovine serum albumin (BSA)-TBS. BSA (0.5 g) was dissolved in TBS (100 ml). 
4-Chloro-1-naphthol substrate solution [0.06% (w/v) 4-chloro-1-naphthol, 0.0015% (v/v) 
H2O2]. 4-chloro-1-naphthol (0.015 g) was dissolved in methanol (5 ml). The volume was made 
up to 25 ml with TBS and 30% (v/v) H2O2 (10 μl) added. 
Ponceau S stain [0.1% (w/v) Ponceau S in 1% (v/v) glacial acetic acid]. Ponceau S (0.1g) was 
dissolved in glacial acetic acid (1 ml) and made up to 100 ml with dH2O. 
 
2.6.2 Procedure 
Gloves were worn throughout the following procedure to prevent skin keratins 
attaching to the nitrocellulose, which could cause background. Following SDS-PAGE of 
duplicate gels (Section 2.4), one gel was stained with Coomassie as a reference gel, and the 
duplicate gel was used to transfer protein onto nitrocellulose. The nitrocellulose, SDS-PAGE 
gel and blotting sheets were immersed in blotting buffer (5 min). The nitrocellulose was 
placed on top of a foam pad and three sheets of filter paper. The gel was carefully placed on 
top of the nitrocellulose, followed by another three sheets of filter paper. A glass rod was used 
to smooth out any air bubbles and the second foam pad was placed on top of the filter paper. 
The sandwich was placed into the blotting sandwich cassette. The cassette was then placed 
into the blotting apparatus with the gel on the anodal side of the nitrocellulose. The blotting 
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apparatus was placed into the tank and immersed in blotting buffer. Transfer of protein from 
the gel to the nitrocellulose was achieved at 100 mA for 16 h. 
The nitrocellulose was removed from the apparatus and immersed in Ponceau S stain 
for a few seconds to determine the efficiency of protein transfer.  The nitrocellulose was 
washed with dH2O to enable viewing of the transferred bands. The molecular weight marker 
bands were marked with pencil, and if transfer had been successful, the Ponceau S stain was 
removed by placing the nitrocellulose in dH2O containing a few drops of NaOH. Once the 
colour had been removed, the nitrocellulose was washed several times with dH2O and allowed 
to air dry. Non-specific binding of antibodies was prevented by blocking with 5% (w/v) non-
fat milk powder in TBS (1 h, room temperature). The nitrocellulose was washed with TBS (3 
x 5 min) and then incubated with primary antibody in 0.5% (w/v) BSA-TBS (2 h). The 
nitrocellulose was washed with TBS again (3 x 5 min). An appropriate HRPO-conjugated 
secondary antibody in 0.5% (w/v) BSA-TBS was incubated with the nitrocellulose (1 h). After 
washing the nitrocellulose with TBS (3 x 5 min), 4-chloro-1-naphthol substrate solution was 
added and the blot left to develop in the dark. Once visible bands had developed against a pale 
background, the nitrocellulose was removed from the substrate, washed several times with 
dH2O and allowed to dry between filter paper before photographing. 
 
2.7 Agarose gel electrophoresis of DNA 
Agarose is a linear polymer composed of alternating residues of D- and L- galactose. 
These alternating residues are linked by α- (1-3) and β- (1-4) glycosidic linkages, forming 
helical fibres that aggregate into supercoiled structures (Sambrook and Russell, 2001). 
Gelation of agarose results in a three dimensional mesh which acts as a molecular sieve, 
separating DNA molecules on the basis of their size and conformation (Snustad and Simmons, 
2000). The movement of larger molecules is thus hindered to a greater degree than smaller 
molecules, resulting in the „sieving‟ process. 
The most common method of viewing DNA in agarose gel is staining the DNA with 
the fluorescent dye ethidium bromide. Ethidium bromide intercalates between the DNA bases, 





50X TAE (Tris-acetate-EDTA) buffer. Tris (24.2 g) was dissolved in 50 ml dH20. Glacial 
acetic acid (5.7 ml) and 0.5 M EDTA (10 ml) were added and the volume made up to 100 ml. 
The buffer was stored at room temperature. 
1X TAE buffer. 50X TAE (20 ml) was diluted to 1 l. 
0.5 M Na2EDTA. Disodium ethylenediaminetetra-acetate.2H2O (Na2EDTA) (18.6 g) was 
dissolved in dH2O (80 ml) and adjusted to pH 8.0 with NaOH. The volume was made up to 
100 ml with dH2O and autoclaved. 
10 mg/ml Ethidium bromide. Ethidium bromide was used at a final concentration of 0.5 μg/ml. 
6x Gel loading buffer [0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol FF, 30% 
(v/v) glycerol]. Bromophenol blue (0.06 g), xylene cyanol FF (0.06 g) and glycerol (7.5 ml) 
were made up to 25 ml with dH2O and thoroughly mixed. The loading dye was stored at 4˚C. 
The 6x gel loading dye (1 μl) was added per 5 μl of DNA sample. 
1% agarose. For mini-gels, agarose (0.25 g) was suspended in 25 ml of 1x TAE. For larger 
agarose gels, agarose (0.8 g) was suspended in 80 ml 1x TAE. The suspension was heated in a 
microwave oven in an Erlenmeyer flask, until the agarose had fully melted. During melting, 
the volume of the suspension would decrease due to evaporation and thus the volume was 
adjusted to its original volume with dH2O. The agarose was allowed to cool to approximately 
60˚C before adding ethidium bromide solution to a final concentration of 0.5 μg/ml, and 
pouring the gel. Low melting point agarose gels were prepared as for normal agarose gels 
except that they were left at 4˚C to solidify rather than at room temperature. 
 
2.7.2 Procedure 
The electrophoresis gel-casting tray was sealed with rubberised clasp seals and the 
comb was placed into the comb grooves on the tray. The casting apparatus was placed on a 
level surface. Melted agarose containing 0.5 μg/ml ethidium bromide, that had been allowed to 
cool to approximately 60˚C was then poured into the casting tray to a thickness of 
approximately 3-5 mm. Air bubbles that formed whilst pouring the gel, were quickly removed 
with a clean pipette tip, before the gel set. The agarose was left at room temperature to solidify 
(low melting point agarose gels were left at 4˚C to solidify). Once the agarose gel had set, the 
comb and seals were removed from the casting tray and the tray was placed into the 
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electrophoresis tank. The gel was orientated in such a way that the wells were placed at the 
cathode. The gel was covered with 1x TAE containing 0.5 μg/ml ethidium bromide to 
approximately 1 mm above the gel. The marker DNA and samples (mixed with 6x gel loading 
buffer) were loaded into the wells using a micropipette. The lid of the electrophoresis 
apparatus was securely fitted to the tank and the electrical leads were connected to a power 
pack so that the DNA would migrate from the negative cathode (black) to the positive anode 
(red). A voltage of 60-80 V was applied until the loading dye had migrated approximately 1 
cm from the end of the gel. The electrical leads were disconnected and the casting tray holding 
gel was removed from the apparatus. The gel was viewed and photographed under UV light 
using the VersaDoc
TM
 imaging system and the Quantity One software from Bio-Rad.  
The size of DNA fragments was determined from DNA ladders run alongside sample 
DNA. A standard curve of the log of the size of the DNA standards vs. the motility (Rf value) 
of the DNA standards was constructed. The size of sample DNA was calculated from the 
curve. 
 
2.8 Preparation of protease inhibitors  
A cocktail of protease inhibitors were included in buffers used for resuspending 
bacterial cell pellets and sonication. Leupeptin was used to inhibit cysteine and trypsin 
proteinases. L-trans-epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) was used to 
inhibit cysteine proteinases and phenylmethyl-sulfonyl fluoride (PMSF) to inhibit serine 
proteinases. In addition the protease inhibitors L-I-tosylamide-2-phenyl-ethyl 
chloromethylketone (TPCK), pepstatin A and disodium ethylenediaminetetra-acetate 
(Na2EDTA) were used to inhibit chymotrypsin-like proteinases, aspartic proteinases and 
metalloproteinases, repectively. 
 
20 mM (10 mg/ml) Leupeptin. Leupeptin (0.01 g) was dissolved in sterile dH2O (1 ml), 
aliquoted and stored at –20˚C. Leupeptin was used at a final concentration of 2 μg/ml. 
10 mM (1.74 mg/ml) Phenylmethyl-sulfonyl fluoride (PMSF). PMSF (0.0174 g) was 
dissolved in propan-2-ol (isopropanol) (10 ml), aliquoted and stored at –20˚C. The inhibitor 
was used at a final concentration of 0.6 mM (100 μg/ml). 
35 
 
3 mg/ml L-I-tosylamide-2-phenyl-ethyl chloromethylketone (TPCK). TPCK (0.03 g) was 
dissolved in ethanol (10 ml), aliquoted and stored at –20˚C. The inhibitor was used at a final 
concentration 100 μg/ml. 
0.5 M Disodium ethylenediaminetetra-acetate.2H2O (Na2EDTA). Na2EDTA (18.6 g) was 
dissolved in dH2O (80 ml) and adjusted to pH 8.0 with NaOH. The volume was made up to 
100 ml with dH2O. EDTA was used a final concentration of 1 mM. 
10 mM L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64). E-64 (0.007 g) was 
dissolved in sterile dH2O (2 ml), aliquoted and stored at –20˚C. It was used at a final 
concentration of 0.02 mM. 
1 mM Pepstatin A. Pepstatin A (0.0066 g) was dissolved in DMSO (10 ml), aliquoted and 
stored at –20˚C. Pepstatin A was used at a final concentration of 1 μM. 
 
2.9 Preparation of bacterial media, antibiotics and isopropyl-β-D-thiogalacto-pyranoside 
(IPTG) 
Antibiotics were used with bacterial expression to ensure that only cells containing 
plasmids having antibiotic resistance grew. Ampicillin was used when cells transformed with 
the plasmids pMAL-c2X, pTS822, pGEX4T1, pGEX4T1C18, pKK223-3-PfLDH and 
pKK223-3-PvLDH were cultured. Ampicillin inhibits the synthesis of the bacterial cell wall 
by interfering with the formation of peptido-glycan cross-links. Ampicillin-resistant plasmids 
possess the bla gene, which codes for the enzyme β-lactamase. β -lactamase cleaves the β -
lactam ring of ampicillin, rendering it inoperable.  
Chloramphenicol was used when bacterial cells transformed with the RIG plasmid 
were grown. Chloramphenicol blocks peptidyl transferase on the bacterial 50S ribosomal 
subunit, thereby inhibiting translation. Plasmids resistant to chloramphenicol possess the cat 
gene that encodes chloramphenicol acetyltransferase. The enzyme inactivates chloramphenicol 
by acylation.  
 
Ampicillin (50mg/ml). Ampicillin (0.5g) was dissolved in sterile dH2O (10 ml) and filter-
sterilised through a 0.22 μm acetate filter. Ampicillin was stored in aliquots at –20˚C and used 
at a final concentration of 50 μg/ml. 
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Chloramphenicol (34 mg/ml). Chloramphenicol (0.034 g) was dissolved in absolute ethanol (1 
ml) and stored at –20˚C. Chloramphenicol was used at a final concentration of 100 μg/ml. 
0.1 M isopropyl-β-D-thiogalacto-pyranoside (IPTG). IPTG (0.238 g) was dissolved in 10 ml 
sterile dH2O and filter-sterilised through a 0.22 μm acetate filter. Stored in the dark at –20˚C.  
Lysogeny broth (LB). Tryptone (10 g), yeast extract (5 g), NaCl (5 g), and glucose (2 g) were 
dissolved in 1 l dH2O and sterilised by autoclaving.  
Note: Although LB broth (Bertani, 1951) is most commonly referred to as Luria broth, the 
acronym LB was intended to stand for lysogeny broth (Bertani, 2004). 
LB agar plates. Tryptone (10 g), yeast extract (5 g), NaCl (5 g), glucose (2 g) and bacto-agar 
(15 g) were dissolved in 1 l dH2O and sterilised by autoclaving before use. The agar was 
cooled to approximately 50˚C before addition of antibiotics and pouring of plates.  
2x Yeast extract, tryptone (2xYT) medium. Tryptone (16 g), yeast extract (10 g), NaCl (5 g) 
and glucose (20 g) were dissolved in 900 ml dH20 and the volume made up to 1 l. The media 
was autoclaved and stored at room temperature until needed. 
Super optimal catabolizer (SOC) media. Tryptone (20 g), yeast extract (5 g), NaCl (0.5 g), 1 
M KCl (2.5 ml) were dissolved in 900 ml of dH2O and adjusted to pH 7 with NaOH. The 
volume was made up to 970 ml and the media was autoclaved. Prior to use, sterile 1 M MgCl2 
(10 ml) and filter-sterilised 1 M glucose (20 ml) was added. 
Super optimal broth (SOB) media. Tryptone (20 g), yeast extract (5 g), NaCl (0.5 g), 1 M KCl 
(2.5 ml) were dissolved in 900 ml of dH2O and adjusted to pH 7 with NaOH. The volume was 
made up to 990 ml and the media was autoclaved. Prior to use, sterile 1 M MgCl2 (10 ml) was 
added. 
 
2.10 Polymerase chain reaction 
PCR was routinely used as a method of screening bacterial colonies for recombinant 
clones. Although colony PCR provides a simple and rapid method for screening for 
recombinant clones, it is possible to generate false-positives, especially if primers designed to 
be specific for the insert DNA are used (Álvarez et al., 2002). Insert DNA that has not ligated 
into the plasmid vector, is still able to be transformed into competent bacterial cells, along 
with non-recombinant plasmid. When the bacterial colonies are screened using PCR, the insert 
specific primers amplify the free insert DNA, giving a positive result for a recombinant clone 
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(Álvarez et al., 2002). To ensure that false-positives are avoided, the primer pair used should 
consist of one insert-specific primer and one plasmid-specific primer, or as used in the present 
study, both primers used should be plasmid-specific. The sequences of the plasmid specific 
primers used are indicated in Table 2.2. 
Different annealing temperatures were used for each primer pair (Table 2.4), as the 
annealing temperature should ideally be 5˚C lower than the lowest melting temperature (Tm) 
of the primer pair (Innis and Gelfand, 1990).  
 




10X PCR buffer reaction buffer (Mg
2+
 and detergent free) (800 mM Tris-HCl, 200 mM 
(NH4)2SO4, pH 9.4-9.5). 
25 mM MgCl2. 
FIREPol
®
 DNA Polymerase I. 
dNTP mix (10 mM each of dATP, dGTP, dCTP and dTTP). 
Concentrated TE [10 mM Tris-HCl, 1 mM EDTA, pH 8]. Tris (0.061g) and EDTA (0.019g) 
was dissolved in dH2O (40 ml) and adjusted to pH 8.0 with HCl. The volume was made up to 
50 ml with dH2O and sterilized by autoclaving. 
100 μM primer stock solutions. Primers were suspended in concentrated TE. The volume used 
to prepare each primer stock solution was calculated as follows: Volume of TE (μl) = 10 X 
nanomoles (nMoles) of primer (Table 2.2). Stock solutions were stored in aliquots at –20˚C. 
10 μM primer working solutions. 100 μM Primer stock solutions (10 μl) were diluted with 
sdH2O (90 μl). The working solution was stored in aliquots at -20˚C. 
Name Sequence Amount supplied 
(nMoles) 
pMAL (Forward) 5‟- GGTCGTCAGACTGTCGATGAAGCC - 3‟ 45.50 
pMAL (Reverse) 5‟ - CGCCAGGGTTTTCCCAGTCACGAC - 3‟ 80.20 
PGEX4T1 (Forward) 5‟ - GGGCTGGCAAGCCACGTTTGGTG - 3‟ 70.00 





A transformed bacterial colony was picked with a sterile toothpick and transferred to a 
microcentrifuge tube containing 20-50 μl sterile dH2O. The cells were completely resuspended 
by vortexing, boiled for 5 minutes and then centrifuged (8 000 g, 2 min). The supernatant (10 
μl) was used for PCR. The PCR reagents were pipetted into sterile PCR tubes according to the 
amounts and order shown in Table 2.3. 
 
Table 2.3. Reaction constituents and conditions for PCR  
Order Reagent Volume (μl) Final concentration 
1 10X PCR buffer (MgCl2 free) (10X) 5 1X 
2 Sterile dH2O 23.5 - 
3 MgCl2 (25 mM) 5 2.5 mM 
4 dNTPs (10 mM of each dNTP) 1 0.2 mM 
5 Forward primer (10 μM) 2.5 0.5 μM 
6 Reverse primer (10 μM) 2.5 0.5 μM 
7 DNA 10 - 
8 Polymerase (5 U/ μl) 0.5 2.5 U 
Final volume 50  
 
The amplification of DNA was achieved using the following conditions: 94˚C for 5 
minutes, followed by 25 cycles of: 94˚C for 30 seconds (denaturation), *χ˚C for 30 seconds 
(annealing of primers), 60˚C for 2 minutes (extension), and then 72˚C for 7 minutes, with 
termination at 4˚C.  
*The temperature for annealing of primers (χ˚C) was set to 5˚C less than the lowest melting 




Table 2.4. Annealing temperatures used for each primer pair used in screening for 
recombinant bacterial clones with PCR 
Name Melting temperature (Tm) Annealing temperature used 
for primer pair in PCR 
pMAL (Forward) 61.3˚C 
56.3 
pMAL (Reverse) 64.1˚C 
PGEX4T1 (Forward) 65.7˚C 
59˚C 
PGEX4T1 (Reverse) 64.0˚C 
 
2.11 Sequencing 
Plasmid DNA isolated by the alkaline lysis method (Section 2.12.1) was sequenced at 
the SEGOLI Sequencing Unit at the International Livestock Research Institute (Nairobi, 
Kenya).  
 
2.12 Isolation of plasmid DNA  
The alkaline lysis method (Ish-Horowicz and Burke, 1981; Birnboim and Doly, 1979) 
(Section 2.12.1) was used for routine plasmid isolation. The Wizard® Plus SV Minipreps 
DNA Purification System (Section 2.12.2) was used for isolating plasmid DNA required for 
cloning purposes. 
 
2.12.1 Midi-preparation of plasmid DNA by alkaline lysis with SDS 
The alkaline lysis method (Ish-Horowicz and Burke, 1981; Birnboim and Doly, 1979) 
of plasmid DNA isolation is a simple, inexpensive procedure that provides reproducible 
results (Sambrook and Russell, 2001). The method involves exposing bacterial cells to SDS at 
alkaline pH. This results in the cell wall degrading and releasing the cell contents, including 
the plasmid DNA, into the supernatant. Chromosomal DNA is completely denatured due to 
the alkaline solution causing disruption of the base pairing. Provided the exposure to the basic 
solution is not too severe or for an extended period of time, the two strands of the plasmid 
DNA will anneal back together correctly when the pH of the solution is neutralised. The 
denatured bacterial proteins, chromosomal DNA and broken cell wall become combined in 
large complexes, which are coated with SDS. When the sodium ions are replaced with 
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potassium ions, the complexes precipitate from the solution (Ish-Horowicz and Burke, 1981). 




LB media. Section 2.9. 
2xYT media. Section 2.9. 
Ampicillin. Section 2.9. 
Alkaline lysis solution I [25 mM Tris-HCl, 50 mM glucose, 10 mM EDTA, pH 8]. Glucose 
(0.9 g), tris (0.3 g) and EDTA (0.37 g) were dissolved in dH2O (90 ml) and adjusted to pH 8. 
The volume was made up to 100 ml with dH2O. The buffer was aliquoted and sterilised by 
autoclaving, before storing at 4˚C. 
Alkaline lysis solution II [0.2 M NaOH, 1% (w/v) SDS). NaOH (1.6 g) was dissolved in dH2O 
(200 ml). This NaOH solution (9 ml) was combined with 10% (w/v) SDS (Section 2.4.1) (1 
ml) just before use. 
Alkaline lysis solution III [5 M potassium acetate, glacial acetic acid]. Potassium acetate 
(29.45 g) was dissolved in glacial acetic acid (11.5 ml) and dH2O (28.5 ml). The buffer was 
stored at 4˚C and transferred to ice just before use. 
Sodium-Tris-EDTA (STE) buffer [10 mM tris-HCl, 0.1 M NaCl, 1 mM EDTA, pH 8]. Tris 
(0.1211 g), NaCl (0.5844 g) and EDTA (0.0372 g) were dissolved in dH2O (90 ml). The 
volume was made up to 100 ml with dH2O. The buffer was aliquoted and sterilised by 
autoclaving. 
Tris-EDTA (TE) buffer [100 mM Tris-HCl, 10 mM EDTA, pH 8.0]. Tris (1.211 g) and EDTA 
(0.3722 g) were dissolved in dH2O (90 ml). The volume was made up to 100 ml with dH2O. 
The buffer was aliquoted and sterilised by autoclaving. 
Phenol. 
Chloroform. 
DNAse-free RNAse A (10 mg/ml). RNAse A from bovine pancreas (0.005 g) was dissolved in 
0.01 M sodium acetate, pH 5.2 (500 μl) and heated at 100˚C for 15 min. The solution was 
slowly cooled to room temperature and 1 M Tris-HCl, pH 7.4 (50 μl) was added to adjust the 




0.01 M Sodium acetate, pH 5.2. Sodium acetate (0.164 g) was dissolved in dH2O (180 ml) and 
adjusted to pH 5.2 with glacial acetic acid. The volume was made up to 200 ml and the buffer 
was autoclaved. 
1 M Tris-HCl, pH 7.4. Tris (3.0 g) was dissolved in dH2O (20 ml) and adjusted to pH 7.4 with 
HCl. The volume was made up to 25 ml and autoclaved. 
 
2.12.1.2 Procedure 
LB or 2xYT media (10 ml) (Section 2.9) containing ampicillin (50 μg/ml) (Section 2.9) 
was inoculated with a single transformed bacterial colony. The culture was allowed to grow 
overnight at 37˚C with shaking. The bacterial cells were pelleted (2 000 g, 10 min, 4˚C) and 
the media was discarded. The pellet was suspended in ice-cold STE buffer (2.5 ml) and 
centrifuged (2 000 g, 10 min, 4˚C). The STE buffer was removed and the bacterial pellet was 
suspended in ice-cold alkaline lysis solution I (200 μl). The solution was vortexed vigorously 
to ensure the bacterial cells were completely suspended in solution and then transferred to a 
1.5 ml microcentrifuge tube. Freshly prepared alkaline lysis solution II (400 μl) was added to 
the microcentrifuge tube and mixed by inverting the microcentrifuge tube rapidly five times. 
This was placed on ice and ice-cold alkaline lysis solution III (300 μl) was added. The 
microcentrifuge tube was inverted several times to ensure mixing of the solution before it was 
left on ice for 5 minutes. The bacterial lysate was centrifuged (10 000 g, 5 min, 4˚C). The 
supernatant (600 μl) was transferred to a fresh 1.5 ml microcentrifuge tube. Phenol: 
chloroform (1:1) solution (600 μl) was added to the supernatant. The organic and aqueous 
phases were mixed by vortexing. The emulsion was centrifuged (10 000 g, 2 min, 4˚C). The 
upper aqueous layer was transferred into a fresh 1.5 ml microcentrifuge tube. To precipitate 
the DNA, propan-2-ol (600 μl) was added to the aqueous solution and vortexed. The solution 
was left at room temperature for 2 min and then centrifuged (10 000 g, 5 min, room 
temperature) to collect the precipitated DNA. The supernatant was removed by gentle 
aspiration. The microcentrifuge tube was inverted on paper towelling to allow any remaining 
supernatant to drain away from the DNA pellet. The pellet was washed with 70% (v/v) ethanol 
(1 ml) and recovered by centrifugation (10 000 g, 2 min, room temperature). The ethanol was 
removed by gentle aspiration. The microcentrifuge tube was left to stand open at room 
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temperature for 5 min to allow any residual ethanol to evaporate. The DNA pellet was 
suspended in TE buffer (100 μl) containing 20 μg/ml DNAse-free RNAse A. The plasmid 




 Plus SV Minipreps DNA Purification System 
For cloning and sequencing purposes, plasmid DNA was isolated using the Wizard
®
 
Plus SV Minipreps DNA Purification System, from Promega (USA), according to the 
manufacturers‟ instructions. The kit provides a simple and reliable method of isolating 
plasmid DNA. Plasmid DNA can immediately be used for other molecular biology 
applications such as restriction enzyme digests, cloning and sequencing, without further 
purification. The kit involves lysis of the transformed bacterial cells with an alkaline solution 
containing SDS. The DNA is then bound to resin in a Minicolumn, washed with ethanol and 
eluted (Wizard
®
 Plus SV Minipreps DNA purification system technical bulletin, Promega). 
 
2.13 Restriction enzyme digestion of DNA 
Restriction enzymes that cut DNA molecules internally at specific base pair sequences 
are type II restriction endonucleases. Digesting two different DNA molecules with the same 
restriction endonuclease, results in the formation of the same sticky end. This allows new 
DNA molecules to be created by combining the restricted fragments from each restriction 
endonuclease digestion. It is for this reason that these enzymes are invaluable tools in 
molecular cloning. 
The restriction enzymes BamHI (5' G↓GATCC 3') and EcoRI (5' G↓AATTC 3'), were 
used in the present study. BamHI and EcoRI exhibit the ability to cleave DNA sequences that 
are similar to their recognition sequence. This phenomenon is known as star activity. Star 
activity only occurs under conditions of high glycerol concentration, excess enzyme, and low 
ionic strength and at non-optimal pH (New England Biolabs pMAL
TM
 Protein Fusion and 






10 X NEBuffer 2 [500 mM NaCl, 100mM Tris-HCl, 100 mM MgCL2, 10 mM dithiothreitol, 
pH 7.9]. 
EcoRI. 
10 × Buffer H (90 mM Tris-HCl buffer, pH 7.5, 10 mM MgCl2, 50 mM NaCl). 
 
2.13.2 Procedure 
The volumes of the reagents used were dependent on the amount of digested DNA 
required. The following procedure was typically used, although it was scaled-up when 
necessary: 10X restriction enzyme buffer (4μl), dH2O (14 μl), plasmid DNA from miniprep 
(20 μl) and restriction enzyme (2 μl) were pipetted into a sterile 1.5 ml microcentrifuge tube 
and incubated at 37C. Omitting the restriction enzyme and adjusting the volume of water 
accordingly, provided a non-digested control. Each restriction enzyme was used with a 
specific restriction enzyme buffer (Table 2.5). Digestion of the plasmid was confirmed by 
viewing the digested and non-digested control DNA on an agarose gel. 
 
Table 2.5. The specific restriction enzymes and buffers used to digest plasmid DNA. 
Enzyme Buffer name Composition of buffer (1X) 
BamHI NEBuffer 2 50 mM NaCl, 10 mM Tris-HCl, 10 mM 
MgCl2, 1mM Dithiothreitol, pH 7.9 at 
25 °C 
EcoRI Buffer H 90 mM Tris-HCl, 50 mM NaCl, 10 mM 
MgCl2, pH 7.5 at 37 °C 
 
2.14 Dephosphorylation 
The linearised plasmid has the ability to re-ligate, which would decrease the number of 
recombinant plasmids obtained upon ligation of the DNA insert into the plasmid vector. To 
minimize the possibility of re-ligation, the plasmid is dephosphorylated with shrimp alkaline 
phosphatase. Phosphatase catalyses the dephosphorylation of the 5‟ phosphate ends of the 
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plasmid DNA, thus preventing re-ligation with the 3‟ end. Shrimp alkaline phosphatase (from 
arctic shrimp) was used, as it is inactivated after 15 min at 65˚C. 
 
2.14.1 Reagents 
Shrimp alkaline phosphatase. 
10X phosphatase buffer [0.5 M Tris-HCl, 50 mM MgCl2, pH 8.5]. 
Sterile dH2O. dH2O was autoclaved to sterilise. 
Linearised plasmid DNA. 
2.14.2 Procedure 
The volumes of the reagents used were dependent on the amount of plasmid DNA 
required to be dephosphorylated. Typically the following procedure was used: plasmid DNA 
(100 μl), 10X buffer (12 μl) and sterile dH2O (4 μl) were mixed together in a 1.5 ml 
microcentrifuge tube by pipetting the contents up and down gently. Shrimp alkaline 
phosphatase (4 μl) was added and mixed as before. The reaction was left at 37˚C overnight 
(approximately 16-18 h). The shrimp alkaline phosphatase was inactivated by incubating the 
microcentrifuge tube in a 65˚C water bath for 15 min. 
 
2.15 Purification of plasmid DNA 
2.15.1 Wizard
®
 DNA Clean-up System 
The Wizard
®
 DNA Clean-up System was used to remove restriction enzymes, salts and 
phosphates from plasmid DNA. The DNA binds to a resin, which is then washed with 80% 
(v/v) propan-2-ol to remove the salts, phosphates or restriction enzymes. The DNA is eluted 
with sterile dH2O pre-warmed to 70˚C. 
 
2.15.1.1 Materials and reagents  
80% (v/v) Propan-2-ol. Propan-2-ol (16 ml) was made up to 20 ml with sdH2O. 
Wizard
®
 DNA Clean-up resin (Promega). 
Wizard
®







 DNA Clean-up resin (1 ml) was added to a sterile 1.5 ml 
microcentrifuge tube. The DNA sample was added and mixed by inverting the 
microcentrifuge tube several times. The plunger from a 2 ml syringe was removed and the 
syringe barrel was attached to the Luer-Lok
®
 extension of a minicolumn. The Wizard
®
 DNA 
Clean-up resin with bound sample DNA was then pipetted into the 2 ml syringe barrel. The 
syringe plunger was carefully inserted into the syringe barrel and the DNA-resin slurry slowly 
pushed into the minicolumn, using the plunger. The minicolumn was disconnected from the 
syringe and the plunger was removed from the syringe barrel. The syringe was then 
reconnected to the minicolumn and 80% (v/v) propan-2-ol was pippetted into the syringe 
barrel. The plunger was inserted into the syringe barrel and the propan-2-ol was pushed 
through the minicolumn. The minicolumn was detached from the syringe and placed into a 1.5 
ml microcentrifuge tube. The resin was dried by centrifugation (10 000 g, 2 min, room 
temperature). The minicolumn was transferred to a sterile microcentrifuge tube and pre-
warmed (70˚C) sterile dH2O (25 μl) was pipetted into the minicolumn to elute the DNA. The 
minicolumn was left for 1 min at room temperature before centrifuging (10 000 g, 20 s, room 
temperature). The elution was repeated once more with a further 25 μl of sterile dH2O, into a 
fresh sterile microcentrifuge tube. 
 
2.15.2 Low melting point (LMP) agarose purification of DNA 
Excising the completely linearised plasmid DNA from low melting point (LMP) 
agarose provided a convenient method for obtaining completely digested DNA from a 
restriction enzyme digest which would often contain a mixture of completely digested linear 
plasmid DNA and partially digested DNA. This method was also useful for separating DNA 
insert from the plasmid DNA that it had been dropped out of by restriction enzyme digestion. 
The excised DNA bands were purified from the LMP agarose using the Wizard

 PCR Preps 
DNA Purification System from Promega (USA). The system works on a method similar to 
that of the Wizard
®
 DNA Clean-up System. 
 
2.15.2.1 Materials and reagents 
Wizard

 PCR Preps DNA purification resin (Promega). 
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Direct purification buffer [50 mM KCl, 10 mM tris-HCl (pH 8.8), 1.5 mM MgCl2, 0.1% (v/v) 
Triton X-100 (Promega). 
Wizard

 minicolumns (Promega). 
 
2.15.2.2 Procedure 
The DNA sample was separated by electrophoresis at 60 V in a TAE agarose gel of the 
required percentage LMP agarose. The gel was observed under UV light and the required 
DNA band was excised from the gel using a clean, sterile scalpel blade. The excised band was 
placed in a sterile 1.5 ml microcentrifuge tube and incubated at 70˚C until the agarose was 
completely melted. The PCR preps resin was warmed at 37˚C for 10 minutes, to dissolve any 
crystals and aggregates. Prior to use, the resin was allowed to cool to 30˚C. The PCR preps 
resin (1 ml) was added to the melted agarose and mixed thoroughly for 20 seconds by 
inverting the microcentrifuge tube several times. The plunger was removed from a 2 ml 
disposable syringe and the syringe barrel was attached to the Luer-Lok

 extension of a 
Wizard

 minicolumn for each sample to be purified. The resin-DNA slurry was pipetted into 
the syringe barrel. The plunger was inserted into the syringe barrel and used to slowly push the 
resin-DNA slurry into the minicolumn. The syringe was detached from the minicolumn and 
the plunger removed. The syringe barrel was reconnected to the minicolumn and 80% (v/v) 
propan-2-ol (2 ml) was pipetted into the syringe barrel. The plunger was inserted into the 
syringe barrel and used to gently push the propan-2-ol through the minicolumn. The 
minicolumn was removed from the syringe and placed into a 1.5 ml microcentrifuge tube. The 
minicolumn was centrifuged (10 000 g, 2 minutes) to dry the resin. The minicolumn was 
transferred to a new sterile microcentrifuge tube and sterile dH2O (50 μl), preheated to 65-
70˚C, was added to the minicolumn to elute the DNA. The minicolumn was allowed to stand 
for 1 minute before centrifuging (10 000 g, 20 seconds). The minicolumn was discarded and 
the eluted DNA stored at –20˚C until required.   
 
2.16 Ligation of plasmid DNA and insert DNA 
Insert DNA was ligated into restriction enzyme-digested plasmid DNA with T4 DNA 
ligase. Ligase catalyses the covalent joining of phosphodiester bonds between 5‟-phosphoryl-
termini and 3‟-hydroxyl-termini of nucleic acid molecules. DNA ligases are very useful for 
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T4 DNA ligase. 
2X Ligation buffer. 
5X DNA dilution buffer. 
 
2.16.2 Procedure 
Plasmid DNA that had been restricted with restriction enzymes, dephosphorylated and 
purified (2.5 μl) was combined with the insert DNA (5 μl), 1X DNA dilution buffer (2.5 μl) 
and 2X ligation buffer (10 μl) in a 1.5 ml sterile microfuge tube. This was mixed by gentle 
pipetting, before adding T4 DNA ligase (1μl). This was mixed by gentle pipetting and 
incubated at 16˚C overnight. The ligation controls used are displayed in Table 2.6. 
 











1 Yes Yes Yes Yes Yes Yes 
2 No No No No Yes Yes 
3 Yes No No No Yes Yes 
4 Yes Yes No No Yes Yes 
5 Yes No Yes No Yes Yes 
6 Yes Yes Yes No Yes Yes 
7 No No No No Yes Yes 
 
2.17 Concentration and purification of DNA 
For cloning procedures, it was often necessary to concentrate DNA samples or change 
the buffer the DNA was suspended in. A method of precipitating DNA with ethanol and 
sodium acetate (Wallace, 1987) was frequently used. The procedure involved exposing a DNA 
sample to salt and ethanol at a low temperature (-20˚C). Precipitated DNA was collected by 
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centrifugation. The DNA was then resuspended in a smaller volume in order to give a more 




3 M Sodium acetate, pH 5.5. Sodium acetate trihydrate (20.4 g) was dissolved in dH2O (40 
ml) and adjusted to pH 5.5 with glacial acetic acid. The volume was made up to 50 ml with 
dH2O. The buffer was sterilized by autoclaving. 
 
2.17.2 Procedure 
Sodium acetate, pH 5.5 was added to the DNA sample to 1/10
th
 of the sample volume 
and mixed by gentle pipetting. Ethanol (100%) was added (2.5x the sample volume) and 
mixed by gentle pipetting. The solution was left at –20˚C for at least 1 h before recovering the 
DNA by centrifugation (14 000 g, 25 min, 4˚C). The supernatant was carefully removed 
without disturbing the pellet. The DNA pellet was washed with 70% (v/v) ethanol (500 μl). 
The DNA was recovered by centrifugation (12 000 g, 5 min, 4˚C). The ethanol was carefully 
removed without disturbing the pellet. The DNA pellet was left to air dry for 10 min before 
being dissolved in an appropriate volume of sterile dH2O. 
 
2.18 Transformation of bacterial cells with DNA 
Two different methods of transformation were used in the present study, depending on 
the type of plasmid DNA being transformed. For supercoiled plasmid DNA, the heat shock 
method (Section 2.18.2) of transformation was used. For ligation reactions, electroporation 
(Section 2.18.1) was used to transform bacteria. In order for the plasmid DNA to be taken up 
by the bacterial cells with each of these methods, the cells first have to be made competent. 
For transformation by electroporation, cells were made competent using the glycerol method 
(Dower et al., 1988) (Section 2.18.1). Cells being transformed by the heat shock method were 
made competent using an adaptation of the CaCl2 method (Section 2.18.2) described by Cohen 





Table 2.7. Genotypes of E. coli cells transformed with recombinant plasmids 
2.18.1 Transformation of competent E.coli (glycerol method) cells by electroporation 
Electroporation is a process allowing bacterial cells to take up free DNA. The 
mechanism involves exposure of the cells to a quick electric pulse, causing a type of structural 
rearrangement of the membrane, resulting in the dimpling of the cell membrane (Weaver, 
1993). These dimples are thought to then form temporary hydrophobic pores ranging in 
diameter from 2 nm to 7 nm (Sambrook and Russell, 2001). Whilst the pores are open, ions 
and water-soluble molecules, including free DNA, are able to cross the membrane into the 
cytoplasm of the cell (Weaver, 1993).  
Name Genotype 
Recombinant plasmid cells 
were transformed with 
E. coli JM103 









E. coli JM109 
endA1 glnV44 thi-1 relA1 gyrA96 recA1 
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Preparation of competent cells for electroporation requires washing the cells with ice-
cold water. Washing the cells at low temperature reduces the risk of arcing, which is the 
uneven transfer of charge across the cell-DNA suspension. Arcing occurs at high temperatures 
and at high ionic strength, and therefore washing with ice-cold water greatly reduces the 
number of ions present, in addition to keeping the cells at a reduced temperature. If arcing 
occurs, the efficiency of transformation is greatly reduced (Sambrook and Russell, 2001). 
 
2.18.1.1 Reagents 
2xYT media. Section 2.9. 
Sterile ice-cold dH2O. dH2O was autoclaved and placed on ice until needed. 
10% (v/v) glycerol. Glycerol (10 ml) was made up to 100 ml with dH2O and mixed thoroughly 
before autoclaving. 
Super optimal broth (SOB) media. Section 2.9. 
 
2.18.1.2 Procedure 
An overnight culture (10 ml; 2xYT media) of appropriate E. coli cells was grown at 
37˚C with shaking. Fresh 2xYT media (99 ml) was inoculated with 1 ml of the overnight 
culture and incubated at 37˚C with shaking until the culture reached an OD600 of 0.9. The 
culture was left on ice for 30 min before centrifuging (3 600 g, 10 min, 0˚C). The supernatant 
was discarded and the cell pellet was resuspended in ice-cold sterile dH2O (100 ml). The cells 
were centrifuged (3 600 g, 10 min, 0˚C) and resuspended in ice-cold sterile dH2O (50 ml). The 
cells were centrifuged (3 600 g, 10 min, 0˚C). The cell pellet was resuspended in ice cold 
sterile 10% (v/v) glycerol (2 ml) before centrifuging (3 600 g, 10 min, 0˚C). The cells were 
resuspended in ice cold sterile 10% (v/v) glycerol (1 ml). Aliquots (50 μl) were stored in 
sterile microfuge tubes on ice until required. DNA (1-2 µl) was gently mixed with freshly 
prepared competent E. coli cells (50 µl) and incubated on ice for 30 min. The DNA and cell 
mixture was pipetted into a pre-chilled, sterile electroporation cuvette (0.2 cm gap). A Bio-
Rad Gene Pulser was used to apply one pulse of 25 microfarads, 2.5 kilovolts, and 200 ohms 
for approximately 4.8 milliseconds. Pre-warmed SOB media (300 μl) was gently mixed with 
the transformed cells. The cells and media were transferred to a sterile microfuge tube and 
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incubated at 37°C for 1 h. LB plates containing appropriate antibiotic were spread with the 
transformed cells (200µl) and incubated at 37°C overnight. 
 
2.18.2 Transformation of competent E. coli cells (calcium chloride method) using heat 
shock 
The mechanism behind the uptake of free DNA by cells with heat shock is not 
understood. The crucial step of the method involves briefly exposing competent cells to an 
elevated temperature. The temperature and length of exposure need to be accurate otherwise 
transformation efficiency is reduced (Sambrook and Russell, 2001). Once transformed, the 
cells are supplemented with a rich media to allow the cells to recover and begin expressing the 
antibiotic resistance marker, encoded by the plasmid. Competent E. coli cells were prepared 
using the modified method of Cohen et al., (1972). It is a highly effective method, typically 
yielding 5 X 10
6
 – 2 X 10
7
 transformed colonies per microgram of supercoiled plasmid 
(Sambrook and Russell, 2001).  
 
2.18.2.1 Reagents 
2xYT media. Section 2.9. 
0.1 M CaCl2. CaCl2.2H2O (1.47 g) was dissolved in 100 ml dH2O and sterilised by 
autoclaving. 
LB agar plates. Section 2.9. 
Super optimal catabolizer (SOC) media. Section 2.9. 
 
2.18.2.2 Procedure 
Media (2xYT, 10 ml) was inoculated with one E. coli colony from an LB plate and left 
to grow at 37˚C with shaking overnight. The overnight culture was added to fresh 2xYT (90 
ml) and left at 37˚C with shaking until an OD600 of 0.3-0.4. The culture was transferred to ice 
cold, sterile centrifuge tubes and left on ice for 10 min. The cells were pelleted (4500 g, 10 
min, 4˚C). The supernatant was discarded and pellet was resuspended in ice-cold sterile 0.1 M 
CaCl2 (40 ml). The cells were pelleted as before, and resuspended in 0.1 M CaCl2 (2 ml). The 
cells were aliquoted (20 μl) into sterile 1.5 ml microcentrifuge tubes and stored on ice until 
use. The cells were used for transformation on the day of preparation. 
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Super coiled recombinant plasmid DNA (1 μl) was incubated with freshly prepared 
competent cells (20 μl) on ice for 30 min. Cells were heat-shocked at 42˚C for 90 s, and then 
immediately placed on ice for 2 minutes. Pre-warmed (37˚C) SOC media (80 μl) was added to 
the cells and gently mixed. The cells were then incubated for 1 h with shaking at 37˚C. LB 
agar plates containing appropriate antibiotics were then spread with the cells (50 μl), and then 
incubated overnight, inverted at 37˚C. 
 
2.19 Preparation of glycerol stocks 
Stocks of transformed bacterial clones and bacterial cell lines were frozen at –70˚C in 
glycerol according to the method described by Sambrook et al. (1989). 
 
2.19.1 Reagents 
Sterile 50% glycerol. Glycerol (25 ml) was made up to 50 ml with dH2O and autoclaved. 
LB media. Section 2.9. 
 
2.19.2 Procedure 
LB media (10 ml) containing relevant antibiotic with a single bacterial colony was left 
to grow overnight at 37˚C with shaking. Sterile 50% glycerol (150 μl) was added to the 
bacterial culture (850 μl) in a sterile 1.8 ml cryotube and vortexed gently to mix. The cells 
were rapidly frozen in liquid nitrogen and then stored at -70˚C.  
 
2.20 Recombinant expression and purification of Pf33-MBP and MBP from pMAL-c2X 
and pTS822 plasmids 
2.20.1 Confirmation of the identity of the pMAL-c2X and pTS822 plasmids 
The plasmids pMAL-c2X and pTS822 used in this study were from glycerol stocks 
previously prepared (Smallie, 2003) and it was thus decided to confirm the identity of the 
insert sequence. Glycerol stocks were streaked onto LB media plates (Section 2.9) and left 
inverted overnight at 37˚C. LB broth (10 ml) (Section 2.9) containing 100 μg/ml ampicillin 
(Section 2.9) was inoculated with a single colony from the LB media plates and incubated at 
37˚C with shaking overnight. Plasmids were isolated using the midi-preparation of plasmid 
DNA by alkaline lysis with SDS (Section 2.12.1) and then restricted with BamHI (Section 
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2.13) to linearise pMAL-c2X, and to drop out the P. falciparum DNA insert from pTS822. 
The restricted plasmid DNA was analysed on a 1.2% (w/v) agarose gel (Section 2.7). In 
addition, the plasmids were confirmed with PCR (Section 2.10) and sequencing (Section 
2.11). 
 
2.20.2 Expression of Pf33-MBP or MBP alone 
2.20.2.1 Reagents 
2xYT media. Section 2.9. 
50 mg/ml Ampicillin. Section 2.9. 
0.1 M IPTG. Section 2.9. 
Column buffer [20 mM Tris-HCl, 200 mM NaCl, 1 mM EDTA, 1 mM NaN3]. Tris (2.42 g), 
NaCl (11.69 g) and EDTA (0.372 g) were dissolved in approximately 980 ml dH2O and 
adjusted to pH to 7.4 with HCl. NaN3 (0.065 g) was added and the volume made up 1 l. 
 
2.20.2.2 Procedure 
An overnight culture (100 ml 2xYT or LB) of pTS822 expressing Pf33-MBP or of 
pMAL-c2X expressing MBP, was diluted 1:10 in fresh 2xYT or LB (900 ml). Ampicillin was 
added to a final concentration of 100 μg/ml and the culture left at 30˚C until an optical density 
at 600 nm of 0.5-0.6 was reached. IPTG was added to a final concentration of 3x10
-4
 M. The 
culture was then supplemented with additional ampicillin (1 ml of a 50 mg/ml stock) and 
placed back into the incubator for 4-6 h. The cultures were supplemented with ampicillin (1 
ml) every 2 h. The cultures were centrifuged to pellet the cells (4000 g, 20 min, 4°C). The 
media was discarded and the pellets were resuspended in column buffer (50 ml). Lysozyme 
was added to a final concentration of 1 mg/ml. Protease inhibitors were added (Section 2.8) 
and the resuspended cells were frozen at -20 ˚C. The cells were thawed and then sonicated (4 x 
30 s). The lysate was clarified by centrifugation (9000 g, 30 min, 4˚C), followed by filtration 




2.20.3 Affinity purification of fusion protein and MBP on amylose resin 
2.20.3.1 Reagents 
Column buffer [20 mM Tris-HCl, 200 mM NaCl, 1 mM EDTA, 1 mM NaN3]. Section 
2.20.2.1. 
10 mM maltose in column buffer [20 mM Tris-HCl, 10 mM maltose, 200 mM NaCl, 1 mM 
EDTA, 1 mM NaN3]. Maltose (0.36 g) was dissolved in column buffer (100 ml). 
0.1% (m/v) SDS. SDS (0.1 g) was dissolved in 100 ml of dH2O. 
 
2.20.3.2 Procedure 
Amylose resin was placed into a glass column (internal diameter 1.5 cm, height 5 cm, 
bed volume 8.8 ml). The resin was washed with 5 column volumes of column buffer (flow rate 
10 ml/h). pMAL or pTS822 lysate was diluted (1:5) with column buffer. The lysate was 
cycled through the column overnight at 4˚C. The column was then washed with column buffer 
until the absorbance of a fraction (1 ml) was approximately 0.010. MBP or Pf33-MBP was 
eluted with 10 mM maltose. Fractions of 1 ml were collected during elution. The absorbance 
of the collected fractions was determined (280 nm). Fractions with absorbance readings above 
0.3 were pooled and protein concentration determined (Bradford, 1976) (Section 2.2). If 
necessary the pooled protein was concentrated using PEG 20 000 (Section 2.3.1). The column 
was regenerated with 3 column volumes of dH2O, 3 column volumes of 0.1% (m/v) SDS, 1 
column volume dH2O and 3 column volumes of column buffer and stored at 4˚C. 
 
2.20.4 Factor Xa cleavage of fusion protein Pf33-MBP 
Factor Xa was used to cleave MBP from Pf33-MBP fusion protein. 
 
2.20.4.1 Reagents 
Cleavage buffer [100 mM NaCl, 50 mM Tris-HCl, 1 mM CaCl2, pH 8.0]. Tris (3 g), NaCl (8.7 
g) and CaCl2.2H2O (0.29 g) were dissolved in 980 ml dH20 and titrated to pH 8.0 with HCl. 
The volume was made up to 1 l. 
Factor Xa. 
1 mg/ml Soybean trypsin inhibitor. Soybean trypsin inhibitor (0.001 g) was dissolved in sterile 
dH2O (1 ml), aliquoted and stored at –20˚C.  
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100 μg/ml Soybean trypsin inhibitor. Soybean trypsin inhibitor (1 mg/ml) (100 μl) was made 
up to 1ml with sterile dH2O. 
 
2.20.4.2 Procedure 
Amylose-purified Pf33-MBP was dialysed against cleavage buffer (3 x 2h). The fusion 
protein was then concentrated with PEG 20 000 (Section 2.3.1). The quantity of protein 
present was determined (Bradford, 1976) (Section 2.2). Factor Xa (200 μg/ml) was added to a 
final concentration of 1 μg per mg of fusion protein. As a positive control, factor Xa was 
added to MBP2* paramyosinΔSal (control fusion protein from New England Biolabs) to the 
same final concentration. As a negative control, an equivalent volume of cleavage buffer was 
added to an equivalent amount of both the fusion protein and the control fusion protein. The 
cleavage reactions, including the controls were carried out overnight at room temperature with 
rotation. Factor Xa activity was inhibited by boiling with reducing treatment buffer (Section 
2.4.1) initially for pilot studies, then with soybean trypsin inhibitor at a final concentration 
equal to that of the final Factor Xa concentration used. 
 
2.20.5 DEAE-Sepharose ion exchange separation of cleaved Pf33-MBP 
2.20.5.1 Reagents 
10 mM Tris-HCl, 25 mM NaCl, pH 8.0. Tris (1.211 g) and NaCl (1.461 g) were dissolved in 
dH2O (980 ml). The pH was adjusted to 8.0 with HCl and the volume made up to 1 l. 
20 mM Tris-HCl, 25 mM NaCl, pH 8.0. Tris (2.422 g) and NaCl (1.461 g) were dissolved in 
dH2O (980 ml). The pH was adjusted to 8.0 with HCl and the volume made up to 1 l. 
20 mM Tris-HCl, 500 mM NaCl, pH 8.0. Tris (2.422 g) and NaCl (14.61 g) were dissolved in 




 The Pf33-MBP Factor Xa cleavage mixture (Section 2.20.4.2) was dialysed against 20 
mM Tris-HCl, 25 mM NaCl, pH 8.0. DEAE-Sepharose (6 ml) was poured into a column 
(approximately 1 x 10 cm) and washed with 10 mM Tris-HCl, 25 mM NaCl, pH 8.0 
(approximately 40 ml). The Pf33-MBP Factor Xa cleavage mixture was loaded onto the 
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column and the flow-through collected in fractions. The column was washed with 10 mM Tris, 
25 mM NaCl, pH 8.0 until the absorbance of the fractions at 280 nm reached a reading of zero. 
A gradient of 25 mM NaCl to 500 mM NaCl (25 ml each) in 20 mM Tris-HCl, pH 8.0 was 
started. Fractions were collected and monitored with absorbance readings at 280 nm.  
 
2.20.6 ‘On column’ cleavage of Pf33-MBP 
2.20.6.1 Reagents 
Column buffer [20 mM Tris-HCl, 200 mM NaCl, 1 mM EDTA, 1 mM NaN3]. Section 
2.20.2.1. 




Amylose resin (1 ml) was placed in a 10 ml polypropylene column and equilibriated 
with column buffer. Clarified lysate from Pf33-MBP expression (Section 2.20.2.2) was cycled 
through the column overnight. The resin was washed with column buffer to remove any 
unbound protein. The absorbance of the column buffer was read at 280 nm to determine when 
all the unbound protein had been washed away. Pf33-MBP bound to the amylose resin was 
equilibriated with cleavage buffer. Cleavage buffer (1 ml) was added to the amylose resin. The 
column was gently rocked from side to side to resuspend the resin in the cleavage buffer. 
Factor Xa (20 μg) was added and the column was left to gently rock overnight at room 
temperature. Fractions (0.5 ml) were collected immediately from the column. Additional 
cleavage buffer was then added and fractions were collected. The absorbance of the fractions 
was monitored at 280 nm to determine when all of the Pf33 had been washed from the 
column. The amylose column was then equilibriated with column buffer and the bound MBP 
was eluted with 10 mM maltose. Fractions were collected and monitored with absorbance 




2.21 Expression of Pf33 as a GST fusion protein 
2.21.1 Subcloning 822 bp PFC0760c gene sequence into pGEX4T1 
The 822 bp portion of the PFC0760c gene sequence was subcloned into the pGEX4T1 
expression vector, resulting in a glutatione-S-transferase fusion protein (Pf33-GST).  
 The pGEX4T1 and pTS822 plasmids were isolated using the Wizard
®
 Plus SV 
minipreps DNA purification system (Section 2.12.2) and digested with BamHI (Section 2.13) 
to linearise the pGEX4T1 plasmid and to release the 822 bp insert from pTS822. Digestion of 
the plasmids was confirmed by agarose gel electrophoresis (Section 2.7). The digested 
pGEX4T1 plasmid was dephosphorylated (Section 2.14). Both the insert DNA and the 
pGEX4T1 plasmid were excised from low melting point agarose gel (Section 2.7), purified 
(Section 2.15.1) and ligated together (Section 2.16). The pGEX4T1Pf33 plasmid was purified 
by sodium acetate-ethanol precipitation (Section 2.17) and electroporated into competent cells 
(Section 2.18.1) which were then spread onto LB media plates (Section 2.9) containing 
ampicillin (Section 2.9). Colonies were assayed for insert by colony PCR (Section 2.10) and 
restriction enzyme digestion (Section 2.13). 
 
2.21.2 Expression of Pf33-GST 
 Expression of Pf33-GST was performed as for Pf33-MBP expression, with three 
modifications. The cells were pelleted by centrifugation (7700 g, 10 min, 4°C) and the cell 
pellet was resuspended in ice cold PBS containing 1% (v/v) triton X-100 (Section 2.21.3.1) 
(40 ml per litre of culture). Protease inhibitors and lysozyme were added as for Pf33-MBP 
expression (Section 2.20.2.2). After sonication, the supernatant was clarified by centrifugation 
(12 000 g, 10 min, 4°C), followed by filteration through Whatman no. 1 paper. GST was 
expressed from non-recombinant pGEX4T1 as a control.  
 
2.21.3 Glutathione agarose purification of Pf33-GST 
2.21.3.1 Reagents 
Phosphate buffered saline (PBS), pH 7.2, 0.02% (w/v) NaN3. NaCl (8 g), KCl (0.2 g), 
Na2HPO4.2H2O (1.15 g) and KH2PO4 (0.2 g) were dissolved in dH2O (approximately 950 ml) 




PBS-Triton [PBS with 1% (v/v) Triton X-100]. Triton X-100 (1 ml) was dissolved in PBS 
(100 ml). 
Glutathione agarose column. Lyophilised glutathione agarose (70 mg) was swollen in dH2O 
(14 ml) overnight at 4°C. This resulted in approximately 1 ml of resin which was placed in a 
Poly-Prep® Chromatography column and equilibrated with 20 column volumes of PBS. 
50 mM Tris-HCl buffer, pH 8. Tris (3.03 g) was dissolved in approximately 470 ml dH2O and 
adjusted to pH 8 with HCl. The volume was made up to 500 ml with dH2O. 
Elution buffer [10 mM reduced glutathione]. Reduced glutathione (0.092 g) was dissolved in 
50 mM tris-HCl buffer, pH 8 (30 ml). 
Cleansing buffer 1 [100 mM Sodium borate buffer, pH 8, 500 mM NaCl]. Boric acid (0.6183 
g) and NaCl (2.922 g) were dissolved in dH2O (90 ml). The pH was adjusted to 8.0 with NaOH 
and the volume made up to 100 ml with dH2O. 
Cleansing buffer 2 [100 mM Sodium acetate buffer, pH 4, 500 mM NaCl]. Sodium acetate 
(0.82 g) and NaCl (2.9 g) were dissolved in dH2O (90 ml). The pH was adjusted to 4.0 with 
glacial acetic acid and the volume made up to 100 ml with dH2O. 
 
2.21.3.2 Procedure 
The glutathione agarose column was equilibriated with PBS-Triton. Sonicated and 
clarified fusion-protein supernatant (20 ml) (Section 2.21.2) was cycled through the column 
(overnight, 4°C). The resin was washed with PBS-Triton until the absorbance reading at 280 
nm was zero. Pf33-GST was eluted with elution buffer. Fractions (1 ml) were collected and 
analysed by SDS-PAGE (Section 2.4). 
Regeneration of the column was achieved by washing with 5 column volumes of 
cleansing buffer 1, 5 column volumes of dH2O, 5 column volumes of cleansing buffer 2, 
followed by 5 column volumes of dH2O. The resin was stored in PBS supplemented with NaN3 
at a final concentration of 0.02% (w/v) at 4°C. 
 
2.22 Intraperitioneal (I. P.) injection of mice 
2.22.1 Materials 





Stabilate was removed from storage in liquid nitrogen and allowed to thaw in water 
that had been pre-warmed at 37˚C. The stabilate was diluted if necessary with filter-sterilised 
PBS and then drawn up into a 1cc 27 Gauge x ½” syringe. The mouse to be injected was 
picked up by grasping the tail with the thumb and forefinger of one hand. Without letting go of 
the tail, the mouse was placed on top of the wire cage and allowed to pull away. Using the 
other hand, the fur on the shoulders and back were grasped between the thumb and forefinger 
and pulled tight, the whole time, still holding onto the tail with other hand. It was necessary to 
pull the skin tightly so as to prevent the mouse from being able to move its head too much as 
this would enable it to turn its head and bite. Still holding the mouse with both hands, the 
mouse was turned so that it was on its back, with its abdomen facing upward. The mouse held 
at a 45 degree angle (head pointing downwards), to ensure that no organs would accidentally 
be penetrated during I.P. injection. Using the third or fourth finger of the hand that was pulling 
the skin tight, the tail was secured between the palm and finger, thereby restraining the mouse 
with one hand. The syringe was held in the first two fingers of the free hand. The needle was 
inserted at an angle of approximately 30 degrees to the surface of the skin and approximately 
45 degrees to the mouse midline. The needle was carefully pushed into the skin until the 
needle enters the peritoneum, which was indicated by a slight easing of resistance to the 
needle. The plunger was depressed with the thumb, to release the required amount of 
parasitized red blood cells. The needle was removed, and the mouse returned to its cage. 
 
2.23 Preparation of blood films for determining parasitemia in mice  
Thin and thick blood films were prepared from blood from the tail midvein of 
Plasmodium infected mice. Thin films were routinely used to monitor the percentage of 
parasitized red blood cells in infected mice. The disadvantage of thin films is that the parasite 
is not easily detected at very low levels. The use of thick blood films offer a higher probability 
of observing parasites when they are at very low levels as a large number of red blood cells are 
concentrated into a very small area. The preparation of thick and thin blood films and the 












The mouse was restrained as for I. P. injection (Section 2.22). The tip of the tail was 
rested on a clean surface top. With a free hand, a sterile lancet was used to prick the tail mid-
vein. A drop of blood was collected onto a clean glass slide. With the corner of another glass 
slide, the blood droplet was spread slightly by moving the second slide gently in a circular 
motion. The blood smear was allowed to air dry and then fixed for 30 seconds in methanol. 
After allowing the slides to air dry, they were stained with Giemsa (Section 2.23.3). 
 
2.23.2 Thin blood film  
2.23.2.1 Reagents 
As for thick blood films (Section 2.23.1.1) 
 
2.23.2.2 Procedure 
A drop of mouse blood was collected onto a clean slide as explained for a thick blood 
film (Section 2.23.1.2). The slide was placed on a level surface and a second clean glass side 
was touched to the drop of blood. This causes the blood to spread along the length of the 
second. The second slide was held at an angle of approximately 45 degrees to the first slide 
pushed firmly along the first slide, ensuring that the slides were in even contact with one 
another. The blood smear was allowed to air dry and then fixed for 30 seconds in methanol. 
After allowing the slides to air dry, they were stained with Giemsa (Section 2.23.3).  
 
2.23.3 Giemsa staining of thick and thin blood films 
2.23.3.1 Reagents 
Methanol. 





Once the films had air dried after fixing in methanol for 30 seconds, they were stained 
for 30 min with Giemsa. The slides were washed under running water and allowed to air dry.  
 
2.24 Determining the number of parasitized red blood cells from thin blood films 
2.24.1 Procedure 
The fixed and stained thin blood films were observed under an oil immersion objective 
(100 X). Suitable fields of view were obtained for counting. These fields had an even spread 
of red blood cells with no red blood cells overlapping. The total number of red blood cells was 
counted within such a field. Then the number of those red blood cells, containing parasites, 
was determined. This was repeated for three to five fields per film. The total number of red 
blood cells divided by the number of parasitized red blood cells, multiplied by one hundred 
gave the percentage parasitemia. 
 
2.25 Collection of blood from mice using retro-orbital bleeding  
Blood was collected from mice from the retro-orbital plexus. This was performed as a 
terminal procedure under anaesthetic. 
 
2.26 Preparation of stabilate from infected blood 
Stocks of parasitized red blood cells (stabilate) were prepared and stored under liquid 
nitrogen so that further mice could be infected if necessary. 
 
2.26.1 Reagents 
RPMI-1640 medium (as per Sigma instructions). RPMI-1640 (0.624 g) was dissolved in 
sterile dH2O (approximately 54 ml). Sodium bicarbonate (0.120 g) was added and stirred until 
dissolved. The pH was adjusted to pH 7.0 with dilute HCl.  The solution was made up to 60 ml 
with sterile dH2O and filter-sterilized with a 0.22 μm acetate filter. Aliquots (5 ml) were stored 
in sterile tubes at 4˚C in the dark. Deterioration of the liquid medium was recognised either by 
a change in pH, colour or by the presence of precipitates or a cloudy appearance. Aliquots of 
Media showing signs of deterioration were discarded.  
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Parasite freezing medium [RPMI-1640 containing 10% glycerol]. Sterile glycerol (1 ml) was 
added to filter-sterilized RPMI-1640 medium (9 ml) and vortexed briefly to mix. The freezing 
media was stored at 4˚C, but was discarded if a colour change was observed or if any 
precipitate was visible. 
Sterile glycerol. Glycerol was autoclaved to sterilise. 
 
2.26.2 Procedure 
The number of parasitized and non-parasitized red blood cells were determined 
(Section 2.24). The whole blood collected from the infected mouse (Section 2.25) was 
transferred from the heparinized vacutainer to a sterile microcentrifuge tube. The volume of 
whole blood was noted. The blood was centrifuged (1000 g, 4 min, 4˚C) to pellet the red blood 
cells. The volume of the plasma supernatant was determined. The plasma was transferred to a 
sterile microcentrifuge tube and stored at –20˚C. The volume of packed red blood cells was 
estimated by subtracting the plasma volume from the whole blood volume. The packed red 
blood cells were very gently washed with RPMI-1640 medium with a volume equal to the 
plasma volume and then centrifuged as before (1000 g, 4 min, 4˚C). Care was taken to not 
shear the red blood cells by using pipette tips that had been cut to give a larger opening when 
resuspending the pellet. The washing was repeated a total of three times. The red blood cells 
were then diluted to the required number of parasitized red blood cells per 100 μl, with RPMI-
1640 containing 10% (v/v) glycerol.  
 
2.27 Determining the number of red blood cells in a mouse blood sample 
It was necessary to determine the number of red blood cells present in a sample of 
mouse blood. This was achieved using a haemocytometer and based on the method described 
by Hudson and Hay (1989) and Mishell et al., (1980). 
 
2.27.1 Reagents 





Whole blood was diluted 1:20 in RPMI-1640 (i.e. 10 μl whole blood made up to 200 μl 
with RPMI-1640). This was further diluted by a factor of 10 to give a final dilution of 1:200 
(i.e. 100 μl of the 1:20 dilution was made up to 1 ml with RPMI-1640). A cover slip was 
placed over the haemocytometer chamber and the 1:200 dilution of whole blood (25 μl) was 
allowed to run under the cover slip and into the chamber. The haemocytometer chamber was 
observed under 40x magnification.  
 
The total number of RBC‟s was calculated as follows: 
 
Total RBC‟s = (sum of RBC counted in 5 blocks)/5 x total blocks x dilution factor x 10
4
 
          = (sum of RBC counted 5 blocks)/5 x 25 x 200 x 10 000 
          = number RBC / ml 
 
2.28 Solubilization of parasitized red blood cells  
Plasmodium infected red blood cells having 30-40% parasitemia were lysed and used 
for western blotting purposes. Uninfected red blood cells were lysed and used as controls. 
 
2.28.1 Reagents 
Solubilization buffer [20 mM Tris-HCl, pH 7.8, 50 mM NaCl, 5 mM EDTA, 1 mM PMSF, 
0.5% (v/v) triton X-100, 0.05% (w/v) NaN3]. Tris (0.12 g), NaCl (0.15 g) and EDTA (0.093 g) 
were dissolved in dH2O (40 ml) and adjusted to pH 7.8 with HCl. PMSF (5 ml of 10 mM 
PMSF) was added. NaN3 (0.025 g) and triton X-100 (250 µl) were added and the volume 
made up to 50 ml with dH20. 
10 mM (1.74 mg/ml) Phenylmethyl-sulfonyl fluoride (PMSF). PMSF (0.0174 g) was 
dissolved in propan-2-ol (isopropanol) (10 ml), aliquoted and stored at –20˚C. 
 
2.28.2 Procedure 
The number of red blood cells was determined (Section 2.27). The red blood cells were 
centrifuged (1000 g, 4 min, 4 ºC). The serum was removed and the red blood cell packed 
volume was estimated. The red blood cells were resuspended in an appropriate volume of 
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solubilization buffer to give a final red blood cell count of 1 X 10
9
 RBC/ ml. The red blood 
cells were left overnight at 4 ºC. The cells were sonicated (10 x 15 s) and the red blood cell 
debris was removed by centrifugation (10 000 g, 1 h, 4 ºC). The supernatant was aliquoted and 
stored at -70 ºC until needed for running on an SDS-PAGE gel and western blotting. 
 
2.29 Coupling peptides to rabbit albumin using glutaraldehyde 
Coupling peptides to proteins with the cross-linking reagent glutaraldehyde is a simple 
effective method, which retains the native antigenicity of the protein and peptides (Reichlin, 
1980). The coupling reaction involves a single free amino group and thus is generally not used 
for peptides with internal amino groups, as this could result in large multimeric complexes 
being formed (Thorpe, 1994). 
 
2.29.1 Reagents 
Phosphate buffered saline (PBS), pH 7.2. NaCl (8 g), KCl (0.2 g), Na2HPO4.2H2O (1.15 g) 
and KH2PO4 (0.2 g) were dissolved in dH2O (approximately 950 ml) and titrated to pH 7.2 if 
necessary. The volume made up to 1 l with dH2O. 
2% (v/v) Glutaraldehyde solution. 25% glutaraldehyde (80 μl) was made up to 1 ml with 
dH2O. 
10 mg/ml NaBH4. NaBH4 (0.002 g) dissolved in dH2O (200 μl). 
 
2.29.2 Procedure 
Peptide FKLGSCYLYIINRNLKEI (0.004g, 1.8 x 10
-6
 moles, Mr 2169.5) was 
dissolved in dimethylsulfoxide (DMSO) (50 μl). Additional DMSO was added in 50 μl 
increments to dissolve the peptide, if necessary. The dissolved peptide solution was then made 
up to 500 μl with PBS, pH 7.2. The carrier protein, rabbit albumin (0.0031 g, 4.5 x 10
-8
 moles, 
Mr 68200) was dissolved in PBS (500 μl). The rabbit albumin and peptide were then combined 
and 2% (v/v) glutaraldehyde solution (1 ml) was added drop wise with gentle stirring. The 
solution was then stirred for a further 2h at 4˚C. The reaction was stopped with the addition of 
10 mg/ml NaBH4 (200 μl). The solution was stirred for 1h at 4˚C. The rabbit albumin-peptide 
conjugate was then dialysed against 3 changes of PBS containing 0.02% (w/v) NaN3 and then 




2.30 Coupling peptides to rabbit albumin using 3-maleimidobenzoic acid N-
hydroxysuccinimide (MBS) 
MBS is a hetero-bifunctional coupling reagent developed by Kitagawa and Aikawa 
(1976). The reagent can be used to link peptides to carrier proteins via cysteine residues and 
free amino groups (Harlow and Lane, 1988). MBS acylates the amino groups on the carrier 
protein via the active ester. This reaction is followed by the formation of thioester bonds upon 
addition of a thiol group to the double bond of the maleimide (Kitagawa and Aikawa, 1976). 
The cysteine residues of the peptide were reduced with DTT prior to coupling, although this 
step was not completely necessary. The reduced peptide was separated from the DTT with 
chromatography. The separation of the reduced peptide from DTT was monitored with 5, 5‟-
Dithiobis (2-nitrobenzoic acid) (DTNB), a reagent commonly referred to as Ellman‟s reagent, 
as it was developed by Ellman (1959). DTNB is an aromatic disulfide that enables the 
detection of thiol groups. It reacts with aliphatic thiols, forming a mixed disulfide and 2-nitro-








 G25 fine. 
100 mM NaH2PO4, 0.02% (w/v) NaN3, pH 7.0. NaH2PO4.2H2O (15.6 g) was dissolved in 
approximately 950 ml dH2O and adjusted to pH 7.0 with concentrated NaOH. NaN3 (0.2 g) 
was added and the volume made up to 1 l.  
Reducing buffer [100 mM Tris-HCl, 1mM EDTA, 0.02% (w/v) NaN3, pH 8]. Tris (1.21 g) and 
EDTA (0.037 g) were dissolved in 90 ml dH2O and titrated to pH 8 with HCl. NaN3 (0.02 g) 
was added and the volume made up to 100 ml. 
Ellman‟s reagent buffer [100 mM Tris-HCl, 10 mM EDTA, 0.1% SDS, pH 8]. Tris (1.21 g) 
and EDTA (0.37 g) were dissolved in approximately 80 ml dH2O and titrated to pH 8 with 
HCl. SDS (0.1 g) was added and the volume made up to 100 ml. 
Ellman‟s reagent (10 mM). Ellman‟s reagent (5, 5‟-dithiobis-(2-nitrobenzoic acid) (0.01 g) 
was dissolved in Ellman‟s reagent buffer (2.5 ml). 
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Reduction of peptides: Peptide CFKLGSCYLYIINRNLKEI (0.004g, 1.8 x 10
-6
 moles, 
Mr 2270.66) and peptide SDDDNRQIQDFEC (0.004 g, 2.5 x 10
-6
 moles, Mr 1583) were 
dissolved in DMSO (50 μl). If necessary, additional DMSO was added in 50 μl increments to 
fully dissolve the peptide. The peptide solution was made up to 1 ml with reducing buffer. 
DTT (1 ml) was added to the peptide solution and left to incubate at 37˚C for 1.5 h. Molecular 
exclusion chromatography (MEC) was used to separate the reduced peptide from unreacted 
DTT. The peptide solution was loaded onto a Sephadex G10 column (15 x 110 mm, 10 ml/h) 
equilibrated with 100 mM NaH2PO4, 0.02% (w/v) NaN3, pH 7.0. The column was continually 
washed with 100 mM NaH2PO4, 0.02% (w/v) NaN3, pH 7.0, whilst collecting 500 μl fractions. 
Each of the fractions was tested for reduced peptide by combining 10 μl of the fraction and 10 
μl of Ellman‟s reagent. The development of a yellow colour indicated the presence of reduced 
peptide. The fractions of reduced peptide were pooled. Unreacted DTT eluted after reduced 
peptide, and produced an intense yellow colour when tested with Ellman‟s reagent. These 
fractions were discarded.  
Activation of carrier: Rabbit albumin (0.003 g, 4.4 x 10
-8
 moles, Mr 68200, for peptide 
CFKLGSCYLYIINRNLKEI; 0.0043g, 6.3 x 10
-8
 moles, Mr 68200, for peptide 
SDDDNRQIQDFEC) was dissolved in PBS (1725 μl) to give a molar ratio of carrier to 
peptide of 1:40. MBS (0.0006 g, 4.7 x 10
-8
 moles, Mr 12570, for peptide 
CFKLGSCYLYIINRNLKEI; 0.0008 g, 6.4 x 10
-8
, for peptide SDDDNRQIQDFEC) was 
dissolved in dimethyl formamide (DMF) (275 μl) to give a molar ratio of carrier protein to 
MBS of 1:40. The rabbit albumin and MBS were combined and stirred for 30 min at room 
temperature. The solution was then passed over a Sephadex G25 column (15 x 130 mm, 10 
ml/h) equilibrated with 100 mM NaH2PO4, 0.02% (w/v) NaN3, pH 7.0, to separate activated 
carrier from excess MBS. The fractions were monitored for activated carrier by reading the 
absorbance of the fractions at 280 nm. Fractions containing activated carrier were combined 
with pooled reduced peptide fractions and stirred gently for 3 h at room temperature. This was 




2.31 Immunisation of chickens with antigen and rabbit albumin-conjugated peptides   
Anti-peptide antibodies were raised in chickens. Two chickens for each immunogen 
were immunised intramuscularly at two sites in their breast muscles. The chickens were 
immunised at week 0, with the rabbit albumin-peptide conjugate (Section 2.29 and 2.30) (100 
μg), emulsified with Freunds complete adjuvant in a 1:1 (v/v) ratio. Booster immunisations 
were performed at weeks 2, 4, and 6 with the same amount of peptide emulsified in Freund‟s 
incomplete adjuvant in a 1:1 (v/v) ratio. Eggs were collected prior to the initial immunisation, 
(week 0) to serve as pre-immune control eggs. After the initial immunisation, the eggs were 
collected for a period of 12 weeks. The eggs were stored at 4˚C until the immunoglobulin Y 
(IgY) from the egg yolk was isolated (Section 2.32). 
 
2.32 Isolation of immunoglobulin Y from chicken egg yolk 
Immunoglobulin Y (IgY) was isolated from chicken egg yolks (Goldring and Coetzer, 
2003). Polson et al. (1980; 1985) developed the technique, which involves the use of a 
hydrophilic polymer, polyethylene glycol (PEG) to precipitate protein. The ability of PEG to 
fractionally precipitate proteins was recognised by Polson et al. in 1964. PEG precipitates 
proteins by excluding the proteins from water. With increasing concentrations of PEG, the 
protein is eventually brought to its solubility limit and precipitates out of solution (Dennison, 
1999). The procedure for the isolation of IgY involved precipitation steps of increasing PEG 
concentration. Vitellin and lipids were precipitated first with 3.5% (w/v) PEG. Increasing the 
PEG concentration to 12% (w/v) precipitates the IgY. 
 
2.32.1 Reagents 
Isolation buffer [100 mM NaH2PO4.2H2O, 0.02% NaN3, pH 7.6]. NaH2PO4.2H2O (15.6 g) was 
dissolved in 950 ml dH2O and titrated to pH 7.6 with NaOH. NaN3 (0.2 g) was added and the 
volume was made up to 1 l. 





The egg yolk was separated from the albumin and gently washed under running water. 
The yolk sac was removed and the volume of yolk determined. A volume of isolation buffer, 
equal to twice the yolk volume, was then added to the yolk and stirred gently. To this 3.5% 
(w/v) PEG 6000 was added. This was stirred until the PEG had fully dissolved and the lipids 
had separated out of solution. The solution was then centrifuged (4 420 g, 30 min). The 
supernatant was filtered through absorbent cotton wool and the volume of resulting filtrate 
noted. The yellow pellet containing the lipid and vitellin fractions was discarded. To the 
filtrate, 8.5% (w/v) PEG 6000 was added. This increased the PEG concentration from 3.5% 
(w/v) to 12% (w/v). The PEG was fully dissolved and the solution was centrifuged (12 000 g, 
10 min) to pellet the IgY. The supernatant was discarded and the pellet was suspended in a 
volume of isolation buffer equal to the yolk volume. PEG 6000 was added to 12% (w/v) and 
dissolved. The solution was centrifuged (12 000 g, 10 min). The supernatant was discarded 
and the pellet was suspended in isolation buffer, in a volume equal to 1/6
th
 of the yolk volume. 
Sodium azide (10% (w/v) solution) was added to a final concentration of 0.1%. The isolated 
IgY was then stored at 4˚C in sterile bottles. 
 
2.32.3 Determination of IgY concentration 
The absorbance of a 1:50 dilution of IgY in isolation bufferr (Section 2.32.1) was read 
at 280 nm in quartz cuvettes. The concentration of IgY in the undiluted solution was then 
determined using the extinction coefficient of a 1 mg/ml of IgY at 280 nm of 1.25 (Coetzer, 
1993).  
 
2.33 Preparation of affinity matrices 
Peptides were coupled to affinity matrices for the purification of antibodies produced 
against the peptides.  
 
2.33.1 Coupling of peptide or protein to AminoLink® 
The AminoLink
®
 coupling gel consists of a 4% cross-linked beaded agarose matrix 
with aldehyde functional groups. The coupling reaction involves the formation of a labile 
Schiff base. This occurs due to the primary amine groups on the peptide or protein reacting 
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with aldehyde groups on the matrix. A stable secondary amine bond is formed between the 
peptide/protein and the matrix through reduction of the of the Schiff base intermediate with 
sodium cyanoborohydride (NaCNBH3). Unreacted aldehyde groups on the matrix are 
quenched with Tris-HCl. Additional NaCNBH3 is added to form a stabile Schiff base. The 
additional NaCNBH3 reduces the Schiff base intermediate formed between the Tris primary 
amine and the matrix. NaCNBH3 is the favoured reducing reagent as it is gentle and it is 
specific toward the Schiff base structure (Hermanson, 1996). 
 
2.33.1.1 Reagents 
Coupling buffer [0.1 M NaH2PO4, 0.05% (w/v) NaN3, pH 7-7.5]. NaH2PO42H2O (7.8 g) was 
dissolved in dH2O (490 ml) and the solution was adjusted to pH 7.4 with NaOH. NaN3 (0.25 
g) was added and the volume made up to 500 ml. 
Quenching buffer [1 M Tris-HCl, pH 7.4]. Tris (12.11 g) was dissolved in dH2O (80 ml) and 
titrated to pH 7.4 with HCl. The solution was then made up to 100 ml with dH2O. 
Washing buffer [1 M NaCl]. NaCl (29.22 g) was dissolved in dH2O (500 ml). 
Sodium cyanoborohydride solution [1 M NaCNBH3]. NaCNBH3 (0.0314 g) was dissolved in 
dH2O (500 μl). This was prepared in a fume hood as NaCNBH3 is toxic. 
Phosphate buffered saline (PBS), pH 7.2. NaCl (8 g), KCl (0.2 g), Na2HPO4.2H2O (1.15 g) 
and KH2PO4 (0.2 g) were dissolved in dH2O (approximately 950 ml) and titrated to pH 7.2 if 
necessary. The volume made up to 1 l with dH2O. 
AminoLink
®
 Coupling Gel. 
 
2.33.1.2 Procedure 
Peptide (0.004 g) was dissolved in DMSO (500 μl). This was diluted 1:3 in coupling 
buffer. To obtain an AminoLink
®
 Coupling Gel bed volume of 2 ml, 4 ml was pipetted into a 
Poly-Prep
®
 chromatography column and washed three times with coupling buffer (each wash 
volume equivalent to 10 column volumes). The gel was allowed to settle and the supernatant 
discarded. The peptide solution was added and the cyanoborohydride solution (25 μl/ml) was 
added in a fume hood. This was mixed for two hours at room temperature and then left to 
stand (4 h, room temperature). The gel was then washed once with quenching buffer. A 
volume of quenching buffer equal to the volume of the gel was then added and 
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cyanoborohydride solution (50 μl/ml) was added in the fume hood. This was then mixed (end-
over-end rotation, 30 min, room temperature). The gel was allowed to settle and was then 
washed with washing buffer until the absorbance of the eluant at 280 nm reached a zero 
reading. The gel was then washed with coupling buffer and stored at 4˚C until required. 
 
2.33.2 Coupling of peptides to SulfoLink® Coupling Gel 
The SulfoLink
®
 coupling gel contains iodoacetyl groups which allow for the 
immobilization of ligands possessing sulfhydryl groups. Prior to coupling, it is necessary to 
reduce the terminal cysteine residues of the peptide to be immobilized with DTT. Ellman‟s 
reagent is used in this protocol to detect reduced peptide as before (Section 2.30.1).  
 
2.33.2.1 Reagents 
50 mM Tris-HCl, 5 mM EDTA, pH 8.5. Tris (6.057 g) and EDTA (1.86 g) were dissolved in 
approximately 950 ml of dH2O and titrated to pH 8.5 with HCl. The volume was then made up 
to 1 l with dH2O. 
Washing buffer [1 M NaCl]. NaCl (58.44 g) dissolved in approximately 950 ml dH2O, and the 
volume made up to 1 l. 
Ellman‟s reagent buffer [100 mM Tris-HCl, 10 mM EDTA, 0.1% SDS, pH 8]. Section 2.30.1. 
10 mM Dithiothreitol (DTT). Section 2.30.1. 
10 mM Ellman‟s reagent. Section 2.30.1. 
SulfoLink
®
 Coupling Gel. 
50 mM L-cysteine. L-cysteine. HCl (0.00878 g) dissolved in general buffer (1 ml). This buffer 
was prepared just prior to use. 
100 mM NaH2PO4, 0.02% (w/v) NaN3, pH 7.0. Section 2.30.1. 
 
2.33.2.2 Procedure 
The peptide (0.005 g) was solubilised in DMSO (50 μl). If necessary, additional 
DMSO was added in 50 μl increments to fully dissolve the peptide. The volume was then 
made up to 500 μl with 50 mM Tris-HCl, 5 mM EDTA, pH 8.5. The dissolved peptide was 
reduced with 10 mM DTT (500 μl) (1.5 h, 37˚C). After incubation, the reduced peptide was 
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separated from unreacted DTT by molecular exclusion chromatography (MEC) as described in 
Section 2.30.1.  
SulfoLink
®
 Coupling gel (2 ml of the 50% (v/v) slurry) was pipetted into a Poly-Prep
®
 
chromatography column to give a bed volume of 1 ml. The gel was washed with 6 column 
volumes of 50 mM Tris-HCl, 5 mM EDTA, pH 8.5. The fractions from the MEC column 
containing reduced peptide was added to the SulfoLink® coupling gel and mixed (end-over-
end rotation, 15 min, room temperature). This was then left to stand (30 min, room 
temperature). The column was washed with 3 column volumes of 50 mM Tris-HCl, 5 mM 
EDTA, pH 8.5, before incubation with 50 mM cysteine (1 ml) to block unreacted sites (end-
over-end rotation, 15 min, room temperature). This was left to stand (30 min, room 
temperature). The column was washed with 16 column volumes of 1 M NaCl, followed by 2 
column volumes of 0.1 M NaH2PO4, 0.05% (w/v) NaN3, pH 6.5. The resin was stored at 4˚C 
until required. 
 
2.34 Affinity purification of chicken IgY anti-peptide antibodies 
IgY isolated from chicken egg yolk contains a pool of polyclonal antibodies, to a 
number of different antigens that the chickens have been exposed to, including the 
immunogen. Antibodies not specific for the peptide they were raised against could interfere 
with assays and it was therefore necessary to isolate specific anti-peptide antibodies from the 
IgY pool. The IgY pool was passed over affinity matrices with the respective peptides 
immobilized to achieve this. 
 
2.34.1 Reagents 
Washing buffer [100 mM NaH2PO4, 0.05% (w/v) NaN3, pH 6.5]. NaH2PO4.2H2O (15.6 g) was 
dissolved in approximately 950 ml dH2O and titrated to pH 6.5 with NaOH. NaN3 (0.5 g) was 
added and the volume made up to 1 l.  
Elution buffer [100 mM glycine, 0.02% (w/v) NaN3, pH 2.8]. Glycine (7.5 g) was dissolved in 
950 ml dH2O and titrated to pH 2.8 with HCl. NaN3 (0.2 g) was added and the volume made 
up to 1 l. 
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Neutralising buffer [1 M NaH2PO4, 0.02% (w/v) NaN3, pH 8.5]. NaH2PO4.2H2O (15.6 g) was 
dissolved in 90 ml dH2O and titrated to pH 8.5 with NaOH. NaN3 (0.02 g) was added and the 
volume made up to 100 ml.  
 
2.34.2 Procedure 
IgY isolated from the eggs collected in weeks 4-8 and 9-12 for each chicken were 
pooled and filtered through Whatman no.1 filter paper. The affinity columns (Section 2.33.1 
and 2.33.2) were equilibrated with washing buffer. The IgY pool was cycled overnight (10 
ml/h, RT) through the column to allow for binding of the anti-peptide antibodies to the peptide 
on the column. The antibodies were cycled backwards through the column to avoid blockages 
and the column running dry. The column was washed with approximately 12 column volumes 
of washing buffer to remove any unbound IgY. Bound IgY was eluted with elution buffer. 
Fractions of 900 μl were collected into 1.5 ml tubes containing neutralising buffer (100 μl). 
The elution of IgY was monitored spectrophotometrically at 280 nm. Elution buffer (900 μl) 
and neutralising buffer (100 μl) was used as a blank. Fractions containing purified IgY were 
pooled and 10% (w/v) NaN3 was added to a final concentration of 0.1%. The antibodies were 
stored at 4˚C. The column was washed with approximately 12 column volumes of washing 
buffer before storing at 4˚C. 
 
2.35 Enzyme linked immunoadsorbent assay (ELISA) 
The progress of antibody production in chicken eggs was monitored using the ELISA 
technique, which was first introduced by Engvall and Perlmann (1971).  
 
2.35.1 Reagents 
Phosphate buffered saline (PBS), pH 7.2. NaCl (8 g), KCl (0.2 g), Na2HPO4.2H2O (1.15 g) 
and KH2PO4 (0.2 g) were dissolved in dH2O (approximately 950 ml) and titrated to pH 7.2 if 
necessary. The volume was made up to 1 l with dH2O. 
Carbonate coating buffer, pH 9.6 [0.159% (w/v) Na2CO3 and 0.293% (w/v) NaHCO3]. 
Na2CO3 (0.159 g) and NaHCO3 (0.293 g) were dissolved in approximately 90 ml dH2O and 
titrated to pH 9.6 with dilute HCl. The volume was made up to 100 ml with dH2O. 
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0.5% Bovine serum albumin (BSA)-PBS. BSA (0.5 g) was dissolved in PBS (100 ml). This 
was prepared just before use. 
0.1% PBS-Tween. Tween 20 (1 ml) was made up to 1 l with PBS. 
0.15 M Citrate-phosphate buffer, pH 5.0. A citric acid solution (21 g/l) was titrated to pH 5.0 
with a solution of Na2HPO4.2H2O (36.5 g/l). 
2, 2′-Azinobis [3-ethyl-2, 3-dihydrobenzthiazole-6-sulfonate (ABTS) substrate solution [0.05 
%( w/v) ABTS, 0.0015% (v/v) H2O2, in citrate-phosphate buffer]. ABTS (0.0075 g) and 30% 
H2O2 (7.5 μl) dissolved in 0.15 M citrate-phosphate buffer, pH 5.0 (15 ml). 
 
2.35.2 Procedure 
Peptides FKLGSCYLYIINRNLKEI, CFKLGSCYLYIINRNLKEI and 
SDDDNRQIQDFEC were coated at a concentration of 1 μg/ml in PBS (150 μl/well). 
Recombinant maltose binding protein was coated at a concentration of 1 μg/ml in carbonate 
coating buffer, pH 9.6 (150 μl/well). The coated plates were left at 4˚C overnight. The ELISA 
plates were emptied and patted upside down on paper towelling to remove any residual liquid. 
Non-specific binding of antibodies was prevented by blocking with 0.5% (w/v) BSA-PBS 
(200 μl/well, 1 h at 37˚C). The plates were then washed three times with PBS-Tween and 
patted dry as before. IgY from individual weeks was used at a concentration of 25 μg/ml in 
0.5% (w/v) BSA-PBS (100 μl/well, 2 h at 37˚C). Affinity purified antibodies were diluted 
appropriately in 0.5% (w/v) BSA-PBS (100 μl/well, 2 h at 37˚C). The plates were then washed 
three times with PBS-Tween and patted dry as before. HRPO-conjugated rabbit anti-chicken 
IgY secondary antibody was diluted 1:20 000 dilution in 0.5% (w/v) BSA-PBS (120 μl/well, 1 
h at 37˚C).  The plates were then washed three times with PBS-Tween and patted dry as 
before. ABTS substrate solution (150 μl/well) was added and the colour was left to develop in 
the dark for 45 min before the A405 of each well was measured using a VERSAmax tunable 
microplate reader. 
 
2.36 Immunofluorescence assays 
Slides were coated with P. yoelii yoelii parasitized mouse red blood cells according to 
the method described by Perlmann et al. (1984). 
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The native P. yoelii yoelii protein PY05757 and P. yoelii yoelii LDH were probed with 
the anti-peptide antibodies on P. yoelii yoelii infected red blood cells. The protocol used was 
based on a method employed by Rasoloson et al. (2004). Anti-chicken antibodies conjugated 
with fluorescein isothiocyanate (FITC) were used to detect bound anti-peptide antibodies. The 
slides were counterstained with 4‟, 6-diamide-2‟-phenylindole dihydro chloride (DAPI) to 
indicate the parasite nuclear material. 
 
2.36.1. Reagents 
Coating buffer. Na2CO3 (0.0795 g) and NaHCO3 (0.1465 g) were dissolved in approximately 
40 ml dH2O and titrated to pH 9.6 with dilute HCl. NaN3 (0.01 g) was added and the volume 
made up to 50 ml. 
Isotonic Tris buffer [0.15 M Tris, pH 7.2]. Tris (0.908 g) was dissolved in sterile dH2O 
(approximately 40 ml) and adjusted to pH 7.2 with HCl. The solution was then made up to 50 
ml with sterile dH2O. As the solution was usually filter sterilized with a 0.22 μm acetate filter, 
the pH was adjusted to approximately pH 7.0 due to the tendency of solutions to increase in 
pH during the filtering process. 
0.9% (w/v) NaCl. NaCl (0.9 g) dissolved in sterile dH2O (100 ml).  
Hanks balanced salt solution (HBSS) [Sigma 9.5 g/l]. HBSS (0.95g) was dissolved in sterile 
dH2O (approximately 90 ml) by stirring gently on a magnetic stirrer. Sodium bicarbonate was 
added to a final concentration of 0.35 g/l. The solution was stirred until the sodium 
bicarbonate dissolved. The solution was then adjusted to pH 6.9 - 7.0 and made up to 100 ml 
with sterile dH2O.  
Tris buffered Hanks balanced salt solution (TBH). Isotonic Tris buffer, pH 7.2 (10 ml), 0.9% 
(w/v) NaCl (90 ml) and Hanks balanced salt solution (HBSS) (100 ml) were combined and 
filter sterilize using a 0.22 μm acetate filter. 
1% (v/v) Glutaraldehyde. 25% (v/v) Glutaraldehyde (200 μl) was made up to 5 ml with PBS. 
0.05% (v/v) Tween-TBH. Tween-20 (50 μl) was diluted to 100 ml with TBH. 
Phosphate buffered saline (PBS), pH 7.2. NaCl (8 g), KCl (0.2 g), Na2HPO4.2H2O (1.15 g) 
and KH2PO4 (0.2 g) were dissolved in dH2O (approximately 950 ml) and titrated to pH 7.2 if 
necessary. The volume was made up to 1 l with dH2O. 





BALB/c mice were infected with P. yoelii yoelii parasitised mouse red blood cells by 
I.P. injection (Section 2.22). Blood was collected from the infected mice by retro orbital 
bleeding (Section 2.25) when the percentage of parasitized red blood cells in the mice was 
determined to be approximately 30% (Section 2.24). The blood was collected into Heparin 
coated Vacutainer
TM
 tubes and kept on ice. The volume of whole blood was determined and 
then the red blood cells were centrifuged (1 000 x g, 1 min). The plasma volume was 
determined in order to calculate the red blood cell packed volume. The red blood cells were 
suspended in a volume of TBH approximately equal to the whole blood volume and 
centrifuged as before to pellet the red blood cells. The supernatant was discarded and the 
packed red blood cells were suspended to 1% (v/v) haematocrit in TBH. The wells of 8 mm 
diameter, 8-welled slides were pre-treated with one drop of coating buffer per well 
(approximately 20 μl per well) for 30 minutes at room temperature. The coating buffer was 
then aspirated. One drop (approximately 20 μl) of the 1% (v/v) haematocrit was placed in each 
of the pre-treated wells and left for 30 minutes in order to allow the red blood cells to settle 
and adhere to the surface of the slide. Unbound red blood cells were washed off the slides by 
immersing them upside down in TBH and gently shaking them. The red blood cells were then 
fixed to the wet slides by covering them in a solution of 1% (v/v) glutaraldehyde in PBS. After 
10 seconds the glutaraldehyde solution was allowed to run off the slides and the fixation 
procedure repeated. The slides were washed with sterile dH2O and allowed to air dry. The 
slides were stored at –20˚C until needed.  
The wells of the slide coated with parasitized mouse red blood cells were blocked with 
2% (w/v) BSA-PBS (20 μl per well, 1 h, RT). The blocking solution was aspirated and the 
wells washed with PBS (20 μl/well, 2 x 3 min). The PBS was aspirated and the wells were 
incubated with primary antibody (pre-immune IgY, anti-PfLDH IgY (controls) and anti-
peptide FKLGSCYLYIINRNLKEI, CFKLGSCYLYIINRNLKEI and SDDDNRQIQDFEC 
IgY, 10 μg/ml in 2% (w/v) BSA-PBS, 1 h, RT). The primary antibody was aspirated and the 
wells were washed with PBS (20 μl/well, 3 x 5 min). The remainder of the protocol was 
carried out in the dark. Each well was incubated with secondary antibody (donkey anti-
chicken-FITC conjugate diluted 1:100 in 2% (w/v) BSA-PBS, 20 μl/well, 1 h, RT). The wells 
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were washed with PBS (20 μl/well, 2 x 5 min) and stained with DAPI (5 μg/ml in PBS) (15 
min, RT). The excess stain was rinsed off with PBS and the slides were stored overnight in the 
dark in a vacuum desiccator. Slides were viewed at a magnification of 1 000x using an 
Olympus AX70 fluorescent microscope. A green filter was used for FITC and a UV filter was 
used for DAPI. Digital photographs of the slides were taken with the CC12 Soft Imaging 
System™ colour camera and viewed with the analySIS™ software. Z-stack images were 




Bioinformatic studies  
 
3.1 Introduction 
Bioinformatics is the study of genes, genomes and proteins at the sequence, structural 
and functional level (Xiong, 2006). The goal of using bioinformatics is to have a better 
understanding of how a gene or protein operates at a molecular level, without necessarily 
having the protein or gene to physically work with. Provided that the sequence is available for 
that protein or gene of interest, it is possible to make predictions about the gene and of the 
proteins structure, function, or location within the cell or organism. However, it must be 
remembered when using bioinformatics that the predictions made are not confirmed facts: 
bioinformatics has limitations and therefore must always be followed up with wet lab 
experiments. 
In the present study, a number of bioinformatics tools were used to find information 
about a hypothetical Plasmodium protein. The protein sequence of a P. chabaudi adami 
protein Pca 96, was used as a query sequence in BLAST searches to find proteins with similar 
sequences. The sequences were also used to search for signal sequences, Plasmodium export 
element (PEXEL) motifs and conserved domains. In addition, predictions were made about the 
sub-cellular locations of the protein. 
 
3.2 Bioinformatic methods 
3.2.1 Basic Local Alignment Search Tool (BLAST) searches and CLUSTALW sequence 
alignments 
The BLAST program (Altschul et al., 1990) is a useful program allowing for a query protein 
or DNA sequence to be compared to other protein or DNA sequences within databases. 
Sequences determined to have sequence similarity to the query sequence are reported with an 
expectation value (E-value). The E-value describes the number of sequences matched to the 
query sequence one might expect to see by chance in a database of a particular size. The lower 
the E-value, the more statistically significant is the sequence match.  
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 The amino acid sequence of Pca 96 was used as a query sequence in a BLASTP 
(protein to protein database) and TBLASTN (protein to translated nucleic acid database) 
search at PlasmoDB (http://www.plasmodb.org/). 
The nucleotide sequences from the TBLASTN search that did not have protein 
sequences available, were downloaded from PlasmoDB (http://www.plasmodb.org/) and 
translated into amino acid sequences at Expasy (http://www.expasy.org/tools/dna.html). The 
amino acid sequence of Pca 96 was aligned with the amino acid sequences and translated 
amino acid sequences producing matches with the BLAST searches. The sequence alignment 
was performed using the program CLUSTALW (Chenna et al., 2003), at the European 
Bioinformatics Institute (EBI) website (http://www.ebi.ac.uk/clustalw/). 
 
3.2.2 Expression profiles 
High-density oligonucleotide arrays were used to create mRNA expression profiles of 
genes for all of the stages of the P. falciparum life cycle (Le Roch et al, 2003). In the present 
study, the data from Le Roch et al. (2003) was used to construct graphs of the mRNA 
expression levels for the gene encoding the P. falciparum protein PFC0760c. This was done to 
determine at what stage of the parasite life cycle the expression increased, as this could 
possibly provide insight into the role PFC0760c has within the parasite life cycle, as it is 
assumed that the mRNA expression levels could possibly reflect the protein expression level, 
although it is understood that this may not necessarily always be the case. P. falciparum 
lactate dehydrogenase (PfLDH) (PF13_0141) was used as a comparison for levels of mRNA 
expression. 
 
3.2.3 Plasmodium export element (PEXEL) motif searches and signal sequence 
predictions 
Secreted Plasmodium protein families such as P. falciparum erythrocyte membrane protein 
(PfEMP1), repetitive interspersed family (RIFIN) and subtelomeric variable open reading 
frame (STEVOR) are exported out of the parasitophorous vacuole and into the host 
erythrocyte, where they alter the host red blood cell to maximize the parasites survival. 
Exported proteins generally have a sequence located at the N-terminus that directs the protein 
to the endoplasmic reticulum (Wickham et al., 2001; Haldar et al., 2002). The proteins are 
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then transported through the parasite membrane via the golgi apparatus, to the parasitophorous 
vacuole. In order for the proteins to be transported from the parasitophorous vacuole into the 
host red blood cell, it appears necessary for the proteins to have both a signal sequence and a 
motif that targets the protein to the host red blood cell. The motif, the Plasmodium export 
element (PEXEL) (Marti et al., 2004) or the vacuolar transport signal (VTS) (Hiller et al., 
2004) as it is also known, consists of a short sequence of alternating charged, hydrophobic 
amino acids separated by non-charged amino acid residues (Marti et al., 2005). The sequence 
R/KxLxQ/E is typically located 15-20 amino acids downstream of the signal sequence (Marti 
et al., 2005). The presence of a PEXEL motif in a protein sequence can aid with predictions of 
where a protein is located within a cell and can essentially aid with predictions of the proteins 
function. All of the different combinations of the motif R/KxLxQ/E were searched for in the 
amino acid sequences of PFC0760c and the P. yoelii yoelii sequence PY05757 which was 
found to have high sequence similarity to PFC0760c and Pca 96 (Section 3.2.1).  
 The programs SIG-Pred (http://bmbpcu36.leeds.ac.uk/prot_analysis/Signal.html), 
and Sigfind 2.1 (http://www.stepc.gr/~synaptic/sigfind.html) were used to determine if the 
sequences possessed hydrophobic N-terminals signal sequences. 
 
3.2.4 Transmembrane domain prediction 
Transmembrane proteins are proteins having one or more sections of their structure crossing a 
biological membrane. These sections have amino acids that are predominantly hydrophobic in 
nature, suiting the hydrophobic environment of a lipid membrane bi-layer. These sections are 
composed of twenty or more amino acid residues (Westhead et al., 2002). The sections of the 
protein that are on either side of the membrane tend to be hydrophilic due to the aqueous 
environment. The membrane spanning regions of proteins often adopt the structure of an alpha 
helix. 
 One method of predicting membrane-spanning regions within proteins is with the 
program TMHMM. It is a program based on a hidden Markov model and is able to predict the 
presence of a transmembrane domain and the orientation, with respect to which sections of the 
protein are inside the membrane, and which are outside the membrane. 
The amino acid sequences of Pca 96, PFC0760c and PY05757 were assessed for 




3.2.5 Subcellular localization predictions 
Prediction of a proteins sub cellular localisation can give insight to the proteins role in 
the cell. Due to so little being known about Pca 96, PFC0760c and PY05757, it was decided 
attempt to predict their subcellular location, using the web-based programs SubLoc and 
pTARGET. 
 
3.2.5.1 pTARGET subcellular localization prediction 
pTARGET (http://bioapps.rit.albany.edu/pTARGET/) has the ability to predict the 
subcellualr location of eukaryotic proteins. The program predicts proteins targeted to the 
cytoplasm, endoplasmic reticulum, golgi, lysozyme, mitochondria, nucleus, plasma 
membrane, peroxisome and whether they are secreted extracellularly (Guda, 2006). The 
prediction algorithm calculates two scores which are then summed to give the final prediction 
of the proteins subcellular localization. One score is based on the relative amino acid weights 
which are calculated from the amino acid composition of the protein sequence. The other 
score is based on the presence or absence of Pfam domains that are in a specific location 
within the protein sequence (Guda and Subramaniam, 2005). pTARGET has been shown to 
accurately predict protein subcellular localization to 96-99% (Guda and Subramaniam, 2006). 
A confidence level is given with each of the predictions which indicate the trustworthiness of 
that prediction. The confidence value is expressed as a percentage of the ratio of the calculated 
score to the total score required for making a true prediction.  
 
3.2.5.2 Prediction of Subcellular Localization by SubLoc 
SubLocv1.0 (http://www.bioinfo.tsinghua.edu.cn/SubLoc/) has the ability to predict the 
subcellular localization of prokaryotic and eukaryotic proteins, based on their amino acid 
composition (Hua and Sun, 2001). For eukaryotes, SubLoc can predict proteins targeted to the 
nucleus, cytoplasm, mitochondria and extra cellular matrix. SubLoc has a prediction accuracy 




3.2.6 Conserved domains 
Conserved domains are compact structural or functional parts of a protein that have 
been used and are still being used throughout the process of evolution (Wheeler et al., 2001). 
Searching for conserved domains in a protein of unknown structure and function could give 
insight into possible functions or structures of the protein (Wheeler et al., 2001). The 
conserved domain search (CD-Search) at the National Centre for Biotechnology Information 
(NCBI) (http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi), allows conserved domains to 
be searched for on a protein query. CD-Search uses the Conserved Domain Database (CDD). 
The CDD contains data from Simple Modular Architecture Research Tool (SMART), Protein 
families (Pfam) and Clusters of Orthologous Groups of proteins (COGs) databases.  
 
3.2.7 Helical wheel plot 
A helical plot shows an end-on view of an alpha helix. The angle of rotation between 
adjacent amino acid residues is 100˚. In the arrangement of alpha helices, the hydrophobic 
amino acid residues are typically located on one side of the alpha helix (Mount, 2001). The 
conserved peptide sequence was used to plot a helical wheel plot using the programs Helixator 
(http://www.tcdb.org/progs/helical_wheel.php) and EMBOSS Pepwheel 
(http://www.tcdb.org/progs/pepwheel.php). The plot was performed to deduce if the sequence 
could possibly be an alpha helix. The programs utilised use different algorithms and thus will 
provide greater confidence in the results if both algorithms provide a similar result. 
 
3.2.8 Structure prediction 
A protein with a known 3 dimensional structure, having significant sequence similarity 
to Pca 96, PFC0760c or PY05757 was searched for using a sequence search at the Protein 
Data Bank (PDB) (http://pdb.org/pdb/search/advSearch.do?st=SequenceQuery). A significant 
sequence similarity of 40-50% would allow the amino acid of the query sequence to be 
superimposed onto the PDB entry, resulting in a sufficiently accurate model of the proteins 
structure (Mount, 2001; Lesk, 2002). In addition, the sequences of the proteins were used as 
query sequences with the program Phyre (www.sbg.bio.ic.ac.uk/phyre/) (Kelley and 




3.2.9 T-cell epitope prediction 
SYFPEITHI (Rammensee et al., 1999) is a database allowing for the prediction of T-
cell epitopes. The database consists of peptide sequences known to bind MHC class I and II 
molecules. The SYFPEITHI program (http://www.syfpeithi.de/) was used to determine if T-
cell epitopes were present in the Pca 96 protein sequence. The epitopes predicted for Pca 96 
were searched for in the amino acid sequence of PFC0760c. 
 
3.2.10 Protein interaction 
A version of the yeast-two hybrid assay has been used to determine P falciparum 
protein-protein interactions (LaCount et al., 2005). The plasmoMAP project at PlasmoDB uses 
the query gene entered to determine functional interactions with other P. falciparum genes. 
Each gene determined to have a functional interaction with the query gene is given a 
likelihood score. The higher the likelihood score the greater the confidence of the functional 
interaction. A likelihood score of 10 or above is a fairly good indication of the functional 
interaction being true. A second program called PlasmoPredict was used for predicting protein 




3.3.1 BLAST searches and sequence alignments 
In order to find other Plasmodium proteins with sequence similarity to Pca 96, the 
amino acid sequence of Pca 96 was used to perform a BLASTP search in all of the 
Plasmodium organisms available at PlasmoDB. The first ten results are displayed in Table 3.1. 
Proteins with high sequence similarity to Pca 96 were detected for P. chabaudi chabaudi, P. 
yoelii yoelii, P. berghei, P. falciparum, P. vivax, and P. knowlesi. Sequence alignments that 
accompany the BLAST results (not shown) revealed a sequence of amino acids that appeared 
to be present in five of the first six proteins listed in Table 3.1: P. chabaudi chabaudi 
PCAS_080770, P. yoelii yoelii PY05757, P. falciparum PFC0760c, P. vivax PVX_095365, 
and P. knowlesi PKH_082410. The P. berghei protein PB000626.03.0 did not appear to 
contain the sequence. The amino acid sequence of Pca 96 was used to perform a TBLASTN at 
PlasmoDB to determine if the protein had high sequence identity to translated DNA sequences 
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not available for BLASTP searches (Table 3.2). The genes encoding the proteins listed in 
Table 3.1 are observed in the TBLASTN results (Table 3.2). In addition, a number of P. 
gallinaceum and P. reichenowi sequences were observed to have sequence similarity to Pca 
96. The alignments accompanying the TBLASTN results revealed regions containing the same 
sequence of amino acids identified in the BLASTP search in a translated P. reichenowi gene 
(Pr_3502696.c000127860.Contig1) and a translated P. gallinaceum gene (Pg_Contig89) 
(results no shown). All of the sequences containing this common amino acid sequence were 
downloaded from PlasmoDB. No protein sequences were available for the P. reichenowi and 
P. gallinaceum genes and therefore the nucleotide sequences were obtained from PlasmoDB 
and were translated into amino acid sequences at Expasy. The sequences were aligned with 
Pca 96, using CLUSTALW (Figure 3.1). The sequence alignment revealed the amino acid 
sequence FKL(G/S)SCYLYIINRN(L/M)KEI that appeared to be highly conserved across all 
the Plasmodium species used (Figure 3.1, text highlighted in grey).  
The data from the alignment in Figure 3.1 was used to construct a basic schematic 
diagram to show how the sequences matched up with respect to one another based on their 
amino acid sequences, and where the consensus sequence FKLGSCYLYIINRNLKEI was 
located on each sequence (Figure 3.2). 
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Table 3.1. Results obtained from a BLASTP
*
 search with Pca 96 at PlasmoDB 
Name Location  E-value 
PCAS_080770 P. chabaudi chabaudi chab08:354177-362783(+) 3.7 X 10
-281
 
PY05757 P. yoelii yoelii str. 17XNL AABL01001868:46-4620(+) 3.0 X 10
-151
 
PB000626.03.0 P.berghei str. ANKA PB_RP3514:1-1014(+) 2.7 X 10
-86
 
PFC0760c P. falciparum 3D7 Pf3D7_03:696215-706399(-) 9.0 X 10
-47
 
PKH_082410 P. knowlesi strain H PK4.chr08:1136597-1145422(+) 7.5 X 10
-34
 
PVX_095365 P. vivax SaI-1 CM000449:1047817-1056702(+) 5.4 X 10
-31
 
PF14_0631 P. falciparum 3D7 Pf3D7_14:2694749-2703985(-) 2.0 X 10
-07
 
PFE0465c P. falciparum 3D7 Pf3D7_05:389914-398997(-) 3.0 X 10
-07
 
MAL13P1.295 P. falciparum 3D7 Pf3D7_13:2368215-2374292(+) 4.0 X 10
-07
 
PB000726.00.0 P.berghei str. ANKA PB_RP0629:2391-4853(+) 1.2 X 10
-06
 
*Only the first ten results are shown 
 
Table 3.2. Results obtained from a TBLASTN
*
 search with Pca 96 at PlasmoDB 
Name Reading frame E-Value 
chab08 P. chabaudi chabaudi 3 1.10 X 10
-294
 
PB_RP3514 P. berghei str ANKA 1 4.70 X 10
-179
 
AABL01001868 P. yoelii yoelii str 17XNL.... 1 1.00 X 10
-159
 
Pg_Contig89 P. gallinaceum -3 9.50 X 10
-45
 
Pf3D7_03 P. falciparum 3D7 -1 1.30 X 10
-37
 
Pr_3502696.c000127860.Contig1 P. reichenowi 2 3.50 X 10
-36
 
PK4.chr08 P. knowlesi strain H 2 1.40 X 10
-26
 
CM000449 P. vivax SaI-1 1 6.40 X 10
-22
 
Pf3D7_14 P. falciparum 3D7 -1 3.10 X 10
-07
 
Pg_2265551.c000128678.Contig1 P.gallinaceum -1 5.80 X 10
-07
 




Figure 3.1. A portion of an alignment of protein sequences and translated nucleotide sequences. 
Sequences producing significant scores with BLAST analysis with Pca 96 and containing the sequence 
FKL(G/S)SCYLYIINRN(L/M)KEI (highlighted in grey) were aligned with Pca 96 using CLUSTALW 
(http://ebi.ac.uk/clustalw/). This sequence appeared to be highly conserved across Plasmodium species. An 
asterisk (*) indicates that all the amino acid residues are identical in all sequences in the alignment at that 
position. A colon (:) is an indication that conserved substitutions are present at the position within the 
sequences in the alignment, and a full stop (.) means that semi-conserved substitutions have been observed at 
that position within the sequences in the alignment. 
Pca 96               ---------------------FSVSSDHITLIKCNILKMFKLGSCYLYIINRNLKEIKIL 39 
P. chabaudi chabaudi -----AESD-NNNLTPSDDREFSVSSDHITLIKCNILKMFKLGSCYLYIINRNLKEIKIL 1949 
P. yoelii yoelii     -----VENDDNNNLNSSKNQEFSVNSDHITLIKCNILKMFKLGSCYLYIINRNLKEIKIL 586 
P. falciparum        NNINNVKNIVDINNYLVNNLQLNKDNDNIIIIKFNILKLFKLGSCYLYIINRNLKEIQML 2406 
P. vivax             --------------------SPSNGSEHIVIIKCNILKLFKLGSCYLYIINRNMKEIQIL 1839 
P. reichenowi        NNVNNVNNIVDINNYLVNNLQLNKDNDNIIIIKFNILKLFKLGSCYLYIINRNLKEIQML 1407 
P. knowlesi          --------------------SPLNGSEHIVIIKCNILKLFKLGSCYLYIINRNLKEIQVL 1822 
P. gallinaceum       -------------------LSLNKDSDNIIIIKCNILKLFKLSSCYLYIINRNLKEIQNL 528 
                                             ..::* :** ****:***.**********:***: * 
 
Pca 96               FDKINSLEENIQSLNLFINNLKDQNKNNEVIKINNEEQILQLKNSLQNNENCINNLNDNL 99 
P. chabaudi chabaudi KDKINSLEDNIQSLNLFINNLKDQNKNNEVIKINNEEQILQLKNSLQNNENCINNLNDNL 2009 
P. yoelii yoelii     KDKIHSFEENIQSLNLFINNLKDQHKNNEMIKINNEEQIVELKNNLKNNENCINNLNDNL 646 
P. falciparum        KNQILSLEESIKSLNEFINNLKNENEKNELIKINNFEEILKLKNNLQDNESCIQNLNNYL 2466 
P. vivax             KNQVSSLKQSIQTQNAFIQSLKKENKKNEVIQVNSIDEIAQLKGDLQTNESSLHSLRNNL 1899 
P. reichenowi        KNQILSLEESIKSLNEFINNLKNENEKNELIKINNFEEILKLKNNLQDNESCIQNLNNYL 1467 
P. knowlesi          KNEVSSLKQSIQTQNEFIQSLKTKNEKDRVIQVSNMDEIAQLKDNLQTNESSIQCLRTNL 1882 
P. gallinaceum       KNQVSCLEQSIESLNKFIDNLKDENNKNELIKVNNLEEILKLKNNIQNNESFIKNLKDNL 588 
                      ::: .:::.*:: * **:.** :::::.:*::.. ::* :**..:: **. :: *.  * 
 
Pca 96               KQKDEMNNSNIKNLIKYKNFIINLVHQTNVFLHIFKTMSTQQVIQNSEYNQLTQLLRKEL 159 
P. chabaudi chabaudi KQKDEMNNSNIKNLIKYKNFIINLVHQTNVFLHIFKTMNTQQVIQNSEYNQLTQLR-KEL 2068 
P. yoelii yoelii     KQKDEMNNSNIQNLIKYKSFIINLVYQSNIFFHIFKNINKQKVIQNSIFNQLTQLR-KEL 705 
P. falciparum        KKNEELNKINVKNIFKYKGYIIHLIQQSNVFCKIFKHFNENKIIDQSIINKLLYLK-KSF 2525 
P. vivax             KNTEQMNKLHEMNLGKCKSFIMHLLQENIIICNIFKMVNSRKRVEASIINQLRGLK-KAF 1958 
P. reichenowi        KKNEELNKINVKNIFKYKGYIIHLIQQSNVFCKIFKHFNENKIIDQTIINKLLYLR-KSF 1526 
P. knowlesi          KNTEEMNKLHALNLGKYKNFIGHLIQQNIVICDIFKIVNSRRRVEDSILNQLKSLK-KAF 1941 
P. gallinaceum       KKNEDINEKNLKNIYKYKSFIVHLIEQSTILCEIFKNISSKKKIDASILNQLSNLR-KSF 647 
                     *:.:::*: :  *: * *.:* :*: :. :: .*** .. .: :: :  *:*  *  * : 
 
Pca 96               DPYLNDSIMISELESK--EKSDEANANNDLLNIPSTFSYENYEHIQIFTNKYNLIIERGQ 217 
P. chabaudi chabaudi DPYLNDSIMISELESK--EKSDEANANNDLLNIASTFSYENYEHIQIFTNKYNLIIERGQ 2126 
P. yoelii yoelii     DFYLNDSIMISELENK--EKSNLNNFENNLLNIVSTFSCENYEHIQIFTNKFNLIIERGQ 763 
P. falciparum        DFYMYDSVIQEIR------------ENKNIIINQDFLTDEYFKHIQTFTKTCNVLIQRG- 2572 
P. vivax             HLYMNDSLVEELQRGGGCDDPILAKQEMRWTNGNCNVVEEVLQNVERFAHSFNSMVGEGR 2018 
P. reichenowi        DFYMYDSVIQEIR------------ENKNILINQDFLTEEYFKHIQTFTKTCNVLIQRG- 1573 
P. knowlesi          HMFMYDTIMDDLQGNVGYDDSTIVKQKGKWTNVNYEIVEEVFQNVQRFANNFNYMIENGK 2001 
P. gallinaceum       NYYMYDSVVEELK--------------KKNLNINNEFNEECLQNIKLFAENYNLKIEKGE 693 























3.3.2 Expression levels  
Expression levels were determined for all P. falciparum genes by high-density oligonucleotide 
arrays of RNA from merozoites and intracellular asexual blood stages of malaria parasites (Le 
Roch et al, 2003). The data from Le Roch et al. (2003) was used to construct graphs of the 
mRNA expression levels of PFC0760c, and compare them to graphs for the data for P. 
falciparum lactate dehydrogenase (PfLDH) (PF13_0141). PfLDH is expressed at high levels 
in all stages of the parasite life cycle, with the highest expression of mRNA observed during 
the early trophozoite through to the early schizont stages of the parasite life cycle with 
absolute expression levels ranging from 3800 to 5400 (Figure 3.3, A and B). PFC0760c 
appears to be expressed at considerably lower levels in comparison to PfLDH (Figure 3.3), 
with the highest levels ranging from 88 to 175, during the early trophozoite to late schizont 
stages of the life cycle (Figure 3.3 A and B). Different expression levels are obtained for the 
two different synchronising methods (Figure 3.3 A and B), but a similar pattern of expression 
is observed in both. Comparison of mRNA expression levels between the gametocyte and the 
Figure 3.2. Position of Plasmodium proteins with high sequence similarity to Pca 96 and with the 
conserved sequence FKL(G/S)SCYLYIINRN(L/M)KEI in relation to one another. The position of 
the conserved sequence (white) is shown for Pca 96, P. falciparum PFCO760c, P. yoelii yoelii PY05757, 
P. chabaudi chabaudi PCAAS_080770, P.vivax PVX_95365, P. knowlesi PKH_082410 and the 





sporozoite stages of the life cycle indicates that PfLDH is expressed at a considerably higher 
level at the sporozoite stage (1266) than at the gametocyte stage (183) (Figure 3.3 C). 
PFC0760c is expressed at a marginally higher level at the sporozoite stage (60) than at the 
gametocyte stage (45) (Figure 3.3, C). 
  The expression data from Le Roch et al. (2003) was used to plot graphs of the genes 
listed in Table 3.3. The proteins encoded by these genes have been identified to be involved in 
metabolism, cell division, cell growth, DNA synthesis, protein synthesis and transcription 
(Bowman et al., 1999). It was thought that by comparing the patterns of mRNA expression for 
PFC0760c to the mRNA expression patterns for these genes, inferences could possibly be 
made about the role of PFC0760c in the parasite, if the expression data of PFCO760c was 
similar to that of the genes in any of the categories in Table 3.3. Unfortunately, no significant 
pattern was evident with regards to what stages of the life cycle these genes were expressed 





Table 3.3. P. falciparum genes and their putative roles in the Plasmodium parasite (Bowman 
et al., 1999) 
Role Genes 
Metabolism 
PFC0050c (acyl-coA synthase PfACS2) 
PFC0170c (dihydrolipoamide acyltransferase, putative) 
PFC0275w (FAD-dependent glycerol-3-phosphate dehydrogenase, putative) 
PFC0395w (asparagines synthase , putative) 
PFC0710w (inorganic phosphate putative) 
PFC0830w (trophozoite stage antigen) 
PFC0935c (N-(acetylglucosamine-1-phosphate transferase, putative) 
PFC0950c (peptidase, putative) 
PFC0995c (acyl coA: diacylglycerol acyltransferase, putative) 
  
Cell growth, division and 
DNA synthesis 
PFC0305w (EB1 homology, putative) 
PFC0340w (DNA polymerase epsilon subunit B, putative) 
PFC0385c (serine/threonine protein kinase, putative) 
PFC0525c (glycogen synthase kinase 3) 
PFC0595c (serine/threonine protein phosphatase, putative) 
PFC0755c (protein kinase, putative) 
PFC0770c (kinesin-like protein, putative) 




PFC0155c (DNA-directed RNA polymerase subunit I, putative) 
PFC0805w (DNA-directed RNA polymerase II, putative) 
PFC0825c (cleavage and polyadenylation specificity factor protein, putative) 
  
Protein synthesis 
PFC0200w (60S ribosomal protein L44, putative) 
PFC0225c (elongation factor (EF-TS), putative) 
PFC0290w (40S ribosomal protein S23, putative) 
PFC0295c (40S ribosomal protein S12, putative) 
PFC0300c (60S ribosomal protein L7, putative) 
PFC0400w (60S acidic ribosomal protein P2, putative) 
PFC0470w (valine-tRNA ligase, putative) 






































Figure 3.3. Expression profiles of P. falciparum proteins. The expression levels of the hypothetical 
protein PFC0760c (hatched columns) compared to P. falciparum lactate dehydrogenase (PF13_0141) 
(open columns) as a control. The data is from high-density oligonucleotide arrays of RNA from 
merozoites and intracellular asexual blood stages of parasites: (A) synchronised by means of a 5% D-
sorbitol treatment, (B) synchronised by means of a temperature cycling incubator and (C) in the 
gametocyte and sporozoites stages of the life cycle (Le Roch et al., 2003). ER - early ring stage; LR - 
late ring stage; ET - early trophozoite stage; LT - late trophozoite stage; ES - early schizont stage; LS - 




3.3.3 Plasmodium export element (PEXEL) motif searches and signal sequence 
predictions  
Due to very little being known about PFC0760c and PY05757, it was decided to determine if 
the proteins were exported from the parasite to the red blood cell. Thus, the amino acid 
sequences of both proteins were checked for signal sequences and PEXEL motifs. 
 The motif R/KxLxQ/E was searched for in the amino acid sequences of PFC0760c 
and PY05757. A number of motifs matching the sequence R/KxLxQ/E were detected for 
PFC0760c (result not shown). However, all of these motifs were typically 60 amino acids or 
more downstream from the N-terminus. True PEXEL motifs are accompanied with a signal 
peptide and tend to be 15-20 amino acids downstream from the hydrophobic signal sequence 
located at the N-terminus of the protein (Hiller et al., 2004). 
 PY05757 had three possible PEXEL motifs. The first motif KKLTD (amino acids 
51-55) was unlikely to be a true PEXEL motif as the second amino acid is charged instead of 
being non-charged. In addition, the motif is located too far downstream from the N-terminus 
to be a true PEXEL motif, as are the second, KVLNE (amino acids 69-73) and the third, 
KYLSE (amino acids 83-87) possible PEXEL motifs. Analysis of the sequences using the 
web-based programs Sig-pred and Sigfind 2.1 revealed no signal peptides for either of the 
proteins (result not shown), thus making it unlikely that the proteins were exported. The 
proteins PFC0760c and PY05757 are hydrophilic at their N-terminus (Chapter 5, Figure 5.1 
and 5.2), which supports the findings of the signal peptide programs, as proteins with signal 
peptides usually have approximately twenty hydrophobic amino acids at the N-terminus. 
 
3.3.4 Transmembrane domain prediction 
The program TMHMM 2.0 was used to predict the presence of transmembrane domains in the 
proteins Pca 96, PFC0760c and PY05757. PFC0760c and PY05757 were predicted to not 
have a transmembrane domain by TMHMM 2.0. A transmembrane domain was predicted on 
the C-terminus of Pca 96 (Figure 3.4). From the TMHMM prediction it appears that the C-

















3.3.5 Subcellular location prediction 
The possible subcellular locations of Plasmodium proteins were evaluated using pTARGET 
and SubLoc. Pca 96, PFC0760c, PY05757 and PCAS_080770 were all predicted to be 
cytoplasmic proteins by pTARGET and nuclear proteins by SubLoc (Table 3.4). Both 
programs had very high confidence levels and reliability indexes for these predictions. The 
subcellular location was predicted for control proteins lipoamide acyltransferase (PFC0170c), 
elongation factor TS (PFC0225c) and glycerol-3-phosphate dehydrogenase (PFC0275w), as 
they have an implied biological function suggesting mitochondrial import (Bowman et al., 
1999). pTARGET accurately predicted PFC0170c and PFC0225c as proteins located to the 
mitochondria and predicted PFC0275w to be located to the golgi. SubLoc predicted PFC0170c 
to be nuclear and accurately predicted PFC0225c and PFC0275w to be located in the 
mitochondria. Although SubLoc predicted the location of PFC0170c incorrectly and 
pTARGET predicted the location of PFC0275w incorrectly according to Bowman et al. 
(1999), the confidence levels, reliability indexes and expected accuracies for these two 
predictions were lower in comparison to those predicted correctly. This could have given an 
indication that the prediction was not accurate, if the actual location of the protein had not 
been known beforehand.  
Figure 3.4. Results for the prediction of transmembrane domains in Pca 96. The program TMHMM 
2.0 (www.cbs.dtu.dk/services/TMHMM/) was used to predict the presence of transmembrane helices for 
the protein Pca 96. Regions predicted to be transmembrane domains are depicted in red, areas predicted 
to be inside the membrane are indicated in blue and areas predicted to be outside the membrane are 









Table 3.4. Subcellular prediction of proteins using pTARGET and SubLoc 
*Control: mitochondrial proteins (Bowman et al., 1999) 
 pTARGET prediction  SubLoc prediction 
Protein Predicted 
location 






Pca 96 Cytoplasm 81.4%  Nuclear 10 ~100% 
PFC0760c (conserved protein, function unknown) Cytoplasm 100.0%  Nuclear 7 95% 
PY05757 (hypothetical protein) Cytoplasm 100.0%  Nuclear 10 ~100% 
PCAS_080770 (conserved protein, function unknown) Cytoplasm 100%  Nuclear 6 97% 
PFC0170c*(dihydrolipoamide acyl transferase, putative) Mitochondria 87.6%  Nuclear 1 56% 
PFC0225c*(elongation factor (EF-TS), putative) Mitochondria 100%  Mitochondria 2 74% 
PFC0275w*(FAD-dependent glycerol-3-phosphate dehydrogenase, 
putative) 
Golgi 75.1%  Mitochondria 2 74% 
93 
 
3.3.6 Conserved domains 
 CD Search in the CDD (Conserved domains database) was used to determine the presence 
of predicted conserved domains within the amino acid sequences of Pca 96, PFC0760c, 
PY05757 and PCAS_080770. No conserved domains were detected for Pca 96. Conserved 
domains were detected for PFC0706c, PY05757 and PCAS_080770 (Figure 3.5 and Table 
3.5). The predominant domain observed in each of the proteins was a SMC (structural 
maintenance of chromosomes) protein domain (SMC_prok_A, SMC_prok_B, SMC_N and 
SMC). A myosin class II heavy chain protein domain (KOG0161) was also identified in 
PY05757 and PCAS_080770. The C-terminal end of the predicted conserved domains for 
the amino acid sequences of PY05757 and PCAS_080770 is located approximately 100 
amino acid residues downstream of the conserved FKLGSCYLYIINRNLKEI sequence 



























(C) P. chabaudi chabaudi PCAS_080770 
(A) P.falciparum PFC0760c 
  (B) P.yoelii yoelii PY05757 
Figure 3.5. The location of conserved domains identified in .P. falciparum, P. yoelii yoelii and P. chabaudi chabaudi proteins. (A) PFC0760c, 
(B) PY05757 and (C) PCAS_080770. Variations of the SMC (structural maintenance of chromosomes) protein domain (SMC_prok_A, 
SMC_prok_B, SMC_N and SMC) were identified using the conserved domain search (http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi). A 








Table 3.5. Results of a conserved domain search in the proteins PFC0760c, PY0575 and 
PCAS_080770 











COG1196: Smc, Chromosome segregation ATPases (Cell 




TIGR02169:, SMC_prok_A, chromosome segregation 




Pfam02463, SMC_N, RecF/RecN/SMC N terminal 
domain 
111369 1x10-4 
PY05757 KOG_ _4825 KOG0161, Myosin class II heavy chain (Cytoskeleton) 35383 2x10-9 
PY05757 COG_ _4873 COG1196, Smc, Chromosome segregation ATPases (Cell 
division and chromosome partitioning) 
31389 0.002 
PY05757 TIGR_ _3603 TIGR02169, SMC_prok_A, chromosome segregation 




COG1196 Smc 31389 3x10-8 
PCAS_080770 Pfam__10340 
PSSMs 
Pfam 02463,SMC_N, RecF?RecN/SMC N terminal 
domain 
111369 1x10-7 
PCAS_080770 KOG_ _4825 KOG0161, Myosin class II heavy chain [Cytoskeleton 35383 3x10-
13 
PCAS_080770 COG_ _4873 COG1196, Smc, Chromosome segregation ATPases (Cell 
division and chromosome partitioning) 
31389 3x10-8 
PCAS_080770 TIGR_ _3603 TIGR02168, SMC_prok_B, chromosome segregation 
protein SMC, common bacterial type 
131223 9x10-7 
PCAS_080770 TIGR_ _3603 TIGR02168, SMC_prok_B, chromosome segregation 




3.3.7. Helical wheel plot of the conserved peptide sequence FKLGSCYLYIINRNLKEI 
The results obtained from Pepwheel and Helixator (Figure 3.6) display the same pattern: one side 
of the helix has predominantly hydrophobic amino acid residues and the other side is composed 
predominantly of polar and charged amino acids. This is a typical alpha helix composition, 
thereby suggesting that the conserved peptide sequence FKLGSCYLYIINRNLKEI could have the 















3.3.8. Structure predictions 
A sequence search at the PDB with Pca 96 and PFC0760c produced no results as no proteins in 
the PDB were determined to have sequence identity to either of the proteins. For this reason the 
sequences were used at the Phyre homology modelling server to determine which known protein 
folds were possibly present. A number of folds were identified for both protein sequences (Tables 
3.6 – 3.8). The following protein folds were identified for both Pca 96 and PFC0760c: 
contractile, transport, signalling, apoptosis, cell adhesion membrane, transmembrane and de novo 
protein folds. An additional four folds were identified for PFC0760c that were not identified in 
Pca 96: triple-helix coiled coil, transcription, cell invasion and beta and beta prime subunits of 
DNA dependent RNA polymerase. 
 
A B 
Figure 3.6. Helical wheel plot of conserved peptide sequence. Peptide sequence FKLGSCYLYIINRNLKEI 
was used with the programs EMBOSS Pepwheel (http://www.tcdb.org/progs/pepwheel.php) (A) and Helixator 
(http://www.tcdb.org/progs/helical_wheel.php) (B), to predict alpha helices. Hydrophobic amino acids are 




Table 3.6. Phyre fold prediction results for Pca 96 
SCOP Code  Percentage identity E-value 
Estimated  
Precision 
Fold/PDB descriptor Superfamily 
c1i84V_  
(length:1184) 
3% 2.8 x 10
-09
 100 %  
PDB header: contractile 
protein 
Chain: V: PDB Molecule:smooth 





 100 %  
PDB header: signaling 
protein 




11% 2.5 x 10
-06
 95 %  
PDB header: contractile 
protein 
Chain: C: PDB Molecule:tropomyosin; 
c2dfsM_  
(length:1080) 
2% 3.4 x 10
-06
 95 %  
PDB header: contractile 
protein/transport protein 
Chain: M: PDB Molecule:myosin-5a; 
c2r03A_  
(length:697) 
4% 3 x 10
-05
 95 %  PDB header: apoptosis 
Chain: A: PDB Molecule: programmed 
cell death 6-interacting protein; 
c2i1kA_  
(length:575) 
4% 0.00017 95 %  
PDB header: cell adhesion, 
membrane protein 
Chain: A: PDB Molecule:moesin; 
c1sjjB_  
(length:863) 
2% 0.00023 95 %  
PDB header: contractile 
protein 
Chain: B: PDB Molecule:actinin; 
c1ciiA_  
(length:602) 
4% 0.00024 95 %  
PDB header: transmembrane 
protein 
Chain: A: PDB Molecule:colicin ia; 
c2fkjC_  
(length:366) 
7% 0.00055 95 %  PDB header: de novo protein 















Fold/PDB descriptor Superfamily 
c1i84V_  
(length:1184) 
5% 7.2 x 10-25 100 %  PDB header: contractile protein 




6% 2.6 x 10-23 100 %  PDB header: transmembrane protein Chain: A: PDB Molecule: colicin ia; 
c1c1gC_  
(length:284) 
12% 3.7 x 10-22 100 %  PDB header: contractile protein Chain: C: PDB Molecule: tropomyosin; 
c1sjjB_  
(length:863) 
5% 1.1 x 10-21 100 %  PDB header: contractile protein Chain: B: PDB Molecule: actinin; 
c2r03A_  
(length:697) 
4% 2.3 x 10-20 100 %  PDB header: apoptosis 




5% 8.5 x 10-20 100 %  PDB header: signaling protein 




5% 2.2 x 10-19 100 %  
PDB header: cell adhesion, membrane 
protein 
Chain: A: PDB Molecule: moesin; 
c1hciB_  
(length:476) 
9% 8.5 x 10-18 100 %  PDB header: triple-helix coiled coil Chain: B: PDB Molecule: alpha-actinin 2; 
c2dfsM_  
(length:1080) 
3% 1.6 x 10-15 100 %  
PDB header: contractile 
protein/transport protein 
Chain: M: PDB Molecule:myosin-5a; 
c2oexB_  
(length:351) 
10% 3.5 x 10-14 100 %  PDB header: protein transport 















Fold/PDB descriptor Superfamily 
c1i84V_  
(length:1184) 
3% 1.3 x 10
-05
 95 %  PDB header: contractile protein 




3% 0.0022 95 %  
PDB header: contractile 
protein/transport protein 
Chain: M: PDB Molecule:myosin-5a; 
c2fkjC_  
(length:366) 




4% 0.11 90 %  PDB header: signaling protein 




4% 0.6 80 %  PDB header: apoptosis 




3% 1 75 %  
beta and beta-prime subunits of DNA 
dependent RNA-polymerase  




3% 1.3 70 %  PDB header: transcription 
Chain: A: PDB Molecule: dna-directed rna 
polymerase ii largest subunit; 
c1c1gC_  
(length:284) 
6% 1.9 60 %  PDB header: contractile protein Chain: C: PDB Molecule: tropomyosin; 
c1zroA_  
(length:602) 
7% 1.9 60 %  PDB header: cell invasion 
Chain: A: PDB Molecule: erythrocyte binding 
antigen region ii; 
100 
 
3.3.9 T-cell epitope predictions 
Approximately 100 epitopes were predicted for Pca 96 (result not shown). Many of these 
epitopes overlapped in sequence due to the SYFPEITHI program searching for decamers, 
nonamers or 15-mers within each HLA-type available. Each of these epitopes was searched 
for in the amino acid sequence of the P. falciparum protein PFC0760c. Two of these 
epitopes, CYLYIINRNL and GSCYLYIINRNLKEI, were found within the PFC0760c 
sequence (Table 3.9). It is interesting to note that these epitopes are part of the conserved 
peptide sequence identified (Figure 3.1). 
Table 3.9. T-cell epitopes present in Pca 96 and PFC0760c 




3.3.10 Protein interaction 
Seven proteins were suggested to have a functional interaction with PFC0760c by the 
plasmoMAP project at PlasmoDB (Table 3.10). The predicted protein interactions with 
PFD0855c and MAL7P1.87 are unlikely to occur due to their likelihood scores being 2. 
Only likelihood scores of 10 or above are deemed to be likely predictions. The remaining 
five predicted interactions with the proteins PF10_0024, PFF0595c, PF11_0249, 
PFL2520w and PFE1255w have likelihood scores ranging from 24 to 33, making them 
likely interactions. It is unfortunate that the majority of these proteins are hypothetical and 
therefore have no known function, as their functions could give insight into the possible 
role of PFC0760c. PFF0595c is leucine-rich repeat protein and PFL2520w is a reticulocyte 
binding-like protein. 
 Results from PlasmoPredict (Table 3.11) protein-protein interaction revealed a 
further 7 different genes with unassigned functions that are likely to interact with 
PFC0760c. The most predominant feature noticed about the proteins predicted to interact 
with PFC0760c here are that the majority of the proteins are involved in binding, of RNA, 
DNA, ATP, proteins or chromatin. A second feature that was noticed is that many of the 




Table 3.10. Proteins likely to interact with PFC0760c (plasmoMAP project at PlasmoDB) 




MAL10: 103,119 - 
104,684 (-)  
Hypothetical protein  33  
PFF0595c  
MAL6: 512,967 - 
519,543 (-)  
Leucine-rich repeat protein 5 33  
PF11_0249  
MAL11: 940,526 - 
944,332 (+)  
Hypothetical protein  24  
PFL2520w  
MAL12: 2,136,038 - 
2,144,859 (+)  
Plasmodium falciparum 
reticulocyte binding-like protein, 
homolog 3  
24  
PFE1255w  
MAL5: 1,045,458 - 
1,051,249 (+)  
Hypothetical protein, conserved  24  
PFD0855c  
MAL4: 787,231 - 
790,227 (-)  
Hypothetical protein, conserved  2  
MAL7P1.87  
MAL7: 814,096 - 
818,253 (-)  
















Table 3.11. Proteins likely to interact with PFC0760c (PlasmoPredict) 
Gene Confidence Current annotation 
PFI0975c 0.743548 Conserved protein, unknown function 
PFE0385w 0.0523973 Conserved protein, unknown function 
PF14_0079 0.477289 Transcription factor, putative. Molecular function: 
transcription factor activity. Cellular component: nucleus. 
PF14_0170 0.0170835 NOT family protein, putative. Cellular component: CCR4-
NOT complex 
PF13_0315 0.0437991 RNA binding protein, putative. Molecular function: protein 
binding; nucleic acid binding; RNA binding. 
PFE1335c 0.403624 Conserved protein, unknown function 
PF13_0073 0.197272 Plasmodium exported protein (hyp12), unknown function 
PF07_0053 0.823403 Conserved protein, unknown function 
PF11780w 0.325308 Plasmodium exported protein (PHISTc), unknown function 
PF10_0232 0.819349 Chromodomain-helicase-DNA-binding protein 1 homolog, 
putative. Cellular component: chromatin; nucleus. Molecular 
function: nucleic acid binding; DNA binding; chromatin 
binding; helicase activity; ATP binding. Biological process: 
chromatin assembly or disassembly 
PFL0350c 0.620328 Conserved protein, unknown function 
PFF0880c 0.061322 Conserved protein, unknown function 
PF11_0524 0.725247 Ism4 homologue, putative 
MAL13P1.206 0.0658551 Sodium-dependent phosphate transporter. Biological 
process: phosphate transport. Cellular component: integral to 
plasma membrane; membrane. Molecular function: inorganic 
phosphate transmembrane transporter activity. 
MAL13P1.310 0.0462875 Calpain. Biological process: proteolysis. Cellular 
component: intracellular. Molecular function: calcium-
dependent cysteine-type endopeptidase activity 





In an attempt to gain some insight into the possible structure and function(s) of 
PFC0760c, a „guilt by association‟ strategy (Tedder, et al., 2010) has been employed in the 
present study, using bioinformatics to attempt to find proteins of known function with 
similar expression profiles to PFC0760c, sub-cellular location of PFC0760c and predicted 
protein-protein interactions, among other parameters. 
 The BLASTP, TBLASTN and CLUSTALW sequence alignments revealed a 
sequence of amino acids FKLGSCYLYIINRKEI that appeared conserved across P. 
falciparum, P. yoelii yoelii, P. chabaudi chabaudi, P. vivax, P. knowlesi, P. gallinaceum 
and P. reichenowi sequences in addition to Pca 96. This sequence being conserved, 
suggests that the sequence is of importance, whether it be of structural or immunological 
importance. The BLAST results and alignments also indicated that PFC0760c is likely the 
P. falciparum equivalent of Pca 96. 
 The role of PFC0760c in the parasite life cycle is currently unknown. Discovering 
the role of PFC0760c within the parasite life cycle would provide valuable information 
about the protein. For this reason the mRNA expression levels (Le Roch et al., 2003) of 
PFC0760c were examined. It was assumed that the mRNA expression levels from Le Roch 
et al. (2003) would be representative of the corresponding protein expression levels, and 
could therefore be used to infer the level of protein expression at the different stages of the 
parasite life cycle, although it is understood that this may not necessarily be the case. 
PFC0760c mRNA expression levels are significantly lower than that of PF13_0141 
(PfLDH), and it was therefore assumed that the protein expression levels for PFC0760c 
would be significantly lower than the protein expression levels for PfLDH. mRNA 
expression profiles are not available for Pca 96 or PY05757. The low levels of mRNA 
expression may result in difficulties arising in detecting the native proteins with western 
blotting or immunofluorescence. Comparing the mRNA levels of PFC0760c to those of 
PfLDH suggests that PFC0760c is unlikely to be a metabolic protein, as one would expect 
the mRNA expression levels to be much greater that what is observed for PFC0760c. 
 PEXEL domains were searched for within PFC0760c and PY05757 to determine if 
the proteins were exported out of the parasitophorous vacuole. Although PFC0760c and 
PY05757 do not appear to have true PEXEL domains, there could still be a possibility of 
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the proteins being exported out of the parasite, as not all exported proteins have a specific 
motif. P. falciparum erythrocyte membrane protein 1 (PfEMP1), has a PEXEL motif, but 
no signal sequence, yet it is exported to the host erythrocyte (Wiser 2007). A second P. 
falciparum antigen (EXP-1) possessing a signal sequence but no PEXEL motif, is exported 
from the parasite to the host erythrocyte (Wiser 2007). A Mauer‟s cleft protein, skeleton-
binding protein 1 (SBP1), has no signal sequence or PEXEL motif (Wiser 2007). There 
appear to be a number of different ways for proteins to be exported out of the parasite 
without PEXEL domains and signal sequences and therefore no assumptions should be 
made before wet lab experiments are done to determine for definite whether the proteins are 
exported out of the parasite or not. The proteins could possibly be fused to green or yellow 
fluorescent reporter proteins and monitored as Marti et al. (2004) did with KAHRP, 
GBP130, Rifin and PfEMP1 to determine whether the proteins are exported or not. 
Although the proteins Pca 96, PFC0760c and PY05757 are similar in sequence, 
only Pca 96 was predicted to have a transmembrane domain. This result is confirmed by 
the fact that the protein was found to be associated with the membranes of red blood cells 
infected with P. chabaudi adami (Wanidworanun et al., 1987). It is possible that 
transmembrane domains do exist for PFC0760c and PY05757 because even though 
analysis of transmembrane prediction programs showed TMHMM to have the best overall 
performance, it does have a tendency to under predict (Möller et al., 2001).  
The proteins Pca 96, PFC0760c and PY05757 were found to have structural 
maintenance of chromosomes (SMC) domains within their amino acid structures. SMC 
proteins are a family of chromosomal ATPases (Gillespie and Hirano, 2002). The proteins 
consist of polypeptides of 1000 –1500 amino acid residues. They form dimers consisting of 
two anti-parallel coiled-coil arms, which are connected via a flexible hinge. An ATP 
binding domain is located at the end of each of the arms. The dimer forms a functional 
complex with a specific set of non-SMC subunits. These functional complexes have been 
associated with forming the core of a cohesion complex that is responsible for chromatid 
cohesion; forming part of the condensing complex which is vital during mitotic 
chromosome condensation; DNA repair, metabolism and recombination and organising and 
separating chromosomes. It is therefore possible that PFC0760c, PCAS_080770 and 
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PY05757 are involved with chromosome maintenance. It would be necessary to confirm 
this with experiments and data first before any definite conclusions could be made. 
The subcellular location was predicted for the proteins Pca 96, PFC0760c, 
PY05757 and PCAS_080770, in addition to control proteins of known location. One 
program predicted Pca 96, PFC0760c, PY05757 and PCAS_080770 to be located in the 
nucleus, and the other program predicted them to be located within the cytoplasm. This 
result emphasises the need to back bioinformatics predictions with experiments to confirm 
the results. Immunofluorescence confocal microscopy with antibodies targeting the protein 
could be one method used to confirm the predicted locations of these predictions. One of 
the scores that pTARGET uses to predict the location of the proteins is based on the 
absence or presence of Pfam domains. CD Search uses Pfam domains (Marchler-Bauer and 
Bryant, 2004) and detected domains in PFC0760c, PY05757 and PCAS_080770 involved 
in chromosome segregation. This could explain perhaps why pTARGET predicted 
PFC0760c, PY05757 and PCAS_080770 to be nuclear proteins.  
Alpha helices, with beta sheets, form the majority of the proteins core structure. The 
amino acid sequences of protein cores tend to remain consistent, due to space and 
environmental constrictions. Loop regions are not confined and have no effect on the 
structures within the protein core. In addition, loop regions tend to have more deletions, 
substitutions and insertions of amino acid residues (Mount, 2001). If the conserved 
sequence FKLGSCYLYIINRNLKEI is in fact an alpha helix as suggested by the programs 
Pepwheel and Helixator, then this may be an explanation of why the sequence appears so 
highly conserved: if the sequence is an alpha helix, the helix will be in the core of the 
protein and therefore unlikely to experience changes in amino acid sequence. The sequence 
KEIQMLKNQILSLEESIKSLNEFINNLKN from PFC0760c, was found to be an alpha 
helical coiled coil domain (Villard et al. 2007). This sequence is located directly after the 
conserved sequence FKLGSCYLYIINRNLKEI in the amino acid sequence of PFC0760c, 
and includes the last three amino acid residues of the conserved sequence, thus reinforcing 
the alpha helix prediction results for the conserved sequence. 
Prediction of the structural folds present in PFC0760c and Pca 96 revealed multiple 
folds predicted to be part of the proteins structure. It would be necessary to go to greater in-
depth investigation to determine the possible overall structure of the proteins. The most 
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accurate way to determine the proteins structure would be to subject the native protein to 
X-ray crystallography or a nuclear magnetic resonance (NMR) study. However, large 
quantities of pure native protein are required to do this, and obtaining large quantities of 
purified native protein is not always practical or possible as was the case here. 
Prediction of T-cell epitopes within the amino acid sequences of Pca 96 and 
PFC0760c produced an interesting result. The two predicted T-cell epitopes that were 
present in both the Pca 96 and PFC0760c amino acid sequences were both part of the 
conserved sequence FLKGSCYLYIINRNLKEI. This result supports the suggestion that the 
conserved sequence is of biological importance.  
 Protein-protein interactions based on the yeast–two hybrid technology (LaCount et 
al., 2005) can provide very useful insight into protein function (Birkholtz et al., 2008) 
because proteins found in the same sub-cellular location, or involved in the same biological 
pathways, are often found to interact with one another (Tedder et al., 2010). Yeast-two 
hybrid technology is however not completely fail-safe, as artefacts and limited coverage 
can cause problems (Tedder et al., 2010). PFC0760c was predicted to functionally interact 
with 23 P. falciparum proteins (Table 3.10 and 3.11). Unfortunately, many of the proteins 
that PFC0760c were predicted to interact with are yet to be assigned a function. This result 
is not surprising, considering that more than 50% of P. falciparum genes have no assigned 
function and thus remain hypothetical genes (Tedder et al., 2010). Hopefully as more genes 
are assigned functions, the clearer the role of PFC0760c will become. However, there were 
a number of proteins involved in binding of DNA, RNA, proteins, ATP or chromatin. This 
result, in conjunction with the conserved domain result strongly suggests that PFC0760c 
plays a role in chromosome maintenance, involving the binding of nucleic acids. 
An additional method for finding out the possible function of PFC0760c, is the 
location of the PFC0760c gene on chromosome 3 as well as PFC0760c gene neighbours 
could be investigated as this may give an idea of the genes possible role in the parasite. The 
var genes, encoding PfEMP1 are located at the sub-telomeres on chromosomes, are 
involved in producing variable antigens on the surface of infected red blood cells and 
contributing to the parasites pathogenesis. Stevor and rif genes are also located at the sub-
telomeres and also involved in variant antigen expression on infected red blood cells 
(Cheng et al., 1998), thereby suggesting that genes of similar function are associated 
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together on the chromosomes, and that different regions of the chromosome have regions 
containing genes responsible for different functions. 
In conclusion, the results from this chapter suggest that PFC0760c is a nuclear 




Recombinant expression of the Plasmodium falciparum protein 
PFC0760C 
 
4.1 Introduction  
There are many different systems for recombinant protein expression, including 
yeast cells (Pichia. pastoris and Saccharomyces cerevisiae), insect cells (baculovirus), 
plant cells and bacterial cells (Escherichia coli). E. coli is possibly the most widely used as 
the organism grows quickly with inexpensive substrates and there are a wide range of 
cloning and expression vectors and host strains available (Baneyx, 1999; Flick et al., 2004). 
Recombinant production of proteins provides an attractive means for obtaining large 
quantities of a protein for characterisation and vaccine development (Birkholtz et al., 
2008). However, not all proteins will be expressed at favourable yields and in their correct 
conformation. A number of factors need to be optimised and considered to obtain high 
yields of correctly folded, active recombinant protein. This is especially true for 
recombinant Plasmodium proteins. Plasmodium genes have a high adenine /thymine 
content. The P. falciparum genome has an AT content of 80.6% (Gardner et al., 2002) and 
the P. yoelii yoelii genome, 77.4% AT (Carlton et al., 2002). The resulting proteins have 
large numbers of lysine and arginine residues in addition to many low complexity regions 
(Flick et al., 2004). Plasmodium parasites favour different codons for amino acids in 
comparison to the E. coli expression hosts (Zhou et al., 2004). These factors, among others 
result in generally very low levels of expression, truncated proteins or proteins that are 
predominantly expressed in inclusion bodies.   
This chapter describes the expression of an 822 bp region of the gene coding the P. 
falciparum hypothetical protein PFC0760c. The 822 bp region was previously cloned into 
the expression vector pMAL-c2X (plasmid pTS822) (Smallie, 2003). In the present study, 
the recombinant protein (Pf33-MBP) was expressed and purified and expression of Pf33 as 
a glutathione S-transferase (GST) fusion protein (Pf33-GST) was performed by sub cloning 
into the pGEX4T1 vector. 
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4.2 pMAL-c2X expression vector  
The polylinker insertion site in the pMAL-c2X vector is positioned downstream 
from the malE gene, which is derived from E. coli K-12 (di Guan et al., 1988). The malE 
gene codes for maltose-binding protein (MBP) and therefore the recombinant protein 
expressed from the pMAL-c2X plasmid is an MBP-fusion protein. The system is under the 
control of the tac promoter. The vector also carries the lacI
q
 gene, coding for the lac 
repressor. In the absence of IPTG, the lac repressor keeps expression from the tac promoter 
low, therefore minimizing expression of the recombinant fusion protein. The signal 
sequence of the malE gene has been deleted and therefore the expressed fusion protein 
remains in the cytoplasm.  
An advantage of using this system is that purification of the fusion protein can be 
easily achieved in a non-denaturing, single affinity purification step (di Guan et al., 1988; 
Maina et al., 1988). MBP binds to cross-linked amylose resin with high affinity and can be 
eluted with 10 mM maltose (di Guan et al., 1988; Maina et al., 1988). The pMAL vector 
includes a sequence that codes for the amino acid sequence Ile-Glu-Gly-Arg, which is a 
specific cleavage sequence for the enzyme Factor Xa. The sequence is positioned between 
the malE gene and the polylinker site (Appendix Figure A1), allowing cleavage of the 
protein of interest from MBP, with a few vector derived amino acid residues remaining 
attached to the protein of interest. 
 
4.3 Results 
4.3.1 Confirmation of the identity of the pMAL-c2X and pTS822 plasmids 
To confirm the identity of the pMAL-c2X (control) and pTS822 plasmids before 
pursuing recombinant expression, each plasmid was digested with BamHI and the digests 
were analysed on an agarose gel (Figure 4.1 A and B). pMAL-c2X yielded a product of 
approximately 6400 bp, which is close to the reported size of 6648 bp (New England 
Biolabs pMAL
TM
 Protein Fusion and Purification System Manual) (Figure 4.1 A, lane 3). 
BamHI digestion of pTS822 resulted in a band of approximately 6400 bp and one of 
approximately 870 bp (Figure 4.1 B, arrow lane 3). The band at 870 bp corresponds to the 
insert DNA, although the expected size is 820 bp. PCR of non-recombinant pMAL-c2X 
with plasmid-specific primers resulted in a PCR product of approximately 230 bp (Figure 
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4.1 C, lane 2), which is close to the expected size of 200 bp. A PCR product of 
approximately 1020 bp was obtained for pTS822, as expected (Figure 4.1 C, lane 3). 
The insert of the plasmid pTS822 was sequenced (JV) and compared to the 
sequence obtained previously by Smallie (2003) (TS) and the PFC0760c sequence using 
CLUSTALW (Section 3.2.1) (Figure 4.2). The sequences are identical except for one base 
pair at position 102 of TS sequence (Cytosine instead of Adenine) and 801 of the TS 
sequence (Thymine instead of Guanine). These differences are possibly due to sequencing 
anomalies in the TS sequence, as the JV sequence obtained in the present study has 100% 
sequence identity to the PFC0760c sequence. Therefore the pMAL-c2X and pTS822 
plasmids were used for recombinant expression. 
 
4.3.2 Optimisation of expression of the recombinant P. falciparum MBP fusion protein 
(Pf33-MBP) 
An attempt was made to optimise the expression of the Pf33-MBP fusion protein 
from the pTS822 vector. Expression at two different temperatures (30˚C and 37˚C) was 
performed (Figure 4.3) for pTS822 and pMAL-c2X as an expression control. No significant 
difference in expression of MBP or fusion protein appeared evident from observation of the 
gel (Figure 4.3). This could be due to possible discrepancies with loading concentration, 
although attempts were made to ensure the same loading concentration for each well. The 
protein bands at 30 kDa and 40 kDa appear to be reasonably consistent with one another, 
providing confidence that the loading concentrations are reasonably uniform. However, 
duplicate cultures should have been used to confirm the consistency of the loading 
concentration.  
 The SDS-PAGE gel of Pf33-MBP expression also confirmed that the pTS822 
plasmid was expressing a fusion protein, as the MBP protein band is not visible in the lanes 
containing pTS822 induced samples (Figure 4.3). 
pTS822 was also induced for different time intervals. The yield of recombinant 
protein increased slightly with increasing length of induction; however the yields of lower 
molecular weight Pf33-MBP proteins increased. Induction for 1 h (Figure 4.4 B, lane 3) 
and 3 h (Figure 4.4 B, lane 4) revealed only two bands (79 kDa; 60 kDa) with western 
blotting using anti-MBP serum. With increasing length of induction (5-11 h), four bands 
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(79 kDa; 60 kDa; 45 kDa; 37 kDa) were detected. These lower molecular weight proteins 
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Figure 4.1. Analysis of PCR products and BamHI restriction enzyme digest of the plasmids pMAL-c2X and pTS822. pMAL-c2X (A, lane 3) and 
pTS822 (B, lane 3) digested with BamHI. Non-digested pMAL–c2X(A, lane 2) and non-digested pTS822 (B, lane 2) controls. Samples were analysed 
on a 1.2 % (m/v) agarose gel, stained with ethidium bromide. PCR products of the pMAL-c2X (C, lane 2) and pTS822 (C, lane 3) plasmids, analysed on 




TS              ------------------------------------------------------TCCAAC 6 
JV              ---------------------------------------------------GGATCCAAC 9 
PFC0760c        AACAATATAAACAATGTTAACAATATAAACAATGTTAAAAACATTGTAGATATTAACAAC 7080 
                                                                        **** 
 
TS              TATCTTGTTAATAATCTTCAATTAAATAAAGACAATGATAATATTATTATTATTAAATTT 66 
JV              TATCTTGTTAATAATCTTCAATTAAATAAAGACAATGATAATATTATTATTATTAAATTT 69 
PFC0760c        TATCTTGTTAATAATCTTCAATTAAATAAAGACAATGATAATATTATTATTATTAAATTT 7140 
                ************************************************************ 
 
TS              AATATTTTAAAACTATTCAAATTAGGTTCATGATATTTATATATTATTAATCGTAATTTA 126 
JV              AATATTTTAAAACTATTCAAATTAGGTTCATGCTATTTATATATTATTAATCGTAATTTA 129 
PFC0760c        AATATTTTAAAACTATTCAAATTAGGTTCATGCTATTTATATATTATTAATCGTAATTTA 7200 
                ******************************** *************************** 
 
TS              AAAGAAATCCAAATGTTGAAAAATCAAATCCTTTCCTTAGAAGAAAGCATTAAAAGCTTA 186 
JV              AAAGAAATCCAAATGTTGAAAAATCAAATCCTTTCCTTAGAAGAAAGCATTAAAAGCTTA 189 
PFC0760c        AAAGAAATCCAAATGTTGAAAAATCAAATCCTTTCCTTAGAAGAAAGCATTAAAAGCTTA 7260 
                ************************************************************ 
 
TS              AATGAATTCATTAATAATCTAAAAAACGAAAATGAAAAAAATGAATTAATTAAAATAAAT 246 
JV              AATGAATTCATTAATAATCTAAAAAACGAAAATGAAAAAAATGAATTAATTAAAATAAAT 249 
PFC0760c        AATGAATTCATTAATAATCTAAAAAACGAAAATGAAAAAAATGAATTAATTAAAATAAAT 7320 
                ************************************************************ 
 
TS              AATTTTGAAGAAATACTCAAATTAAAAAATAATCTACAAGATAATGAAAGTTGTATACAA 306 
JV              AATTTTGAAGAAATACTCAAATTAAAAAATAATCTACAAGATAATGAAAGTTGTATACAA 309 
PFC0760c        AATTTTGAAGAAATACTCAAATTAAAAAATAATCTACAAGATAATGAAAGTTGTATACAA 7380 
                ************************************************************ 
 
TS              AACTTAAATAATTATTTAAAAAAAAATGAAGAATTAAATAAAATTAATGTAAAAAATATT 366 
JV              AACTTAAATAATTATTTAAAAAAAAATGAAGAATTAAATAAAATTAATGTAAAAAATATT 369 
PFC0760c        AACTTAAATAATTATTTAAAAAAAAATGAAGAATTAAATAAAATTAATGTAAAAAATATT 7440 
                ************************************************************ 
 
TS              TTCAAATATAAAGGATATATAATTCATTTAATACAACAAAGTAATGTCTTTTGTAAAATT 426 
JV              TTCAAATATAAAGGATATATAATTCATTTAATACAACAAAGTAATGTCTTTTGTAAAATT 429 
PFC0760c        TTCAAATATAAAGGATATATAATTCATTTAATACAACAAAGTAATGTCTTTTGTAAAATT 7500 
                ************************************************************ 
 
TS              TTTAAACATTTTAATGAAAATAAAATTATTGATCAAAGTATTATAAACAAATTACTTTAT 486 
JV              TTTAAACATTTTAATGAAAATAAAATTATTGATCAAAGTATTATAAACAAATTACTTTAT 489 
PFC0760c        TTTAAACATTTTAATGAAAATAAAATTATTGATCAAAGTATTATAAACAAATTACTTTAT 7560 
                ************************************************************ 
 
TS              TTAAAAAAATCCTTTGATTTTTATATGTATGATTCGGTTATACAAGAAATAAGAGAAAAT 546 
JV              TTAAAAAAATCCTTTGATTTTTATATGTATGATTCGGTTATACAAGAAATAAGAGAAAAT 549 
PFC0760c        TTAAAAAAATCCTTTGATTTTTATATGTATGATTCGGTTATACAAGAAATAAGAGAAAAT 7620 
                ************************************************************ 
 
TS              AAAAATATAATAATAAATCAAGATTTTTTAACAGATGAATATTTTAAACATATACAAACC 606 
JV              AAAAATATAATAATAAATCAAGATTTTTTAACAGATGAATATTTTAAACATATACAAACC 609 
PFC0760c        AAAAATATAATAATAAATCAAGATTTTTTAACAGATGAATATTTTAAACATATACAAACC 7680 
                ************************************************************ 
 
TS              TTTACCAAAACATGTAATGTATTAATTCAAAGGGGATATCTCAGCATCTTAAAAGATACA 666 
JV              TTTACCAAAACATGTAATGTATTAATTCAAAGGGGATATCTCAGCATCTTAAAAGATACA 669 
PFC0760c        TTTACCAAAACATGTAATGTATTAATTCAAAGGGGATATCTCAGCATCTTAAAAGATACA 7740 
                ************************************************************ 
 
TS              AACAATGATTTCTTTATACAAAACAAACAAAGTAATCAACAAGGAAATCAAAATGGTAAC 726 
JV              AACAATGATTTCTTTATACAAAACAAACAAAGTAATCAACAAGGAAATCAAAATGGTAAC 729 
PFC0760c        AACAATGATTTCTTTATACAAAACAAACAAAGTAATCAACAAGGAAATCAAAATGGTAAC 7800 
                ************************************************************ 
 
TS              CATATAAATATGTGTAACATATATCCAGATGATGAAATCAATGTAACTGCTGATCAACAA 786 
JV              CATATAAATATGTGTAACATATATCCAGATGATGAAATCAATGTAACTGCTGATCAACAA 789 
PFC0760c        CATATAAATATGTGTAACATATATCCAGATGATGAAATCAATGTAACTGCTGATCAACAA 7860 
                ************************************************************ 
 
TS              ATTTTTGATGGGACGGAAAACGTACCACATCGGA-------------------------- 820 
JV              ATTTTTGATGGTACGGAAAACGT------------------------------------- 812 
PFC0760c        ATTTTTGATGGTACGGAAAACGTACAACAGTCCTTACAAAATGAGGAAGATTATGTAAAT 7920 
                *********** ***********                   
Figure 4.2. Alignment of the sequence compiled from the forward and reverse sequencing results of 
the pTS822 DNA insert (JV) with PFC0760c and the sequence obtained by Smallie (2003) (TS). Base 
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Figure 4.3. Comparison of Pf33-MBP and MBP expression at different temperatures. Expression of 
Pf33-MBP and MBP was conducted at 30˚C (lanes 2-5) and 37˚C (lanes 6-9). Lane 1, molecular weight 
marker; lane 2, pMAL uninduced; lane 3, pMAL induced; lane 4, pTS822 uninduced; lane 5, pTS822 
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Figure 4.4. Analysis of Pf33-MBP expression samples from pTS822 induced for different time intervals. (A) 10% SDS-PAGE gel, (B) Western blot 
analysis of the MBP-fusion protein Pf33-MBP with rabbit anti-MBP serum (New England Biolabs). Lane 1, Amersham High-Range Rainbow Molecular 
Weight Marker; lane 2, uninduced pTS822 lysate (12h); lanes 3-8, pTS822 lysates induced with IPTG for different time intervals of 1h, 3h, 5h, 7h, 9h, and 




To rule out the possibility of protease degradation of the protein during lysis of the 
host cells, protease inhibitors were always used. However, an „in house‟ preparation of 
individually prepared protease inhibitors was routinely used. It was thought possible that 
some of the inhibitors may not be fully active in the preparation. It was thus decided to 
compare the banding pattern on SDS-PAGE of cells lysed in the presence of the 
commercially prepared protease inhibitor cocktail to the „in house‟ protease inhibitor 
preparation routinely prepared in the laboratory (Figure 4.5) No difference in banding 
pattern was observed between the use of the two different inhibitor cocktails. Four protein 
bands recognised by anti-MBP antibodies (approximately 79 kDa, 60 kDa, 45 kDa and 37 
kDa) were observed for both samples (Figure 4.5, arrows lanes 5 and 7).  
A low level of Pf33-MBP expression was observed from pTS822 and thus the 
plasmids pKK223-3-PfLDH (expressing P. falciparum lactate dehydrogenase) and 
pKK223-3-PvLDH (expressing P. vivax lactate dehydrogenase) were used as additional 
expression controls (Figure 4.6). A protein band of approximately 34 kDa, corresponding to 
LDH was detected by anti-LDH IgY (Figure 4.6 B). The same protein bands are clearly 
visible in the SDS-PAGE analysis (Figure 4.6 A), indicating successful expression of both 
PfLDH and PvLDH. 
A number of factors are thought to cause low yields and difficulties with 
expression: percentage AT base pair composition (Baca and Hol, 2000; Matambo et al., 
2004), molecular weight and pI (Mehlin et al, 2006; Vedadi et al., 2007), and protein 
disorder (Linding et al., 2003). The theoretical molecular weight and pI, base pair 
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Figure 4.5. Comparison of protein expression when different protease inhibitors are used during isolation of Pf33-MBP 
from pTS822. (A) 10 % (m/v) acrylamide gel, (B) western blot analysis with rabbit anti-MBP serum. E. coli cells containing the 
pTS822 plasmid expressing recombinant Pf33-MBP were lysed open in the presence of a protease inhibitor cocktail consisting of 
individual inhibitor stocks prepared in the lab (i) (lanes 4 and 5) and in the presence of a protease inhibitor cocktail from Sigma (ii) 
(lanes 6 and 7). Lane 1, Bio-Rad low molecular weight marker; lane 2, uninduced pMAL-c2X lysate; lane 3, IPTG-induced 
pMAL-c2X lysate expressing recombinant MBP; lanes 4 and 6, uninduced lysates from expression of recombinant Pf33-MBP; 
lanes 5 and 7, IPTG-induced lysates from expression of recombinant Pf33-MBP; lane 8, E. coli lysate (with no plasmid). 
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Figure 4.6. P. falciparum lactate dehydrogenase (PfLDH) and P.vivax lactate dehydrogenase 
(PvLDH) expression lysates. Lysates were analysed by SDS-PAGE (10% acrylamide) (A) and western 
blotting with anti-LDH IgY at 1 μg/ml (B). Lane 1, Bio-Rad low molecular weight marker; lane 2, 
uninduced PfLDH; lane 3, IPTG-induced PfLDH; lane 4, uninduced PvLDH; lane 5, IPTG-induced 
PvLDH; lane 6, lysate of turbo competent E. coli host cells (New England Biolabs). 
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4.3.3 Theoretical molecular weight and pI of proteins 
Mehlin et al. (2006) examined if the molecular weight and pI of a protein could 
hamper the soluble recombinant expression of that protein. Mehlin et al. (2006) found that 
proteins having a pI above 9.5 would be unlikely to be solubly expressed. Only 0.4% of all 
the Plasmodium proteins with a pI above 9.5 tested by Mehlin et al. (2006) were solubly 
expressed. In addition, only 1.6% of proteins with a molecular weight over 56 kDa were 
solubly expressed. 
Therefore the theoretical molecular weights and pI for each protein in the present 
study were determined from their amino acid sequences (www.expasy.org) (Table 4.1). All 
of the proteins investigated (Table 4.1) had a pI below 9.5 with the highest pI being 
recorded at 7.63 for PvLDH, followed by a pI of 7.11 for Pf33. Recombinantly expressed 
Pf33-MBP was determined to have a theoretical molecular mass of 79 kDa and MBP 
expressed alone was determined to have a molecular mass of 54 kDa. 
 
4.3.4 Base pair composition of Plasmodium proteins 
The base pair composition of Plasmodium proteins and recombinant proteins was 
determined using the sequence utilities at the DNA Learning Centre (DNALC) (Table 4.2) 
(http://www.dnalc.org/bioinformatics/dnalc_nucleotide_analyzer.htm). The base pair 
composition for P. falciparum lactate dehydrogenase (PfLDH) and P. vivax lactate 
dehydrogenase (PvLDH) were analysed as controls. All DNA sequences coding for the 
Plasmodium proteins of interest were calculated to be AT rich, with percentages of A and T 
base pairs as high as 79% for PFC0760c. The least AT rich Plasmodium gene examined 
was that for Pv116630 (PvLDH) with an AT base pair composition of 54% (Table 4.2). The 




Table 4.1. Theoretical molecular weight and pI of Plasmodium proteins and the MBP-
fusion (Pf33-MBP) and MBP and Pf33 after Factor Xa cleavage. 
Protein Theoretical molecular weight (kDa) Theoretical pI 
Pf33-MBP 79.07 5.59 
Pf33 (cleaved from Pf33-MBP) 33.28 7.11 
MBP (cleaved from Pf33-MBP) 45.8 5.09 
MBP (pMAL-c2X expressed)* 54.33 5.28 
PF13_0141 (PfLDH)* 34.108 7.63 
Pv116630 (PvLDH)* 32.915 6.67 
PFC0760c 402.956 4.43 




Table 4.2. Base pair composition and sizes of the genes encoding Plasmodium proteins 
* Expression control proteins 
 
4.3.5 Protein disorder prediction 
Proteins can be ordered or disordered. Ordered proteins will experience small, 
thermally driven movements around the atoms making up the backbone of the protein. In 
contrast, intrinsically disordered proteins will experience more dynamic movements of the 
atoms and position of the protein backbone (Vucetic et al., 2005). Proteins intrinsically 
disordered at their N or C-termini, or even in regions within the protein tend to lead to 
difficulties in protein expression, purification and crystallization (Linding et al., 2003). It 
was for this reason that the PFC0760c and the Pf33-MBP fusion protein sequences were 
analysed for protein disorder probability using the VSL2 predictor of intrinsically 
disordered regions at Disprot (www.disprot.org/predictors.php). The prediction data was 
processed into a graphical format (Figure 4.7). MBP and P. falciparum LDH (PfLDH) were 
Name Size (bp)  AT composition 
Pf33-MBP 1999 62.28% 
Pf33 826 80.39% 
MBP* 1386 48.34% 
PF13_0141 (PfLDH)* 951 66.98% 
Pv116630 (PvLDH)* 912 54.06% 
Pca 96 3288 70.53%  
PFC0760c 10185 79.03% 
PY05757 4575 75.69% 
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included as controls (Figure 4.7 B and D) as recombinant expression of PfLDH (Turgut-
Balik et al., 2001) and MBP (present study, Figure 4.3, lane 3) has been successful. 
Proteins are considered disordered if they have one or more disordered regions 
(Vucetic et al., 2005). A disordered region is considered so if its probability prediction 
value is above 0.5 (Peng et al., 2006) (red line, Figure 4.7). Multiple regions were predicted 
disordered for protein PFC0760c (Figure 4.7 C). In contrast, only four very short regions of 
P. falciparum LDH were predicted to have a disorder probability above 0.5, resulting in the 
majority of the protein predicted to be ordered (Figure 4.7 D). Large sections of the fusion 
protein Pf33-MBP (Figure 4.7 A) were predicted disordered, as was MBP (Figure 4.7 B). 
From these results, protein disorder prediction does not appear to be a reliable prediction of 
difficulty in protein expression in the present study. 
 
4.3.6 Purification of Pf33-MBP 
Lysates from pTS882 and pMAL-c2X expression were passed over separate 
amylose columns to purify Pf33-MBP and MBP, respectively. Pf33-MBP and MBP were 
eluted from the amylose with 10 mM maltose in 20 mM tris-HCl, 200 mM NaCl, 1 mM 
EDTA, pH 7.4. The absorbance at 280 nm of the collected fractions was determined 
(Figure 4.8).  
Pf33-MBP eluted after 6-13 ml of 10 mM maltose (Figure 4.8 A). The average yield 
of Pf33-MBP obtained from amylose purification was 3 mg. This consisted of the full 
length Pf33-MBP (79 kDa band), in addition to the lower molecular weight Pf33-MBP 
proteins that also bound to the amylose column. SDS-PAGE analysis of amylose purified 
Pf33-MBP (Figure 4.9, lane 2), revealed three major bands (approximately 79 kDa, 60 kDa 
and 45 kDa) and one minor band (approximately 33 kDa), in addition to a couple of minor 
bands below 21.5 kDa and above 97.4 kDa. The protein bands at 79 kDa, 60 kDa, 45 kDa 
and 33 kDa are the same protein bands detected by the anti MBP antibodies in Figures 4.4 
and 4.5. MBP eluted in four fractions after 2-3 ml of 10 mM maltose had passed through 
the column (Figure 4.8 B). Maximum absorbance values were obtained for fractions four 
and five. SDS-PAGE analysis of the fractions revealed the MBP to be considerably pure 









Figure 4.7. Protein disorder predictions for Plasmodium proteins. Protein disorder predictions were performed for maltose-binding (MBP) 
fusion protein Pf33-MBP (A), MBP (control) (B), P. falciparum hypothetical protein PFC0760c (C) and P. falciparum lactate dehydrogenase 
(PF13_0141) (control) (D), using the VSL2 predictor of intrinsically disordered regions at Disprot (www.disprot.org/predictors.php) (Vucetic et al., 
2005). Proteins are considered disordered at probabilities over 0.5 (red line). 
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Figure 4.8. Amylose purification of Pf33-MBP and MBP. Lysate from pTS822 expression (A) and 
pMAL-c2X expression (B) was passed over an amylose column. The Pf33-MBP and MBP proteins 
were eluted with 10 mM maltose in 20 mM tris-HCl, 200 mM NaCl, 1 mM EDTA, pH 7.4. Fractions 
(1 ml) were collected and the absorbance at 280 nm determined. 
  A 
 





4.3.7 Factor Xa cleavage of Pf33-MBP 
To separate Pf33 from MBP, amylose-purified Pf33-MBP was incubated with Factor 
Xa at different concentrations ranging from 10 µg/ml to 0.05 µg/ml, at room temperature and 
at 4˚C. The samples were left to cleave for 46 h and were immediately boiled in the presence 
of reducing SDS-PAGE buffer and analysed on an SDS-PAGE gel (Figure 4.9). Pf33 was 
almost completely cleaved from MBP with 10 µg/ml Factor Xa, incubated at room 
temperature for 46 h. Protein bands of approximately 79 kDa, 63 kDa, 43 kDa and 34 kDa 
were observed (Figure 4.9 A, lane 3). The protein bands at 79 kDa, 63 kDa and 34 kDa appear 
as minor bands, having low intensity. With increasing Factor Xa concentration, these bands 
become virtually invisible on the gel, whereas the prominent protein band at 43 kDa, becomes 
more intense. 
The protein band at 34 kDa is close to the expected size of cleaved Pf33 (33 kDa). 
However, this band appears to be too low in intensity to represent Pf33 The dominant protein 
band observed at 43 kDa is close to the expected size of cleaved MBP (45kDa). As there is 
only one dominant band after complete cleavage, it was assumed that Pf33 and MBP are 
possibly the same size after Factor Xa cleavage, and thus appear together as one dominant 
band at 43 kDa. Western blotting analysis and probing with 2 different antibodies such as an 
anti-peptide antibody raised against MBP and an anti-peptide antibody raised against Pf33, 




 ion exchange chromatography to separate 
Pf33 from MBP after Factor Xa cleavage 
The cleaved Pf33-MBP sample was passed over DEAE Sepharose to separate Pf33 from 
MBP. Proteins with a net negative charge at the pH being used become bound to the positively 
charged resin. At pH 8.0, both Pf33 and MBP are predicted to have a net negative charge, as 
the pH of the buffer is above their pI of 7.11 and 5.09, respectively. Thus they would both 
bind to the resin and be eluted with a NaCl gradient. Pf33 is likely to elute at a lower NaCl 
concentration than MBP. 
The absorbance of the fractions collected was monitored at 280 nm for the presence of 
protein (Figure 4.10 A). Four absorbance peaks were observed. The first peak would have 
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been excess Pf33-MBP cleavage mixture. The second peak was observed after the NaCl 
gradient was started. The protein eluted from the column at a NaCl concentration of 
approximately 100 mM. This should correspond to Pf33 as it was expected to elute first due to 
a lower nett negative charge. The second peak of protein was observed to elute at a 
concentration of approximately 370 mM NaCl, which is expected to be MBP. The last 
absorbance peak was observed at a NaCl concentration of approximately 400 mM. This peak 
could be due to small amounts of un-cleaved Pf33-MBP. This peak could also be due to Factor 
Xa as it elutes at a NaCl concentration in the region of 400 mM (New England Biolabs 
pMAL
TM
 Protein Fusion and Purification System Manual). Cleaved MBP is reported to elute 
as a sharp peak at 100-150 mM NaCl (New England Biolabs pMAL
TM
 Protein Fusion and 
Purification System Manual), however this doesn‟t appear to be the case here.  
MBP expressed from non-recombinant pMAL-c2X was passed over the DEAE 
Sepharose column as a control (Figure 4.10 B). MBP eluted at a NaCl concentration of 
approximately 275 mM. MBP expressed from pMAL-c2X has a different pI (5.28) and 
molecular mass (54 kDa), in comparison to cleaved-off MBP (pI/of 5.09; molecular mass of 
45.8) from Pf33-MBP and would therefore be expected to elute at different NaCl 
concentrations. MBP expressed from pMAL-c2X would be expected to elute at a lower salt 
concentration in comparison to cleaved-off MBP and therefore MBP expressed from pMAL-
c2X was not an adequate control. 
The eluted fractions (filled diamonds, Figure 4.10 A) from the DEAE purification of 
cleaved Pf33-MBP was analysed on an SDS-PAGE gel (Figure 4.11) to determine which 
fractions contained Pf33 and which contained MBP. Protein bands of approximately 43 kDa 
(Figure 4.11 A lanes 5-8 and lane 13; B lanes 9-10), 45 kDa and 50 kDa (Figure 4.11 lane 11) 
were observed. The protein bands of 43 kDa correspond to the same molecular mass observed 
for the predominant band in the cleaved Pf33-MBP sample (Figure 4.9, A, lane 3). 
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Figure 4.9. Analysis of protease cleavage of amylose-purified Pf33-MBP with Factor Xa on a 12.5% acrylamide gel. (A) 
Samples from incubation with factor Xa at room temperature for 46 h, (B) Samples from incubation with factor Xa at 4˚C for 46 h. 
Factor Xa was used at a final concentration of 10 μg/ml (lane 3), 5 μg/ml (lane 4), 2.5 μg/ml (lane 5), 500 ng/ml (lane 6), 250 ng/ml 
(lane 7) and 50 ng/ml (lane 8). Pf33-MBP incubated with buffer, as a non-cleaved control (lane 2) and a protein molecular weight 




Figure 4.10. DEAE Sepharose purification of cleaved Pf33 and MBP. Factor Xa-treated Pf33-MBP 
(A) was separated with ion exchange chromatography. Amylose-purified MBP expressed from pMAL-
c2X was used as a control (B). The absorbance of each fraction (1 ml) was read at 280 nm. A NaCl 
gradient of 25 mM – 500 mM NaCl was used (dashed line) to elute bound protein. Filled diamonds () 




























































































































Figure 4.11. Analysis of fractions obtained from DEAE Sepharose purification of cleaved 
Pf33-MBP. (A) Fractions from DEAE Sepharose purification of cleaved Pf33-MBP. Lane 1, Bio-
Rad low molecular weight marker; lane 2 fraction 1; lane 3, fraction 6; lane 4, fraction 7; lane 5, 
fraction 8; lane 6, fraction 29; lane 7, fraction 30; lane 8, fraction 31; lane 9, fraction 32; lane 10, 
fraction 64; lane 11, fraction 67; lane 12, fraction 68; lane 13, amylose-purified factor Xa-cleaved 
Pf33-MBP; lane 14, amylose-purified, non-cleaved Pf33-MBP. (B) Fractions from DEAE 
Sepharose purification of cleaved Pf33-MBP. Lane 1, Bio-Rad low molecular weight marker; 
lane 2 fraction 5; lane 3, pooled fractions 14-26; lane 4, fraction 36; lane 5, fraction 41; lane 6, 
fraction 42; lane 7, fraction 43; lane 8, fraction 45; lane 9, fraction 53; lane 10, fraction 54; lane 
11, fraction 59; lane 12, fraction 64; lane 13, fraction 67; lane 14, amylose-purified MBP. 
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4.3.9 ‘On-column’ Factor Xa cleavage of Pf33-MBP 
„On-column‟ cleavage of Pf33-MBP was attempted as an alternative method for separating 
MBP and Pf33. Pf33-MBP was cycled over an amylose resin column, to allow binding of 
the MBP fusion to amylose. The Pf33-MBP bound to the amylose resin was then incubated 
with Factor Xa to cleave off Pf33, leaving MBP bound to the amylose. The MBP was later 
eluted with 10 mM maltose. The absorbances of the fractions collected were determined at 
280 nm to determine the presence of protein (Figure 4.12). An SDS-PAGE gel and western 
blot of the „on-column‟ cleavage fractions was run (Figure 4.13). The bound MBP fraction 
(Figure 4.13, lane 8) has a banding pattern almost identical to the cleaved off Pf33 (Figure 
4.13, lane 7), except that there is more of the 43 kDa band in lane 7 than in lane 8. 
However, when probed with anti-MBP antiserum (Figure 4.13 B) the banding pattern is 
identical, suggesting that all of the 3 bands observed in each lane are MBP or have MBP as 
part of their sequence.  
It was thought possible that Pf33 was being recognised by anti-MBP antibodies as 
perhaps MBP and Pf33 had some similar epitopes. To ensure that there were no linear 
epitopes, an alignment of their amino acid sequences was done using the ClutalW program 
(Section 3.2.1). No sequence similarity exists between the two sequences (Result not 
shown) and therefore the anti-MBP antibodies are detecting MBP in Figure 4.13 B. The 
possibility also existed that there was perhaps a second Factor Xa recognition site that 
perhaps resulted in some of the MBP still being attached to Pf33. Factor Xa cleaves at the 
sequence IEGR and sometimes IDGR. Only one IEGR was observed in the MBP-fusion 
amino acid sequence, at a position corresponding to the plasmid derived Factor Xa site 
(result not shown). 
A further possibility to explain the results could be that after cleavage, some of the 

































Figure 4.12. Absorbance readings of fractions collected from ‘on-column’ cleavage of Pf33-MBP. 
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Figure 4.13. Separation of Pf33 from MBP using ‘On-column’ cleavage. (A) 10 % (m/v) acrylamide gel, (B) western blot analysis with 
rabbit anti-MBP serum. Lane1, Bio-Rad low molecular weight marker; lane 2, uninduced pTS822 lysate; lane 3, IPTG-induced pTS822 lysate; 
lane 4, pellet from centrifugation of sonicated, IPTG-induced pTS822 lysate; lane 5, supernatant from centrifugation of sonicated, IPTG-
induced pTS822 lysate; lane 6, Pf33-MBP purified from IPTG-induced pTS822 supernatant on amylose resin; lane 7, product from „on-
column‟ cleavage of Pf33-MBP with Factor Xa; lane 8, bound fraction from „on-column‟ cleavage of Pf33-MBP, eluted with 10 mM maltose. 
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4.4 Expression of Pf33 as a glutathione S-transferase fusion protein 
4.4.1 Sub-cloning of the P. falciparum insert into pGEX4T1 
It was decided to attempt expression of the recombinant P. falciparum protein in a 
second vector, pGEX4T1, to determine if better yields of Pf33 could be obtained. 
The plasmid pGEX4T1 has a polylinker region downstream from the gene 
expressing a 26 kDa glutathione S-transferase (GST) protein from Schistosoma japonicum 
(Smith and Johnson, 1988). When a gene of interest is cloned into the polylinker, the 
resulting expressed protein is a GST fusion, with GST at the N-terminus of the protein, and 
the protein of interest at the C-terminus. GST fusions can be affinity purified on a 
glutathione agarose column. Elution of the fusion protein is under non-denaturing 
conditions, using reduced glutathione (Smith and Johnson, 1988). The GST can be removed 
by cleavage with thrombin, as a thrombin cleavage site is positioned between the gene 
expressing GST and the polylinker (Appendix Figure A2).  
 The P. falciparum DNA insert was excised from pTS822 with BamHI (Figure 4.1 
B, arrow) and ligated into BamHI-digested pGEX4T1. Originally the insert was to be 
excised by double digestion with EcoRI and SalI, to ensure that the insert was ligated into 
the vector in the correct orientation. However, restriction enzyme site analysis of the insert 
DNA with restriction enzyme mapper software, revealed an EcoRI site within the insert 
sequence (Figure 4.14). Digesting with XmnI and SalI was not an option either, as the 
pGEX4T1 vector does not possess an XmnI site in the poylinker region (Appendix Figure 
A2). The insert could be amplified with primers having suitable restriction enzyme sites, 
but it was decided to first attempt cloning with the insert restricted with BamHI. 
 pGEX4T1 was linearised with BamHI and analysed by agarose gel electrophoresis 
(Figure 4.15). The expected size of 4 900 bp for pGEX4T1 was observed (Figure 4.15). 
The insert from pTS822 (Figure 4.1 B) was ligated into linear pGEX4T1 and transformed 
into E. coli cells. Transformed colonies were screened using colony PCR. The PCR 
products were analysed on an agarose gel (Figure 4.16 A and B). Five of the fifteen 
colonies screened had a PCR product of approximately 1 000 bp, indicating the presence of 
the DNA insert. The remaining ten colonies had a PCR product of approximately 200 bp, 
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which matched the size obtained for the non-recombinant pGEX4T1 control that was PCR 



















Due to the insert DNA being able to ligate into the vector in two different 
orientations, it was necessary to confirm the orientation of the insert. In pGEX4T1, an 
EcoRI site is located 3 base pairs downstream from the BamHI site (Appendix Figure A2), 
into which the DNA insert was ligated. An EcoRI site is also present in the insert DNA, 
approximately 195 bp away from the BamHI site at the 5‟ end of the insert (Figure 4.14). It 
was thought possible to use the EcoRI sites to determine the orientation of the ligated insert 
DNA. The PCR products were digested with EcoRI and analysed by agarose gel 
electrophoresis (Figure 4.16 C). The PCR product of a recombinant plasmid having the 
DNA insert in the correct orientation would yield products of 636 bp, 100 bp and 259 bp 
upon digestion with EcoRI (Figure 4.17). A DNA insert in the incorrect orientation in a 


















Figure 4.14. Restriction enzyme map of the P. falciparum insert DNA. Underlined portions are 
part of the pMAL-c2X vector polylinker region. An internal EcoRI site, GAATTC (red, boldface) 
and HindIII site, AAGCTT (grey, boldface) were predicted using a restriction enzyme mapper 
program (www.restrictionmapper.org). XmnI, GAGGATTT (brown boldface); BamHI, GGATCC 
(blue boldface); XbaI, TCTAGA (purple, boldface); SalI, GTCGAC (orange boldface) and PstI, 




201 bp, 100 bp, and 694 bp (Figure 4.17). On inspection of the agarose gel, it was very 
difficult to determine which of the inserts were in the correct orientation as the products 
yielded by digestion of inserts in the incorrect orientation would have very similar sizes to 
those of correct orientation. In addition, the DNA ladder used did not have sufficiently 
small DNA fragments to obtain accurate sizes for the digested PCR products. PCR products 
from colony 18 appeared to have the closest match to the theoretical sizes of an EcoRI 
digestion of the PCR product from an insert in the correct orientation. Plasmid 
(pGEX4T1Pf33) was isolated from colony 18 and sequenced. The results from sequencing 
pGEX4T1Pf33 was aligned with the PFC0760c DNA sequence, and a sequence which was 
constructed from the DNA sequencing results obtained previously for the insert DNA in 
pTS822 (Section 4.3.1 and Figure 4.2), and the pGEX4T1 vector DNA sequence 
(http://seq.yeastgenome.org/vectordb/vector_descrip/COMPLLETE/PGEX4T1.SEQ.html) 
(result not shown). The sequence is identical to the PFC0760c sequence and the sequence 


















Figure 4.15. BamHI restriction enzyme digest of pGEX4T1. Lane 1, DNA ladder; lane 2, non-
digested pGEX4T1 (control); lane 3, BamHI-digested pGEX4T1. Samples were analysed on a 1% 



































Figure 4.16. Analysis of E. coli colonies transformed the 822 bp P. falciparum DNA insert 
ligated into pGEX4T1. The transformed colonies were analysed by colony PCR. (A) Colony 22 
(lane 7), colony 26 (lane 11) and colony 28 (lane 13) all appear to have an insert. (B) Colony 15 
(lane 4), and colony 18 (lane 7) appear to have an insert. Non-recombinant pGEX4T1 was included 
as a control (lane 3). PCR products corresponding to the size of the non-recombinant pGEX4T1 (200 
bp) did not possess the DNA insert (arrow). The PCR products indicating the presence of insert DNA 
were digested with EcoRI. (C) EcoRI digested PCR products from colonies 15 (lane 5), 18 (lane 7), 
22 (lane 9), 26 (lane 11) and 28 (lane 13) and non-digested controls for colonies 15 (lane 4), 18 (lane 
6), 22 (lane 8), 26 (lane 10) and 28 (lane 12) were analysed on a 1% (w/v) agarose gel. Non-
recombinant pGEX4T1 digested with EcoRI (lane 3) and non-digested non-recombinant pGEX4T1 























4.4.2 Recombinant expression of GST and the GST-fusion protein (Pf33-GST) 
As experienced with the pMAL system, the expression level of the GST-fusion 
protein (Pf33-GST) from the pGEX4TPf33 plasmid was low. No fusion-protein band was 
clearly evident on the gel (Figure 4.18 A, lane 5). Expression of the GST control was 
clearly visible on with SDS-PAGE analysis, with a dominant protein band observed at 
approximately 26 kDa (Figure 4.18 A, lane 3). Detection of Pf33-GST with monoclonal 
anti-GST antibodies produced a very faint signal (Figure 4.18 B, lane 5 arrow) at a 
molecular mass of 59 kDa. This compares favourably to the predicted molecular weight of 
approximately 59.5 kDa of Pf33-GST. However this size is also very close to the dimer 
molecular weight for GST of 58.5 kDa (GST Gene Fusion System Handbook, Amersham 
Biosciences), but a dimer was not observed in the control. 
The anti-GST antibodies detected another protein of approximately 22 kDa in all of 
the lanes (Figure 4.18 B). As no E. coli lysate was included in this experiment as a control, 
it could not be determined if the bands being detected were possibly E. coli proteins. It is 
possible the protein band at 22 kDa is E. coli biotin carboxyl carrier protein (BCCP). BCCP 
Figure 4.17. Schematic representation of the PCR products that would result from pGEX4T1 
recombinants ligated with the insert DNA. Two possible orientations could result from ligation of the 
insert into pGEX4T1: the correct orientation (A) and the incorrect orientation (B). EcoRI digestion of 
PCR products from recombinant plasmids with the insert in the correct orientation would yield DNA 
fragments of 259 bp, 636 bp and 100 bp. EcoRI digestion of PCR products from recombinant plasmids 
with the insert in the incorrect orientation would yield DNA fragments of 694 bp, 195 bp and 100 bp. 
The EcoRI and BamHI restriction enzyme sites are shown. 
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is a small subunit of E. coli acetyl-CoA carboxylase that migrates on a reducing SDS-
PAGE gel at 22.5 kDa (Li and Cronan, 1992). The anti-GST antibody is a biotinylated 
antibody and requires streptavidin for detection. Thus BCCP would produce a signal on the 
nitrocellulose upon addition of streptavidin. 
An attempt was made to improve expression of Pf33-GST using the RIG plasmid 
which expresses rare tRNAs. The addition of the RIG plasmid should result in increased 
expression of Pf33-GST if the reason for low expression is due to insufficient rare tRNAs. 
Expression of Pf33-GST was attempted with E. coli cells co-transformed with 
pGEX4T1Pf33 and the RIG plasmid. The presence of the RIG plasmid did not appear to 
increase expression levels of Pf33-GST (result not shown). 
 
4.4.3 Purification of GST and Pf33-GST 
Pf33-GST and GST were purified using a glutathione-agarose affinity column. The 
fractions were analysed by SDS-PAGE and western blotting (Figure 4.19). SDS-PAGE 
analysis of the fractions collected from purification of Pf33-GST revealed protein bands at 
approximately 59 kDa, 53 kDa and 46 kDa in addition to minor protein bands below a 
molecular mass of 45 kDa (Figure 4.19 A). Western blotting with monoclonal anti-GST 
antibodies only detected the protein band at 59 kDa (Figure 4.19 B). 
SDS-PAGE analysis of glutathione agarose purified GST revealed a major protein 
band at approximately 26 kDa (Figure 4.19 C), corresponding to GST. In addition, a 
number of minor protein bands were observed between 45 kDa and 66.2 kDa, and at 
approximately 20 kDa. These bands were not detected by the anti-GST antibodies in the 
western blot (Figure 4.19 D), which suggests that they are contaminating E. coli proteins 
that were not removed with glutathione agarose purification. However, a protein of 
approximately 59 kDa was also detected by anti-GST antibodies, in the fractions collected 
from GST purification. This is the same size observed for Pf33-GST. It is unclear if the 59 
kDa band observed in both gels is simply an anomaly or Pf33-GST. 
Further expression of Pf33 as a GST fusion protein was abandoned as it was thought 
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Figure 4.18. Analysis of expression of the GST-fusion protein, Pf33-GST, by SDS-PAGE and western blotting. (A) 10% SDS-PAGE, (B) 
western blot with monoclonal anti-GST tag antibodies. Lane 1, Bio-Rad low molecular weight marker; lane 2, un-induced non-recombinant 
pGEX4T1; lane 3, IPTG-induced non-recombinant pGEX4T1 expressing GST; lane 4, un-induced recombinant pGEX4T1C18; lane 5, IPTG-
induced recombinant pGEX4T1C18 expressing Pf33-GST. The arrow indicates the position where a faint band, corresponding to Pf33-GST, was 
























Figure 4.19. SDS-PAGE gel analysis and western blotting of glutathione-agarose-purified GST fusion protein, Pf33-GST from 
expression of pGEX4T1Pf33 and recombinant GST. (A) 10 % (m/v) acrylamide gel of Pf33-GST expression. (B) Western blot analysis 
of Pf33-GST expression with biotinylated monoclonal anti-GST antibodies (1 μg/ml). Lane 1, Bio-Rad low molecular weight marker; 
Lanes 2-13, fractions 1-12 from the affinity gel. (C) 10 % (m/v) acrylamide gel of glutathione-agarose-purified recombinant glutathione-S-
transferase (GST) from expression in pGEX4T1. (D) Western blot analysis with biotinylated monoclonal anti-GST antibodies (1 µg/ml). 
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The pMAL-c2X and pTS822 plasmid identities were established by restriction 
enzyme digests, PCR and sequencing (Figures 4.1 and 4.2). The determined experimental 
plasmid sizes of the plasmids were similar to the theoretical sizes expected. The sequencing 
result for pTS822 was identical to the PFC0760c sequence and it was therefore confirmed 
that the plasmid was the correct one.  
Different temperatures (Figure 4.3) and periods of IPTG induction (Figure 4.4) were 
used to optimise expression of Pf33-MBP. It was determined that inducing for long periods 
of time resulted in a larger yield of lower molecular weight Pf33-MBP proteins. The 
observation of lower molecular weight proteins with the pMAL system has been 
experienced by others using the pMAL plasmids to produce recombinant proteins. Lower 
molecular weight bands were observed by di Guan et al. (1988) with expression of MBP-β-
galactosidase hybrid protein and MBP PstI hybrid protein. These lower molecular weight 
proteins were assumed to be degradation products. Protease inhibitors were used during 
harvest of the Pf33-MBP protein and therefore it was thought unlikely that the lower 
molecular weight proteins were due to protease cleavage post-expression. Transforming the 
pTS822 plasmid into a protease deficient E. coli host strain, such as E. coli BL21 (DE3), 
may be beneficial but was not explored. It is also possible that the lower molecular weight 
Pf33-MBP proteins are due to cryptic start sites, which are not unusual for Plasmodium 
genes (Amante et al., 1997; Rathore et al., 2005; Bharadwaj et al., 1998). These cryptic 
start sites result in truncated products when expressed in E. coli. 
 Recombinant protein expression at 30˚C instead of the conventional temperature of 
37˚C did not appear to increase protein expression. An alternative temperature for 
expression could be utilised. A temperature of 25˚C for expression has resulted in 
successful, soluble, full-length expression of falcipain 1 from P. falciparum (Goh et al., 
2005). Cho et al. (2008) experienced a 1.2 fold increase in total expressed protein when 
their MBP fusion protein was expressed at 22˚C as opposed to 37˚C. It is likely that 
particular temperatures for expression will be more beneficial for some proteins than others 
and it may be necessary to experiment with a range of temperatures to obtain 
predominantly full-length Pf33-MBP protein. 
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 Successful expression has been achieved with inducing protein expression at post-
log phase (A600 of 2.0), rather than at mid-log phase (A600 of 0.6) (Flick et al., 2004). The 
protein from induction at mid-log phase resulted in a truncated protein, with a small yield 
of the overall protein being the full-length intact protein, as is the case with Pf33-MBP. 
Induction at post-log phase resulted in intact, full-length protein. Inducing expression at 
post-log phase needs to be tested to determine if this will result in a higher yield of full-
length Pf33-MBP. 
The base pair composition of the recombinant proteins was determined, as high 
adenine/thymine content has been argued to cause problems with recombinant protein 
expression (Kane, 1995; Baca and Hol, 2000; Matambo et al., 2004). The DNA sequence 
for Pf33 has an adenine/thymine content of 80%, but when combined with the MBP 
sequence (adenine/thymine content of 48%), to form Pf33-MBP, the adenine/thymine 
content is 62%. PfLDH has an adenine/thymine content of 67%, however it expressed more 
efficiently than Pf33-MBP, which had greater adenine/thymine content. Mehlin et al., 
(2006) found that codon usage and base pair composition did not appear to be contributing 
factors towards poor recombinant protein expression. It appears that base pair composition 
is possibly not a contributing factor to the poor Pf33-MBP expression either, although 
PfLDH and Pf33-MBP were expressed from different plasmids which may have had a part 
to play. 
All of the proteins expressed had predicted disorder within their protein sequences 
(Figure 4.7). Pf33-MBP appeared to have approximately eleven regions within the protein 
sequence that were predicted to be disordered. PfLDH was predicted to have four 
disordered regions and MBP was predicted to have approximately eight disordered regions. 
Both of these proteins were successfully expressed, which suggests that protein disorder 
does not appear to have a significant impact on the expression of PfLDH and MBP. 
Expression of Pf33 was attempted as a GST fusion protein to try to increase protein 
expression, but proved to be less successful. Comparisons of recombinant protein 
expression as an MBP-fusion versus a GST-fusion has previously been done and the MBP 
constructs produced superior recombinant fusion proteins in comparison to the GST 
constructs (Wang et al., 1999; Cho et al., 2008). It is possible that recombinant expression 
of Pf33-GST could have been improved, by altering the growth temperature to between 
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20°C and 30°C, inducing at a higher cell density for a shorter period, increasing aeration of 
the cells or using a different E. coli strain (Saluta and Bell, 1998). Further expression with 
the GST fusion construct pGEX4T1Pf33 was not continued. 
Pf33-MBP was not expressed as successfully as MBP, PfLDH and PvLDH. For this 
reason the pI, and molecular mass and number of rare codons was determined, as these 
factors have been implicated to play a role in poor recombinant protein expression (Mehlin 
et al, 2006; Vedadi et al., 2007; Saul and Battistutta 1988; Kane, 1995; Sayers and Price, 
1995; Baca and Hol, 2000; Yadava and Ockenhouse, 2003; McNulty et al., 2003; Matambo 
et al., 2004; Zhou et al., 2004). The pI‟s of the proteins were all below 9.5, and should 
therefore not impact protein expression negatively (Mehlin et al., 2006). MBP (54 kDa), 
PfLDH (34 kDa) and PvLDH (33 kDa) all have a molecular mass below 56 kDa, and Pf33-
MBP has a molecular mass greater than this (79 kDa). This correlates well with the findings 
of Mehlin et al, (2006) as all the proteins with molecular mass below 56 kDa were 
successfully expressed. The one protein with a molecular mass above this, Pf33-MBP, was 
poorly expressed. 
The presence of the lower molecular weight Pf33-MBP proteins was thought to 
possibly be due to Plasmodium using codons that are very rarely used in E. coli. 
Recombinantly expressing a gene having these rare E. coli codons in an E. coli host, often 
results in translational errors, frame shifts and decreases in protein expression (Saul and 
Battistutta 1988; Kane, 1995; Sayers and Price, 1995; Baca and Hol, 2000; Yadava and 
Ockenhouse, 2003; McNulty et al., 2003; Matambo et al., 2004; Zhou et al., 2004). For this 
reason, the number of rare codons was determined for the Pf33 DNA and for Plasmodium 
LDH DNA sequences (Table 4.3). Expression of Plasmodium LDH‟s were used as controls 
for expression conditions throughout the present study (Figure 4.6). Eleven percent of the 
codons (30/275 codons) in the Pf33 sequence are rare codons for E. coli. PfLDH and 
PvLDH were found to have very similar percentages of rare codons: 12% (38/317 codons) 
and 10.5% (32/304 codons) respectively. PfLDH and PvLDH expressed more successfully 
than Pf33-MBP, even though their codon usage was similar to that of Pf33. This suggests 





Table 4.3. Rare E. coli codons and their frequency within the Plasmodium proteins being 
recombinantly expressed.  






CGG (Arginine) 1 0 0 
AGA (Arginine) 1 6 2 
AGG (Arginine) 1 0 2 
ATA (Isoleucine) 15 5 3 
GGA (Glycine) 4 10 11 
ACA (Threonine) 3 5 3 
CCA (Proline) 2 9 5 
GGG (Glycine) 1 0 4 
ACC (Threonine) 2 3 2 
 
The RIG plasmid (Baca and Hol, 2000) codes for three tRNAs (ArgU, IleX and 
GlyT) cloned from E. coli (Appendix Figure A3). These genes enable the expression of 
tRNAs recognising the codons AGA/AGG (arginine), ATA (isoleucine) and GGA (glycine) 
(Baca and Hol, 2000). Due to cloning artefacts, the RIG plasmid also carries genes for 
tRNAs recognising the codons TAC (tyrosine) and ACA/ACC (threonine) (Baca and Hol, 
2000). It was thought that high levels of these tRNAs could possibly aid E. coli translation 
of Plasmodium mRNAs that are abundant in these codons, and thus potentially increase the 
yield of the recombinant protein. Success with expressing full-length P. falciparum proteins 
and reducing the quantity of lower molecular weight proteins with co-transformation of this 
plasmid has been observed (Matambo et al., 2004). However, no improvement in 
recombinant protein expression was observed with utilisation of the RIG plasmid in the 
present study. Zhou et al. (2004) also did not experience any improvement in expression of 
a Plasmodium vaccine candidate with the RIG plasmid. However, altering the codons to 
match those most commonly used by E. coli, without changing the amino acid sequence, 
resulted in an intense increase in protein expression (Yadava and Ockenhouse, 2003; Zhou 
et al., 2004). It is therefore possible that if the Pf33 sequence was optimised for an E. coli 
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host, a larger yield of full-length Pf33-fusion protein may be obtained and fewer truncated 
proteins expressed. 
Truncated proteins could be due to priming from an internal Shine-Dalgarno 
sequence (Shine and Dalgarno, 1974), upstream of an internal methionine residue as 
Turgut-Balik et al. (2001) and Berwal et al. (2008) experienced with the expression of P. 
falciparum LDH. However, no Shine-Dalgarno sequence was found to be present in this 
sequence (result not shown). 
Pf33-MBP was purified with amylose affinity chromatography. Analysis of the 
purified protein by SDS-PAGE revealed three major bands (approximately 79 kDa, 60 kDa 
and 45 kDa) and one minor band (33 kDa), in addition to a couple of minor bands below 
21.5 kDa and above 97.4 kDa. Maina et al. (1988) obtained similar results: multiple protein 
bands were observed after amylose purification of their MBP-paramyosin fusion protein. It 
was proposed that the multiple protein bands were due to early termination of the fusion 
protein or due to digestion by E. coli proteases. 
 Pf33-MBP fusion protein was cleaved by Factor Xa at a concentration of 10 μg/ml. 
DEAE Sepharose
TM
 was used to separate Pf33 from MBP after Factor Xa cleavage. 
Analysis of the fractions off the column by SDS-PAGE revealed protein bands of 
approximately 43 kDa for the fractions assumed to contain Pf33, and the fractions assumed 
to contain MBP. Un-cleaved Pf33-MBP should have been passed over the DEAE 
Sepharose column as a control as the sample loaded would inevitably contain at least a 
small proportion of un-cleaved Pf33-MBP. It is also possible that the MBP and Pf33 
remained associated even after Factor Xa cleavage and therefore eluted together, as 
experienced by Ko et al. (1993). Unfortunately, the fractions were not subjected to western 
blotting in addition to SDS-PAGE analysis. 
An alternative strategy could be to pass the cleavage mixture over the amylose 
column for a second time in place of using ion exchange chromatography, even though 
others had experienced no success with this method (Dr Alain Boulangé, University of 
KwaZulu-Natal, South Africa, personal communication). This method should remove the 
cleaved off MBP, as performed by Maina et al. (1988). Maina et al. (1988) did however 
experience a small quantity of MBP that would not bind to column with this method.  
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 Factor Xa cleavage followed by ion exchange chromatography, did not appear to be 
successful at separating Pf33 from MBP. „On column‟ cleavage was attempted as an 
alternative as this method had been successful with a glutathione-S-transferase (GST) 
fusion protein (Huson, 2006). „On column‟ cleavage of the GST fusion protein resulted in a 
highly purified protein, free of GST. „On column‟ cleavage of Pf33-MBP however, did not 
appear to result in purified Pf33. SDS-PAGE analysis and western blotting of the fraction 
that should have contained Pf33 looked similar to the fraction that should have contained 
MBP (Figure 4.14). It is possible that the Factor Xa cleaved non-specifically as experienced 
by others (Ko et al., 1993) and therefore Pf33 would possibly still have had a portion of 
MBP attached. It is possible that MBP and Pf33 formed a tight association even after Factor 
Xa cleavage as experienced by Ko et al. (1993), as described earlier. This tight association, 
in addition to the possibility of MBP being weakly bound to the amylose, may provide 
some explanation for the results observed in Figure 4.14. 
 The way forward with expression of Pf33 may be to involve a different system such 
as the one used by Cho et al. (2008) and Pryor and Leiting (1997). They used a dual tag 
system of MBP and His-tag, thereby increasing the purification options available after 
Factor Xa cleavage. A second option could be to use a system constructed by Muench et 
al., (2003) after they had numerous problems expressing and purifying an enoyl reductase-
MBP fusion protein. They added a tobacco etch virus protease cleavage site into the 
pMAL-c2X plasmid linker region, between the region coding for MBP and the region 
coding for enoyl reductase. Following the tobacco etch virus cleavage site they inserted a 
histidine tag. The cells containing this new modified plasmid were co-transformed with a 
plasmid expressing the tobacco etch virus protease. As the fusion protein was expressed, 
the MBP was cleaved off and the enoyl reductase was purified using the histidine tag. A 
system like this could possibly solve many of the problems experienced with the 
purification of Pf33. 
Despite the problems associated with recombinantly expressing Plasmodium 
proteins, it appears that successful expression is possible. Successful recombinant 
expression of Plasmodium proteins include falcipain-2 MBP-fusion (Goh et al., 2003); 
falcipain 1 cysteine protease (Goh et al., 2005); enoyl reductase (Muench et al., 2003); 
LDH (Turgut-Balik et al., 2001; Turgut-Balik et al., 2004; Brown et al., 2004); orotidine-
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5‟-monophosphate decarboxylase (Cinquin et al., 2001); erythrocyte membrane protein 1 
(Flick et al., 2004); F2 domain of erythrocyte binding antigen-175 (Yadava and 
Ockenhouse, 2003); heat shock protein 70 (Matambo et al., 2004); FALVAC-1 (Zhou et 
al., 2004); in addition to 63 P. falciparum proteins (Mehlin et al., 2006). It appears to just 














Antibodies were produced in chickens against two Plasmodium proteins. Chickens 
were chosen for the production of the antibodies as they yield high concentrations of 
specific antibodies (Krief et al., 2002; Gassmann et al., 1990; Gruber and Hartung, 2004; 
Chui et al., 2004). In addition, antigens injected into chickens are often more immunogenic 
than the same antigen injected into mammals due to the chickens phylogenetic distance 
from mammals (Gassmann et al., 1990). Large amounts of antibodies are maternally 
transferred to the egg yolk (Patterson et al., 1962) providing immunity for the developing 
chick. Therefore the eggs of immunized chickens are collected and the IgY isolated from 
the egg yolks using polyethylene glycol (PEG) precipitation (Polson et al., 1980; 1985; 
Goldring and Coetzer, 2003). This provides a non-invasive method of harvesting 
antibodies, thus minimizing distress to the animals (Gassmann et al., 1990; Krief et al., 
2002; Gruber and Hartung, 2004; Tini et al., 2002).  
Chicken anti-peptide antibodies were raised against peptides from P. falciparum 
PFC0760c protein and the P. yoelii yoelii protein PY05757 (http://www.plasmodb.org). 
Using peptides as antigens is advantageous, especially when the target protein is not easily 
obtained or available in sufficient quantities for immunisation. Provided that the anti-
peptide antibodies produced were able to react with the native protein, those antibodies 
would prove invaluable for isolating and characterizing the native protein. The anti-peptide 
antibodies produced in this study were used to probe for the native proteins in an 
immunofluorescence assay and in western blotting of Plasmodium infected red blood cells. 
In addition, the peptides were coupled to affinity matrices and used to purify human anti-
malaria antibodies able to bind to these peptides, from an antibody pool prepared from 




5.2 Production of antibodies in chickens against synthetic peptides 
5.2.1 Selection of peptides 
The amino acid sequences of the Plasmodium falciparum protein, PFC0760c and 
the Plasmodium yoelii yoelii protein, PY05757, were analysed for regions predicted to be 
immunogenic using the Predict 7 program (Cármenes et al., 1989). The algorithms 
predicting hydrophilicity (Hopp and Woods, 1981; Kyte and Doolittle, 1982), flexibility 
(Karplus and Shulz, 1985), surface probability (Janin et al., 1978) and antigenicity (Welling 
et al., 1985) were used for the entire amino acid sequences of PY05757 (Figure 5.1 A) and 
PFC0760c (Figure 5.2 A). Regions of 12 or more consecutive amino acids having values 
above zero for hydrophilicity, flexibility, and surface probability were considered 
sequences possible for peptide synthesis. A number of sequences were predicted to be 
favourable for peptide synthesis for both proteins. However, many of these sequences 
produced significant matches during BLAST searches, to other P. yoelii yoelii proteins, 
mouse (Mus musculus) and chicken (Gallus gallus) proteins (results not shown). It was 
necessary to select peptide sequences that would be sufficiently foreign to chickens, in 
order to raise chicken anti-peptide antibodies. It was also essential for the peptide sequence 
selected for PY05757 to not have sequence similarity with mouse proteins, or other P. 
yoelii yoelii proteins, as the antibodies raised would be required to detect the native 
PY05757 protein in P. yoelii yoelii infected mouse red blood cells. Plasmodium proteins 
tend to be lysine rich (Flick et al., 2004; Vedadi et al., 2007) and therefore any sequences 
having multiple lysine residues were also not further considered for synthesis. 
The peptide sequence SDDDNRQIQDFE, corresponding to amino acid residues 
1341-1352 of PY05757 was identified as a candidate for raising antibodies. The plots of 
hydrophilicity, flexibility and surface probability were all above zero (Figure 5.1 B). In 
addition, a BLAST search at NCBI with the “search for short nearly exact matches” option 
(http://www.ncbi.nlm.nih.gov/blast/Blast.cgi) produced a significant match only for the 
hypothetical protein PY05757 (Table 5.1). No Gallus gallus (chicken) or Mus musculus 
(mouse) proteins produced significant matches, suggesting that the peptide sequence is 
likely to be foreign and hence immunogenic in chickens and mice  
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 Due to the small molecular mass of the peptide, it was necessary to couple the 
peptide to a carrier protein, rabbit albumin, to increase the antibody production. The peptide 
SDDDNRQIQDFE was synthesized with a cysteine residue at the C-terminus, allowing 
coupling to the rabbit albumin carrier with 3-maleimidobenzoic acid N-
hydroxysuccinimide (MBS) via the sulfhydryl group (Section 2.30). The cysteine residue 
was synthesised on the C-terminus of the peptide, as Predict 7 predicted the amino acids at 
the C-terminus to be slightly less immunogenic than those at the N-terminus (Figure 5.1 B). 
In addition, peptides FKLGSCYLYIINRNLKEI and CFKLGSCYLYIINRNLKEI 
were synthesized (GenScript Corporation, USA). These peptides were identical in 
sequence, except that one was synthesized with a cysteine residue at the N-terminus for 
coupling to rabbit albumin with MBS (Section 2.30). The positioning of the cysteine 
residue was due to the C-terminus predicted to be more immunogenic than the N-terminus 
with Predict 7 (Figure 5.2 B). Peptide FKLGSCYLYIINRNLKEI was coupled to rabbit 
albumin using glutaraldehye (Section 2.29). The peptides were synthesised with 
substitution of the internal cysteine residue with an alpha amino-butyric acid.  
Peptide FKLGSCYLYIINRNLKEI corresponds to amino acid residues 567-584 of 
PY05757 (Figure 5.2 A, between solid black lines) and amino acid residues 2386-2403 of 
PFC0760c (Figure 5.2 A, between red dotted lines). The peptide was chosen for synthesis, 
as an alignment of the amino acid sequences of Plasmodium proteins having high sequence 
identity to Pca 96, revealed the sequence to be highly conserved across eight Plasmodium 
species (Chapter 3).  
Peptide FKLGSCYLYIINRNLKEI did not appear to be a sequence that would be 
particularly immunogenic according to the predictions of Predict 7 (Figure 5.2 B), but it 
was decided to attempt to raise antibodies against it nevertheless, as it was thought useful to 
have a peptide that could potentially recognize the protein of interest in multiple 
Plasmodium species.  
The peptide sequence was used to perform a BLAST search using the “search for 
short nearly exact matches” option at NCBI (http://www.ncbi.nlm.nih.gov/blast/Blast.cgi), 
to ensure that no sequence similarity existed between the peptide sequence and chicken 
proteins. Hypothetical proteins from P. falciparum, P. yoelii yoelii and P. chabaudi 
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chabaudi returned significant matches (Table 5.2), corresponding to proteins having high 
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Figure 5.1. Hydrophilicity, surface probability, flexibility and antigenicity predictions of the full 
length P. yoelii yoelii protein PY05757. Prediction of the hydrophilicity (), surface probability (▲), 
flexibility () and antigenicity (x) of protein PY05757 with Predict 7 (A). The position of the conserved 
sequence FKLGSCYLYIINRNLKEI is located between the solid black lines, and the position of peptide 
SDDDNRQIQDFE is located between the red dotted lines. An enlargement of the section where peptide 
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Figure 5.2. Hydrophilicity, surface probability, flexibility and antigenicity predictions of the full length P. falciparum protein PFC0760c. Prediction 
of the hydrophilicity (), surface probability (▲), flexibility () and antigenicity (x) of protein PFC0760c using Predict 7 (A). The position of the 
conserved sequence FKLGSCYLYIINRNLKEI is located between the dotted black lines. An enlargement the section where peptide 




Table 5.1. Significant matches returned by a BLAST search at NCBI* with the 
SDDDNRQIQDFE peptide 
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Table 5.2. Significant matches returned by a BLAST search at NCBI* with the 
FKLGSCYLYIINRNLKEI peptide 























     




























5.3.1 Production of chicken anti-peptide antibodies against P. falciparum protein 
PFC0760c and P. yoelii yoelii protein PY05757 
5.3.1.1 Measuring anti-peptide antibody titres in chickens  
The peptides FKLGSCYLYIINRNLKEI, CFKLGSCYLYIINRNLKEI and 
SDDDNRQIQDFE were coupled to rabbit albumin and injected into two chickens as 
described in Sections 2.29, 2.30 and 2.31. The production of chicken anti-peptide 
antibodies was monitored using ELISA. High levels of antibodies detecting peptide 
FKLGSCYLYIINRNLKEI were observed between weeks three and nine for one chicken 
immunized with the peptide (Figure 5.3 A). The second chicken immunized with peptide 
FKLGSCYLYIINRNLKEI did not produce antibodies to the peptide. Chickens immunized 
with peptide CFKLGSCYLYIINRNLKEI produced high levels of antibodies against the 
peptide FKLGSCYLYIINRNLKEI (Figure 5.3 A). Production of antibodies was evident 
between weeks four and twelve (chicken 1) and weeks seven and ten (chicken 2) (Figure 
5.3 A). Antibodies produced against peptide SDDDNRQIQDFE were observed at high 
levels from weeks two to six (chicken 2) and six and eight (chicken 1), before the antibody 
levels started to go down (Figure 5.3 B).  
The production of IgY against the carrier protein, rabbit albumin, was also 
monitored with ELISA (Figure 5.4). All chickens immunized with rabbit albumin peptide 
conjugates produced high levels of anti-rabbit albumin IgY, rising around week 3 and 
reaching a plateau at week 12. One chicken immunized with peptide 
FKLGSCYLYIINRNLKEI conjugate (Figure 5.4 A) produced lower levels of antibodies to 
















































Figure 5.3. ELISA analysis of chicken anti-peptide antibody (IgY) production against peptide 
FKLGSCYLYIINRNLKEI and SDDDNRQIQDFEC.The peptides were coated at 1 μg/ml in PBS. 
The anti-peptide IgY produced against peptide FKLGSCYLYIINRNLKEI (▲;∆), peptide 
CFKLGSCYLYIINRNLKEI (■;□) (A) and peptide SDDDNRQIQDFEC (;) (B) were used at a 
final concentration of 25 μg/ml. IgY from chicken 1 is represented by closed symbols and IgY from 
chicken 2 is represented by open symbols. Chickens were immunized with the peptide conjugate 
emulsified in Freund‟s complete adjuvant at week 0, and in Freund‟s incomplete adjuvant at weeks 2, 
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Figure 5.4. ELISA of antibody production in chickens against the carrier protein rabbit 
albumin. (A) Anti-peptide FKLGSCYLYIINRNLKEI (▲;∆) and CFKLGSCYLYIINRNLKEI (■;□) 
IgY detecting rabbit albumin. (B) Anti-peptide SDDDNRQIQDFEC (♦;◊) IgY detecting rabbit 
albumin. Rabbit albumin was coated at 1 μg/ml and the anti-peptide antibodies were used at 25 μg/ml. 
Chickens were immunized with the peptide conjugate emulsified in Freund‟s complete adjuvant at 
week 0, and in Freund‟s incomplete adjuvant at weeks 2, 4, and 6 (arrows). The absorbance readings 





5.3.1.2 Affinity purification of anti-peptide antibodies 
The anti-peptide FKLGSCYLYIINRNLKEI antibodies isolated from each week were 
pooled and affinity purified on an AminoLink
®
 column coupled with peptide 
FKLGSCYLYIINRNLKEI (Figure 5.5 A) (Section 2.33.1 and 2.34). The yield of purified 
anti-peptide FKLGSCYLYIINRNLKEI IgY from multiple purifications was 6 mg. The 
anti-peptide CFKLGSCYLYIINRNLKEI antibodies from each week were pooled and 
affinity purified on a SulfoLink
®
 column coupled with peptide 
CFKLGSCYLYIINRNLKEI (Figure 5.5 B) (Section 2.33.2 and 2.34). The yield of purified 
anti-peptide CFKLGSCYLYIINRNLKEI IgY from multiple purifications was 12 mg. The 
anti-peptide SDDDNRQIQDFEC antibodies were pooled and affinity purified on a 
SulfoLink
®
 column coupled with peptide SDDDNRQIQDFEC (Figure 5.5 C) (Section 
2.33.2 and 2.34). The yield of affinity purified anti-peptide SDDDNRQIQDFEC IgY from 
multiple purifications was 11 mg. The anti-peptide FKLGSCYLYIINRNLKEI and 
CFKLGSCYLYIINRNLKEI antibodies typically eluted after 5-6 ml of 100 mM glycine, 
pH 2.8 (Figure 5.5 A and B). The anti-peptide SDDDNRQIQDFEC antibodies eluted 
earlier, generally after 4-5 ml of 100 mM glycine, pH 2.8 (Figure 5.5 C). 
 
5.3.1.3 Evaluation of purified anti-peptide antibodies with ELISA 
The affinity purified anti-peptide antibodies were tested for their specificity for peptide 
using ELISA. Purified anti-peptide FKLGSCYLYIINRNLKEI antibodies and purified anti-
peptide CFKLGSCYLYIINRNLKEI antibodies recognized both peptides with similar 
specificity (Figure 5.7 A and B). All of the affinity purified antibodies had superior 
recognition of the peptides in comparison to the non-purified antibodies, as they produced 
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FKLGSCYLYIINRNLKEI 
    CFKLGSCYLYIINRNLKEI 
             SDDDNRQIQDFEC 
Figure 5.5. Elution of affinity purified chicken anti-peptide antibodies from the peptide affinity 
matrix. (A) Anti-peptide FKLGSCYLYIINRNLKEI IgY (chicken 1, weeks 9-12) (▲), (B) anti-
peptide CFKLGSCYLYIINRNLKEI IgY (chicken 1, weeks 9-12) (□) and (C) anti-peptide 
SDDDNRQIQDFEC IgY (chicken 2, weeks 4-7) (■). Anti-peptide FKLGSCYLYIINRNLKEI IgY 
was purified on AminoLink® resin coupled with peptide FKLGSCYLYIINRNLKEI. Anti-peptide 
CFKLGSCYLYIINRNLKEI IgY was purified on SulfoLink® resin coupled with peptide 
CFKLGSCYLYIINRNLKEI. Anti-peptide SDDDNRQIQDFEC IgY was purified on SulfoLink® 
resin coupled with peptide SDDDNRQIQDFEC. The anti-peptide antibodies were eluted at low pH 
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Figure 5.6. Analysis of anti-peptide FKLGSCYLYIINRNLKEI antibodies before and after 
affinity purification. ELISA plates were coated with peptide FKLGSCYLYIINRNLKEI (A) and 
CFKLGSCYLYIINRNLKEI (B) at 1 μg/ml. Affinity purified anti-peptide FKL IgY (∆), affinity 
purified anti-peptide KEI IgY (□), non-purified anti-peptide FKL IgY and non-purified anti-peptide 
KEI IgY (x) and non-immune control IgY (●) were diluted from 50 μg/ml to 0.048 μg/ml with serial 


















5.3.2 Anti-Plasmodium lactate dehydrogenase antibodies 
Antibodies against Plasmodium lactate dehydrogenase (PfLDH) were raised in chickens 
(Achilonu, 2008; Hurdayal et al., 2010). Chickens were immunized with peptide 
APGKSDKEWNRDDLC coupled to rabbit albumin. The peptide sequence corresponds to 
a amino acid residues 85-98 of P. falciparum lactate dehydrogenase (LDH) 
(UniProtKB/Swiss-Prot primary accession Q27743). This peptide sequence appears 
conserved in all Plasmodium LDH‟s, thus making the anti-peptide antibodies produced 
against it, a useful control, irrespective of the strain of Plasmodium being used. PfLDH 
appears to be expressed at much higher levels than PFC0760c (Chapter 3, Le Roch et al., 
2003), and therefore it was decided to use PfLDH as a positive control for immunological 
studies performed with the anti-peptide FKLGSCYLYIINRNLKEI, 
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Figure 5.7. Analysis of anti-peptide SDDDNRQIQDFEC antibodies before and after affinity 
purification. ELISA plates were coated with peptide SDDDNRQIQDFEC at 1 μg/ml. Affinity purified 
anti-peptide SDDDNRQIQDFEC IgY (ж), non-purified anti-peptide SDDDNRQIQDFEC IgY (▬) and 
pre-immune control IgY (●) were diluted from 50 μg/ml by serial doubling dilutions to 0.048 μg/ml. The 
absorbance readings at 405 nm represent the average of duplicate experiments. 
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5.3.3 Localisation of native P. yoelii yoelii protein, PY05757 and LDH with 
immunofluorescence 
The affinity purified anti-peptide antibodies were used in an immunofluorescence 
assay to probe for the native PY05757 protein in mouse red blood cells infected with P. 
yoelii yoelii parasites (Figure 5.8 A-D). As a control, native P. yoelii yoelii LDH was 
probed for with anti-PfLDH antibodies (Figure 5.8 D). Green fluorescence is a result of the 
fluorescein isothiocyanate (FITC) and blue fluorescence due to the staining of parasite 
nuclear material with 4, 6-diamidino-2-phenylindole (DAPI). The antibodies produced to 
detect PY0575, and those produced to detect Plasmodium LDH, both appeared to detect 
proteins associated with the parasite. Fluorescence resulting from the antibody produced 
against PY05757 was seen predominantly in parasites that appear to be in the ring, 
trophozoite and schizont stages of the parasite life cycle. This observation compares well to 
the mRNA expression values obtained by Le Roch et al. (2003) for PFC0760c, which has 
high sequence similarity to PY05757. The mRNA for PFC0760c appears to be expressed at 
its highest levels during the trophozoite and schizont stages of the life cyle (Figure 3.3) (Le 
Roch et al., 2003). The anti-LDH antibodies detected a protein that appeared to be 
associated with the parasite cytoplasm (Figure 5.8 D) as an even distribution of green 
fluorescence was observed. Although the fluorescence resulting from the anti-peptide 
CFKLGSCYLYIINRNLKEI, FKLGSCYLYIINRNLKEI and SDDDNRQIQDFEC IgY‟s 
also produced an even green fluorescence throughout the cytoplasm, the fluorescence 
appeared to be more intense in the nucleus of the parasite.  
Slides probed with anti-peptide CFKLGSCYLYIINRNLKEI IgY‟s were observed 
with confocal microscopy (Figure 5.9) to obtain a better insight into the possible location of 
the protein being detected with the antibodies. As observed before, an incessant fluorescent 
signal was observed throughout the cytoplasm in addition to the intense signal observed on 
the nucleus of the parasite. These results suggest that the protein is associated with both the 
parasite nuclear material and the parasite cytoplasm. This compares favourably with the sub 
cellular location predictions performed (Section 3.3.5). However, co-localisation studies 
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Figure 5.8. Immunofluorescence images of the native P. yoelii yoelii protein, PY05757 and P. yoelii 
yoelii lactate dehydrogenase in P. yoelii yoelii parasitized red blood cells. P. yoelii yoelii infected 
mouse red blood cells were probed with anti-peptide SDDDNRQIQDFEC IgY (SDD) (A), anti-peptide 
CFKLGSCYLYIINRNLKEI IgY (KEI) (B and C) and anti-peptide FKLGSCYLYIINRNLKEI IgY 
(FKL) (D) to detect native PY05757, and with anti-peptide APGKSDKEWNRDDLC IgY (LDH) (E) to 
detect native P. yoelii yoelii lactate dehydrogenase. The anti-peptide antibodies were detected with a 
donkey anti-chicken antibody conjugated to fluorescein isothiocyanate (FITC). Parasite DNA was 



























Figure 5.9. Confocal immunofluorescence microscopy of a P. yoelii yoelii infected red blood 
cell to show the location of the protein PY05757. (A) Confocal image of an infected red blood 
cell probed with anti-peptide CFKLGSCYLYIINRNLKEI chicken antibodies (10 μg/ml). (B) 
Merged images of a Z-stack progression 0 to 8 through an infected red blood cell, probed with 
anti-peptide CFKLGSCYLYIINRNLKEI chicken antibodies (10 μg/ml). The anti-peptide 
antibodies were detected with a donkey anti-chicken antibody conjugated to fluorescein 
isothiocyanate (FITC). Parasite DNA was stained with 4, 6-diamidino-2-phenylindole (DAPI) (5 
μg/ml). 
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5.3.4 Western blotting of parasite material 
Mouse red blood cells infected with mouse strains of Plasmodium (P. yoelii yoelii; P. yoelii 
yoelii chloroquinine resistant; P. chabaudi chabaudi; P. berghei) were lysed open (Section 
2.28) and the material was analysed on SDS-PAGE and transferred electrophoretically to 
nitrocellulose (Section 2.4 and 2.6).  
The nitrocellulose was probed with anti-PfLDH antibodies (Figure 5.10). Detecting 
Plasmodium proteins on the gel proved difficult as the banding pattern of the proteins 
observed on the gel for the uninfected control blood sample appeared identical to the 
banding pattern of the blood samples infected with mouse strains of Plasmodium (Figure 
5.10 A). The anti-PfLDH antibodies detected a protein band in both P. yoelii yoelii samples 
(arrow, Figure 5.10 B) in the region of 37 kDa, which is close to the predicted size for P. 
yoelii yoelii LDH of 34 kDa (http://www.plasmodb.org/). No LDH was detected in samples 
infected with P. berghei or P. chabaudi chabaudi, or in the uninfected control sample. A 
second protein band was detected at 26 kDa with the anti-PfLDH antibodies. This band was 
also evident in the uninfected sample. The anti-peptide FKLGSCYLYIINRNLKEI and 
CFKLGSCYLYIINRNLKEI antibodies did not detect any Plasmodium proteins in western 
blot analysis, even when the antibody concentration was increased as high as 25 μg/ml and 
50 μg/ml (result not shown). 
The anti-peptide SDDDNRQIQDFEC antibodies were used to probe for P. yoelii 
yoelii protein PY05757 (Figure 5.11 B) on a western blot of P. yoelii yoelii infected red 
blood cells. The anti-peptide SDDDNRQIQDFEC antibodies detected multiple protein 
bands. The predicted size of protein PY05757 is 178 kDa (http://www.plasmodb.org/). The 
antibodies detected a protein of 178 kDa in the soluble fraction of the P. yoelii yoelii 
infected (lane 3, Figure 5.11 B) red blood cells, and not in the membrane bound fraction 
(lane 4). This results correlates well with the transmembrane domain prediction result, 
which predicted that PY05757 was not membrane bound (Chapter 3). The anti-peptide 
SDDDNRQIQDFEC antibodies detected protein bands of 250 kDa (lanes 3 and 4), 218 
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Figure 5.10. Western blotting of P. yoelii yoelii LDH. Plasmodium-infected mouse red blood cells 
were analysed on a 10% SDS-PAGE gel (A), and probed with anti-LDH IgY at 10 μg/ml with 
western blotting (B). Lane 1, Bio-Rad low molecular weight marker; lane 2, Control (uninfected 
mouse blood); lane 3, P. yoelii yoelii infected blood; lane 4, P. yoelii yoelii (chloroquinine resistant 
strain) infected blood; lane 5, P. berghei infected blood; lane 6, P. chabaudi chabaudi infected 



















5.3.5 Purification of human anti-malaria antibodies 
A pool of human anti-malaria IgG's was passed through an affinity matrix coupled with the 
peptide for the P. falciparum protein, PFC0760c (peptide FKLGSCYLYIINRNLKEI) 
(Figure 5.12). A low yield (445 μg) of human anti-peptide FKLGSCYLYIINRNLKEI 
antibodies eluted after 7-8 ml of 100 mM glycine, pH 2.8. The same pool of human anti-
malaria IgG‟s was passed through an affinity matrix coupled with a peptide derived from P. 
falciparum lactate dehydrogenase (PfLDH) (peptide APGKSDKEWNRDDLC). Elution 
from this matrix yielded 841 μg/ml of human anti-peptide APGKSDKEWNRDDLC 
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Figure 5.11. Western blotting of P. yoelii yoelii protein PY05757. Lysed blood samples from P. 
yoelii yoelii infected mice were analysed on a 5% SDS-PAGE gel (A) and probed with purified anti-
peptide SDDDNRQIQDFEC IgY at 10 μg/ml in a western blot (B). Lane 1, Fermentas PageRulerTM 
Unstained Protein Ladder, lane 2, control (uninfected mouse blood), lane 3, P. yoelii yoelii infected 
blood (soluble fraction), lane 4, P. yoelii yoelii infected blood (membrane fraction). The arrows 








Choosing a peptide for raising antibodies can be problematic as Plasmodium proteins are 
lysine rich (Flick et al., 2004; Vedadi et al., 2007). A peptide with many lysine residues 
would more than likely result in non-specific antibodies that react with multiple 
Plasmodium proteins due to the recognition of lysine residues. It was therefore difficult to 
choose peptide sequences using the parameters from Predict 7 as the peptide regions that 
were predicted to have high antigenicity, almost always contained multiple lysine residues. 
One peptide selected contained two lysine residues in the peptide sequence 
(FKLGSCYLIINRNLKEI) (Figure 5.2), although Predict 7 did not predict the peptide to be 
particularly antigenic. A second peptide was selected without any lysine residues 
(SDDDNRQIQDFE) (Figure 5.1). Anti-peptide antibodies were successfully raised against 
both peptides in this study. 
The ELISA results indicated that the chickens produced antibodies to all of the 
peptides and the carrier proteins immunised (Figures 5.3 and 5.4). One chicken immunized 
with the peptide FKLGSCYLYIINRNLKEI-rabbit albumin conjugate, did not produce 












Figure 5.12. Affinity purification of anti-peptide antibodies from a pool of sera from malaria 
patients. Human antibodies recognising peptide CFKLGSCYLYIINRNLKEI (P. falciparum protein, 
PFC0760c) (□) and peptide APGKSDKEWNRDDLC (P. falciparum LDH) (x), from a pool of 
antibodies from human malaria patients. 
169 
 
although there were less antibodies produced in comparison to the antibodies from the three 
other chickens. Both chickens immunised with the FKLGSCYLIINRNLKEI peptide were 
immunised from the same rabbit albumin peptide conjugate, therefore it is unlikely that the 
difference in antibody production between the two chickens was due to the immunogen. 
This result emphasized the need to immunize more than one chicken during immunization 
schedules, as it is often observed that several animals immunized with the same dose of 
immunogen and under the same conditions can produce antiserum with completely 
different characteristics (Harlow and Lane, 1988; van Regenmortel et al., 1989). 
The anti-peptide antibodies produced were pooled and affinity purified (Figure 5.5). 
The highest yield of purified antibodies (12 mg) was obtained with the 
CFKLGSCYLIINRNLKEI peptide column and respective antibody pool. The lowest yield 
of purified antibodies (6 mg) was obtained with the FKLGSCYLIINRNLKEI peptide 
column and the respective antibody pool. This could possibly be due to better coupling 
being achieved with the methods used for the CFKLGSCYLIINRNLKEI peptide. The 
methods used to couple the peptide FKLGSCYLIINRNLKEI would not have been as 
successful due to the internal lysine residue. The peptide would have been coupled via 
either or both of the lysine residues. It may have been beneficial to pass the anti-peptide 
FKLGSCYLIINRNLKEI antibody pool over the CFKLGSCYLIINRNLKEI peptide 
column, and vice versa to determine if any further antibodies could be purified.  
The purified antibodies were compared to non-purified antibodies, and in all three 
cases, the affinity purified antibodies had a higher specificity for the peptide at a lower 
concentration of antibody in the ELISAs (Figure 5.6 and Figure 5.7). This would be due to 
the affinity purification having removed non-specific antibodies, and concentrated the 
specific anti-peptide antibodies. 
Anti-peptide antibodies raised against Plasmodium proteins in chickens, have 
successfully been used to detect native Plasmodium proteins in western blots (Merckx et 
al., 2003; Dorin et al., 2005; Reininger et al., 2005), immunofluorescence microscopy 
(Dorin et al., 2005; Nunes et al., 2007) and have been used to immunoprecipitate native 
Plasmodium proteins (Merckx et al., 2003; Nunes et al., 2007). The purified antibodies 
produced in this study were used to detect the native P. yoelii yoelii protein PY05757 with 
immunofluorescence (Figure 5.8 and Figure 5.9) and western blotting (Figure 5.11). 
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Antibodies produced against Plasmodium LDH were used as a positive control in both the 
immunofluorescence assay (Figure 5.8 and Figure 5.9) and for the western blotting (Figure 
5.10). All the antibodies detected protein in the immunofluorescence assay. This provides 
evidence that a native P. yoelii yoelii protein containing the epitopes 
FKLGSCYLYIINRNLKEI and SDDDNRQIQDFEC is expressed in the P. yoelii yoelii life 
cycle. The protein detected by the anti-peptide antibodies appeared to be associated with 
the parasite cytoplasm and nuclear material, although this could not be confirmed in the 
present study. Co-localisation studies would need to be undertaken with antibodies against 
proteins known to be associated with the parasite nucleus and cytoplasm to confirm this. 
The protein appeared to be detected predominantly in parasites in the ring and schizont 
stages of the parasite life cycle. This correlates well with the predicted expression profile of 
the P. falciparum protein PFC0760c, which has high sequence similarity to PY05757 
(Chapter 3, Le Roch et al., 2003). However, the slides were prepared from blood with 
mixed stages of the life cycle, therefore it would be necessary to synchronise parasites and 
repeat the immunofluorescence assay for each stage of the life cycle to confirm the 
observation made. 
 The FITC fluorescent signal observed was weak and thus alternative fluorophore 
conjugates could be used to improve the immunofluorescence images. FITC photobleaches 
rapidly, making the capture of images of low-abundance proteins difficult, as these samples 
require a longer exposure time. FITC also tends to quench after only a few fluorophores 
have been attached to the antibody, resulting in a weak signal. Alexa Fluor® 488 dye from 
Invitrogen (http://www.invitrogen.com/site/us/en/home.html, 2010) produces a much 
brighter signal that is far more photostable than FITC. During conjugation of the Alexa 
Fluor® 488 dye to antibody, a far greater number of fluorophores attach before quenching, 
thereby creating a brighter conjugate that requires far less to be used to obtain optimal 
results. The stability of the conjugate also allows for longer observation and image capture 
time, which is beneficial for low abundance proteins. 
The anti-peptide SDDDNRQIQDFEC antibodies in the western blot detected 
multiple protein bands (Figure 5.11). One band of particular interest was detected at 177 
kDa. This corresponds very closely to the predicted molecular mass of PY05757 of 178 
kDa (http://www.plasmodb.org). The anti-peptide FKLGSCYLYIINRNLKEI and 
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CFKLGSCYLYIINRNLKEI antibodies did not detect any protein bands on the western 
blot. It is possible that the epitope FKLGSCYLYIINRNLKEI was not available to interact 
with the antibodies. The peptide was predicted to be located at the surface of the protein 
and hydrophilic only at the C-terminus of the peptide. Very little is known of the 3-
dimensional structure of the protein and it is therefore possible that the epitope could be 
unavailable for interacting with the antibodies during reducing SDS-PAGE and 
electrophoretic transfer to nitrocellulose. 
Antibodies from a pool of human anti-malarial antibodies bound to peptide 
CFKLGSCYLYIINRNLKEI when the pool was passed over peptide-bound SulfoLink
®
 
column (Figure 5.12). This result suggests that the hypothetical protein PFC0760c is 
expressed within the P. falciparum proteome. It is possible that the antibodies purified on 
the peptide CFKLGSCYLYIINRNLKEI column could be from the P. vivax protein 
Pv095365, as this protein had a sequence of amino acid residues that had 61% identity to 
the epitope FKLGSCYLYIINRNLKEI (Table 5.2). The antibody pool was from a number 
of infections and so therefore it is likely that there are antibodies to P. falciparum, P. vivax, 
and P. ovale among others (Goldring et al., 1992; Taylor et al., 1992). Greater yields of 
human antibodies binding to the LDH peptide column were purified in comparison to the 
peptide FKLGSCYLYIINRNLKEI column. This suggests that Plasmodium LDH is 
possibly a more abundant and a more immunogenic protein than PFC0760c and its 
homologues, thus more antibodies were purified from the same sample on the peptide 
APGKSDKEWNRDDLC affinity matrix than on the peptide FKLGSCYLYIINRNLKEI 
affinity matrix. This provides practical evidence of what was observed from the data of Le 
Roch et al.  (2003), and is in agreement with the data (Chapter 3). These human antibodies 
could be used in western blots or immunofluorescence microscopy to determine if results 
similar to those observed with chicken antibodies are obtained. 
 In future, the anti-peptide antibodies could be used to immunoprecipitate the native 
proteins so that the native proteins could be further characterised. A Plasmodium lysate 
could be passed over an affinity matrix coupled with the anti-peptide antibodies, to obtain 






Malaria is a serious disease caused by infection with Plasmodium parasites. There 
were an estimated 863 thousand deaths as a result of Plasmodium infections in 2008, with 
the majority of those deaths being in Africa (World Health Organisation, 2009). Measures 
to effectively control malaria infection are desperately needed. A vaccine against malaria 
would be the ideal way to prevent the devastating effects of the disease. With sequencing of 
the genomes of P. falciparum (Gardener et al., 2002) and P. yoelii yoelii (Carlton et al., 
2002) and the development of the field of bioinformatics, it is possible to identify likely 
targets for vaccine candidates and to putatively characterise them. It is also possible to 
clone and recombinantly express vaccine targets allowing for their further study. 
 A 96 kDa P. chabaudi adami protein (Pca 96) has shown to produce a protective 
immune response in challenged mice (Wanidworanun et al., 1987), implying that Pca 96 
might be a viable vaccine candidate. A human malaria orthologue to Pca 96 needs to be 
found in the proteomes of other Plasmodium species, to be considered as a human vaccine 
candidate.  
In this study, the sequence of Pca 96 was used as a probe to find a P. yoelli yoelli 
and a P. falciparum protein equivalent to Pca 96. The PY05757 and PFC0760c genes 
appeared to be good candidates. BLAST searches and sequence alignments with Pca 96 
revealed a sequence of 18 amino acids conserved (88% identity) across seven Plasmodium 
species. T-cell epitope predictions for both Pca 96 and PFC0760c, revealed possible T-cell 
epitopes, located within the highly conserved amino acid sequence. A helical wheel plot of 
the sequence indicated the sequence formed an alpha-helical structure. These results 
support the sequence to be of structural importance. As PFC0706c is of unknown function 
(Bowman and Horrocks, 2000) further characterisation of PFC0760c was deemed 
necessary. Bioinformatics data predicted PFC0760c to be a nuclear associated protein. This 
result was supported by the predicted presence of a protein domain usually found in 
proteins involved with the structural maintenance of chromosomes. This result suggests that 
PFC0760c could be involved with chromosome maintenance. In addition, PFC0760c was 
predicted to interact with a number of proteins involved in binding of DNA, RNA, 
chromatin, ATP or proteins with yeast-two hybrid predictions. Immunofluorescence studies 
173 
 
with anti-peptide antibodies specific for the conserved amino acid sequence, produced an 
intense fluorescent signal within the nucleus of P. yoelii yoelii infected mouse red blood 
cells, supporting a nuclear associated protein. However, immunofluorescence microscopy 
with P. falciparum infected human red blood cells needs to be performed to determine if a 
similar pattern is observed to that seen for P. yoelli yoelii infected red blood cells to 
confirm the result. Immunofluorescence microscopy with synchronized parasites would 
also provide practical evidence of the stages of the life cycle where PFC0760c is expressed 
and possibly even give a comparative indication of the levels at which it is expressed. 
Electron microscopy would provide an additional technique to further characterize the 
location of PFC0760c and PY05757 within P. falciparum and P. yoelii yoelii parasites 
respectively, however this was outside the scope of the present study. 
In the present study, a number of proteins with known function were compared to 
PFC0760c, with respect to their mRNA expression levels (Le Roch et al., 2003) with the 
hope of this data giving a further indication of the role PFC0760c plays within the parasite 
life cycle. No obvious patterns for the selected proteins were detected. A computer 
algorithm to detect emerging patterns would be useful to help with this analysis however 
this was beyond the scope of the present study. An algorithm capable of aiding in the 
comparative analysis of mRNA expression levels would also allow the mRNA expression 
levels for PFC0760c to be compared to the mRNA expression levels of other P. falciparum 
genes that are expressed at low levels, to determine if there is any commonality. There is 
evidence of genes such as the Rifin, Stevor and Var genes being located together in 
particular areas of chromosomes and sharing similar functions (Cheng, et al., 1998). Thus, 
examining the genes neighbouring PFC0760c and their location on the chromosome may 
give further insight to the gene. A brief investigation into PFC0760c gene neighbours did 
not give any clues to the function of the gene. 
An 822 bp region of PFC0760c was previously cloned into the pMALc-2X vector 
(Smallie, 2003). In the present study, the resulting 33 kDa protein was expressed as a MBP 
fusion protein (Pf33-MBP) and affinity purified. The next step that needs to be taken is to 
immunise mice with Pf33-MBP and MBP as a control and then challenge the mice with 
parasites. However, Pf33 is of P. falciparum origin and therefore may not result in 
protection against rodent malaria. The P. chabaudi chabaudi (PCAS_080770) or P. yoelii 
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yoelii (PY05757) genes that are the proposed equivalents of PFC0760c would need to be 
cloned and expressed. These proteins could then be used to immunise mice which would 
then be challenged with P. chabaudi chabaudi or P. yoelii yoelii parasites. Alternatively, 
the conserved peptide could be coupled to a carrier protein and used to immunised mice. 
The choice of adjuvant would be very important as different adjuvants can give very 
different protection results (Stoute et al., 1997). The CpG oligodeoxynucleotide adjuvant 
(Pinzon-Charry et al., 2010) might be one adjuvant that could be used. Challenge of these 
mice with parasites would provide answers to whether the conserved sequence is of 
immunological importance.  
Currently there are two studies suggesting that PFC0760c could be of 
immunological importance. Scorza et al (2005) used a multi-epitope DNA vaccine, derived 
from a genomic P. chabaudi adami DNA expression library of 30 000 plasmids. The 
vaccine induced immunity in mice challenged with P. chabaudi adami DK. Vaccine sub-
pools were identified and subjected to bioinformatic analysis, which revealed that many of 
the open reading frames were orthologues of predicted P. falciparum proteins. Many were 
also found to be conserved across three or more Plasmodium species. One of these open 
reading frames was for PFC0760c reinforcing the idea that PFC0760c could have a 
potential role in protecting against malaria. PFC0760c also made an appearance in the 
Villard et al. (2007) investigation to find vaccine candidates based on an alpha-helical 
coiled coil protein motif, again indicating the possibility of PFC0760c possibly having a 
role in protection against malaria 
The Pf33-MBP could also be useful for coupling to a resin, over which parasite 
lysate could be passed. This experiment would give an indication of which parasite proteins 
interact with Pf33-MBP. This could also be repeated using the peptide coupled to resin. 
Characterisation of the proteins bound on the column due to interaction with Pf33-MBP or 
the peptide, by mass spectrometry or N-terminal sequencing, could give further insight to 
the possible role of PFC0760c, to confirm predicted protein-protein interactions.  
Antibodies were successfully produced against the conserved peptide and shown to 
recognise native P. yoelii yoelii protein in immunofluorescence microscopy. These 
antibodies could provide useful for affinity purifying native PFC0760c from parasite lysate 
by passing lysate over a column coupled with purified anti-peptide antibodies. Having 
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access to the native protein would be invaluable for aiding in characterisation of the 
protein, with regards to structure, function and immunological importance. The native 
protein could also be used to raise antibodies in chickens, thereby providing polyclonal 
antibodies to the whole protein, which may be useful for detecting the protein in western 
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Figure A1. Map of plasmid pMAL-c2X indicating the restriction enzyme sites and Factor Xa 
protease recognition sequence in the polylinker site. (New England Biolabs). 
Figure A2. Map of plasmid pGEX4T1 indicating the restriction enzyme sites and thrombin 








Figure A3. The RIG plasmid. 
